

# **CURRICULUM VITAE**

**Professor Hung-Fat TSE**  
**MBBS (HK), MD (HK), PhD (HK)**

**Clinical Professor, Chair of Cardiovascular Medicine**  
**William MW Mong Endowed Professorship in Cardiology**

**Chief, Cardiology Division of Queen Mary Hospital**

Department of Medicine

Li Ka Shing Faculty of Medicine

The University of Hong Kong

---

## **QUALIFICATIONS AND POSITIONS**

### **I. EDUCATION**

1. 1986-1991 The University of Hong Kong, Hong Kong- Bachelor of Medicine and Bachelor of Surgery (*MB.BS*)
2. 1997-1999 The University of Hong Kong, Hong Kong- Doctor of Medicine (*M.D.*)
3. 2004- 2007 The University of Hong Kong, Hong Kong- Doctor of Philosophy (*Ph.D*)

### **II. PROFESSIONAL TRAINING AND APPOINTMENTS**

1. 1991-1992 House officer, Department of Medicine and Department of Surgery, The University of Hong Kong, Queen Mary Hospital
2. 1992-1996 Medical officer, Department of Medicine, The University of Hong Kong, Queen Mary Hospital
3. 1996-2001 Clinical Lecturer, Department of Medicine, The University of Hong Kong
4. 1998- 2005 Honorary Senior Medical Officer, Department of Medicine, Queen Mary Hospital, Hospital Authority
5. 1998-1999 Electrophysiology fellow, Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, USA.
6. 2001-2004 Associate Professor, Department of Medicine, The University of Hong Kong
7. 2004- 2006 Associate Professor (Senior Lecturer), Department of Medicine, The University of Hong Kong
8. 2005- 2008 Assistant Dean (External Affairs & Fund Raising), Li Ka Shing Faculty of Medicine, The University of Hong Kong.
9. 2005- present Honorary Consultant, Department of Medicine, Queen Mary Hospital, Hospital Authority
10. 2006- present Clinical Professor, Department of Medicine, The University of Hong Kong
11. 2006- 2015 Honorary Consultant, Department of Medicine, Kwong Wah Hospital, Hospital Authority

12. 2007- 2016 Academic Chief, Cardiology Division, Department of Medicine, The University of Hong Kong
13. 2007-present Honorary Consultant, Department of Medicine, Tung Wah Hospital, Hospital Authority
14. 2007-present Honorary Consultant, Department of Medicine, Ruttonjee Hospital, Hospital Authority
15. 2008-present William MW Mong Professorship in Cardiology, LKS Faculty of Medicine, the University of Hong Kong.
16. 2011-present Professor, Chair of Cardiovascular Medicine, LKS Faculty of Medicine, the University of Hong Kong.
17. 2012-present Honorary Consultant, Hong Kong Sanatorium and Hospital
18. 2012-present Chief and Honorary Consultant of Cardiology Division, Department of Medicine, The University of Hong Kong - Shenzhen Hospital
19. 2016-present Chief, Cardiology Division, Department of Medicine, Queen Mary Hospital, Hong Kong.
20. 2016-present Chief and Honorary Consultant, Cardiology Division, Department of Medicine, Gleneagles Hong Kong Hospital, Hong Kong

### **III. MEMBERSHIP OF ACADEMIC AND PROFESSIONAL ORGANISATION**

1. 1991- Present *Registration*, General Medical Council (*G.M.C.*)
2. 1994- Present *Member*, Royal College of Physicians (*M.R.C.P.*)
3. 1999- Present *Member*, North American Society of Pacing and Electrophysiology
4. 2000- Present *Fellow*, Hong Kong College of Cardiology
5. 2000- Present *Fellow*, Hong Kong College of Physician (*F.H.K.C.P.*)
6. 2000- Present *Fellow*, Hong Kong Academy of Medicine (*F.H.K.A.M.*)
7. 2001- Present *Fellow*, American College of Cardiology (*F.A.C.C.*)
8. 2003- Present *Fellow*, Royal College of Physicians (*F.R.C.P.*, Edinburgh)
9. 2008- Present *Fellow*, Royal College of Physicians and Surgeon (*F.R.C.P.*, Glasgow)
10. 2009- Present *Fellow*, Royal College of Physicians (*F.R.C.P.*, London)

11. 2010- Present *Fellow*, Eurpean Society of Cardiology (*F.E.S.C.*)

#### **IV. OTHER ACADEMIC/PROFESSIONAL APPOINTMENT**

1. 2001-2009 *Director*, Sun Chieh Yeh Cardiovascular Research and Training Laboratory, the University of Hong Kong
2. 2004- 2007 *Deputy Director*, Institute of Cardiovascular Sciences and Medicine, the University of Hong Kong.
3. 2005- 2008 *Assistant Dean (External Affairs & Fund Raising)*, Li Ka Shing Faculty of Medicine, The University of Hong Kong.
4. 2005- Present *Deputy Director*, Research Centre of Heart, Brain, Hormone and Healthy Aging Research Center, the University of Hong Kong
5. 2005- present *Visiting Professor*, Bengbu Medical College, Bengbu, China
6. 2005 (*Hon*) *Visiting Senior Research Fellow*, Department of Cardiology at City Hospital, University Department of Medicine, Birmingham, UK.
7. 2007- present *Visiting Professor*, Nanjing Medical University, Nanjing, China
8. 2008-9 *Visiting Professor*, University of Chicago, USA
9. 2011-12 *Visiting Professor*, Keck School of Medicine, University of Southern California, USA
10. 2011-12 *Visiting Professor*, University of Minnesota, USA.
11. 2011-2013 *Chairman*, Basic Research Subcommittee, Asia-Pacific Heart Rhythm Society
12. 2012-present “*Horonary Principle Investigator*”, Guangzhou Institute of Biomedicine and Health (GIBH), China
13. 2014-present *Chairman*, Clinical Research Subcommittee, Asia-Pacific Heart Rhythm Society
14. 2014-present *Co-director*, Hong Kong-Guangdong Stem Cell and Regenerative Medicine Research Centre, The University of Hong Kong, Hong Kong

## **PATENTS AND INVENTIONS**

1. 2002 *US Patent* (No. PCT/CN03/00271): A bayesian discriminator for rapidly detecting arrhythmias.
2. 2006 Provisional US Patent: Novel genetic approaches to reduce or inhibit tumorigenicity of human embryonic stem cells and derivatives following transplantation
3. 2007 Catheter-based gene delivery method to construct a bioartificial SA node in mammalian heart. (UC Case No. 2007-041-1)

## **PUBLICATIONS**

### **I. BOOK CHAPTERS**

1. **Tse HF**, Lau CP. Single lead DDD pacing with atrial stimulation via floating ring electrode using overlapping biphasic impulse stimulation. In Sethi KK (*eds*): VI Asian-Pacific Symposium on Cardiac Pacing and Electrophysiology. Monduzzi Editore, Bologna, Italy, pp 117-120, 1997.
2. **Tse HF**, Lau CP. Early recurrence of atrial fibrillation after successful defibrillation in patients with chronic atrial fibrillation. In Sethi KK (*eds*): VI Asian-Pacific Symposium on Cardiac Pacing and Electrophysiology. Monduzzi Editore, Bologna, Italy, pp 355-360, 1997.
3. **Tse HF**, Lau CP. New Understandings and Options in the Management of Atrial Fibrillation. In Nguyen T, Hu D, Saito S, Leng LY, Dave V (*eds*): Practical Handbook: Consultant's Approach to Complex Cardiac Problems. Armonk, NY: Futura Publishing Co, Inc, Armonk, NY, USA. pp 113-132, 2000.
4. **Tse HF**, Lau CP. New Understandings and Options in the Management of Atrial Fibrillation. In Nguyen T, Hu D, Saito S, Leng LY, Dave V (*eds*): Management of Complex Cardiovascular Problems: The Consultant's Approach, *2nd Edition*, Futura Publishing Co, Inc, Armonk, NY, USA. pp 113-132, 2001.
5. **Tse HF**, Lau CP. Advances in Internal and External Cardioversion. In Israel CW, Barold SS (*eds*): Advances in the Treatment of Atrial Tachyarrhythmias, Pacing, Cardioversion and Defibrillation. Futura Publishing Co, Inc. Armonk, NY, USA, pp 419-435, 2001.
6. Lau CP, **Tse HF**, Lee KLF, Barold SS. Unusual indication for cardiac pacing. In Barold SS, Mugica J (*eds*): The Fifth Decade of Cardiac Pacing. Futura Publishing Co, Inc. Armonk, NY, USA pp. 32-43, 2003.
7. **Tse HF**, Lee PY, Lau CP. Bone Marrow Cell Transplantation for Myocardial Regeneration and Therapeutic Angiogenesis. In Laham R, Balm DS (*eds*): Angiogenesis and Direct Myocardial Revascularization. Totowa, NJ: Humana Press Inc., pp. 261-281, 2005.

8. Sin PY, **Tse HF**, Siu CW, Tsang V, Lam CLK, Lau CP. Successful pulmonary vein isolation using transvenous catheter cryoablation improves quality-of-life in patients with atrial fibrillation. In **Tse HF**, Tse TF, Lau CP, Woo KS (eds): First Global Conference on Cardiovascular Clinical Trials and Pharmacotherapy - 2nd WHF Global Conference on Cardiovascular Clinical Trials and 13th International Society of Cardiovascular Pharmacotherapy Congress. Monduzzi Editore, Bologna, Italy, pp 51-56, 2005.
9. Sin PY, **Tse HF**, Siu CW, Tsang V, Lam CLK, Lau CP. Impairment of quality-of-life in patients with atrial fibrillation. In **Tse HF**, Tse TF, Lau CP, Woo KS (eds): First Global Conference on Cardiovascular Clinical Trials and Pharmacotherapy - 2nd WHF Global Conference on Cardiovascular Clinical Trials and 13th International Society of Cardiovascular Pharmacotherapy Congress. Monduzzi Editore, Bologna, Italy, pp 45-50, 2005.
10. Zhang QY, **Tse HF**, Chen JZ, Zhang QG, Ge JB. Mast cells contribute to angiogenesis after coronary microembolization. In **Tse HF**, Tse TF, Lau CP, Woo KS (eds): First Global Conference on Cardiovascular Clinical Trials and Pharmacotherapy - 2nd WHF Global Conference on Cardiovascular Clinical Trials and 13th International Society of Cardiovascular Pharmacotherapy Congress. Monduzzi Editore, Bologna, Italy, pp 87-90, 2005.
11. Hettrick DA, Schwartzman D, **Tse HF**, Pagel PS. Mechanical Basis of Atrial Fibrillation. In Schwartzman D, Zenati MA (eds): Innovative management of atrial fibrillation. Blackwell Futura Publishing Co, Inc, Armonk, NY, USA., pp29-49, 2005.
12. **Tse HF**. Imaging- ECG: In Lau CP (eds): Problem-Based Medical Case Management. Hong Kong University Press, Hong Kong, pp299-322, 2006.
13. **Tse HF**, Lau CP. Sensors for Implantable Devices: Ideal Characteristics, Sensor Combination, and Automaticity: In Ellenbogen KA, Wilkoff BL, Kay GN, Lau CP (eds): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *3rd Edition*, Saunders Elsevier, Philadelphia, USA, pp201-233, 2007.
14. Lau CP, **Tse HF**, Kay Neal. Sensor Driven Pacing: Device Specifics. In Ellenbogen KA, Wilkoff BL, Kay GN, Lau CP (eds): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *3rd Edition*, Saunders Elsevier, Philadelphia, USA, pp499-530, 2007.
15. **Tse HF**, Lau CP. Atrial Fibrillation. In Nguyen T, Hu D, Kim MH, Grines C (eds): Management of Complex Cardiovascular Problems: The Evidence-based Medicine Approach, *3rd Edition*, Blackwell Futura Publishing Co, Inc, Armonk, NY, USA. pp 287-318, 2007.
16. **Tse HF**. Hypertension in Patients with Concomitant Cardiac Disorders: Heart Failure, Atrial Fibrillation and Coronary Heart Disease. In Lip GYH, Hall JE (eds): Comprehensive Hypertension. Elsevier, Inc, New York, USA, pp 753-760, 2007.
17. Lau CP, Siu CW, **Tse HF**. Sensor Driven Pacing. In Ellenbogen KA, Natale A, Al-Ahmad Amin, Wang PJ (eds): Pacemakers and Implantable Cardioverter

Defibrillators: An Expert's Manual. Cardiotext Publishing, Minneapolis, Minnesota, USA. pp 179-202, 2010.

18. Siu CW, **Tse HF**. Cryoablation for Atrial Fibrillation. In Bredikis AJ, Wiber D (eds): Cryoablation of Cardiac Arrhythmias. Elsevier Saunders. pp 167-172, 2011.
19. Yiu KH, Wang M, **Tse HF**. Stress echocardiography evaluation after percutaneous coronary intervention. In Tintoiu I, Popma JJ, Bae J, Galassi AR, Gabriel C (eds): Coronary stent restenosis. The Publishing House of the Romanian Academy. pp 369-378, 2011.
20. Yiu KH, Siu CW, Yiu YF, **Tse HF**. Electrocardiogram. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 6-9, 2011.
21. Yiu KH, Cheung BM, **Tse HF**. Systolic heart failure: pharmacological treatment. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 238-241, 2011.
22. Yiu KH, Lee CH, **Tse HF**. Non-pharmacological treatment for hypertension. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 124-125, 2011.
23. Yiu KH, Cheung BM, **Tse HF**. Hypertension: pharmacological treatment. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 126-131, 2011.
24. Siu CW, **Tse HF**. Atrial flutter and fibrillation. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 68-73, 2011.
25. Hai JJ, **Tse HF**. Sudden cardiac death. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 80-85, 2011.
26. Hai JJ, **Tse HF**. Ventricular tachyarrhythmias. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 74-79, 2011.
27. Yiu YF, Yiu KH, **Tse HF**. Inappropriate sinus tachycardia. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 90-93, 2011.
28. Yiu KH, **Tse HF**. Cardiac gene and stem cell therapy. In **Tse HF**, Lip GY, Coats AJS (eds): Oxford Desk Reference. Oxford. Oxford University Press. pp 436-438, 2011.
29. Au KW, Chow AM, Wu EX, **Tse HF**. Iron oxide nanoparticles and cardiac stem cells. In Hunter RJ, Preedy VR (eds): Nanomedicine and the cardiovascular system. Science Publishers. Pp 391-406, 2011.
30. Siu CW, **Tse HF**. Device Therapy for Bradycardia. Cardiac arrhythmias: From Basic Mechanism to State-of-the-Art Management. In Tintoiu IC, Knight B, Phillipon F (eds). The Publishing House of the Romanian Academy. Pp 591-598, 2012.

31. Lau CP, **Siu CW**, **Tse HF**. Implantable Sensor for Rate Adaptation and Hemodynamic Monitoring In Ellenbogen KA, Kay GN, Lau CP, Wilkoff BL (*eds*): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *4<sup>th</sup> Edition*, Saunders Elsevier, Philadelphia, USA, pp144-176, 2011.
32. Hai JJ, **Tse HF**. Biophysical Principles and Properties of Cryoablation. In Chan NY (*eds*). Catheter Cryoablation Treatment for Cardiac Arrhythmias. John Wiley & Sons, Ltd, Oxford, UK. doi: 10.1002/9781118451793.ch1, 2013.
33. **Tse HF**, Schwartz PJ. Neural and spinal stimulation. In Ellenbogen KA, Wilkoff BL, Kay GN, Lau CP (*eds*): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *5<sup>rd</sup> Edition*, Saunders Elsevier, Philadelphia, USA, 2016.
34. Chan YH, **Tse HF**. Selenium Status Assessment by Questionnaire in Clinical and Cardiovascular Studies. In Preedy VR (*ed*): Food and Nutritional Components in Focus- Selenium: Chemistry, Analysis, Function and Effects. Royal Society of Chemistry, Cambridge, UK, pp 258-272, 2015
35. Chan YH, **Tse HF**. Current Clinical Perspectives of Selenium in Vascular Function and Cardiomyopathy. In Preedy VR (*ed*): Food and Nutritional Components in Focus- Selenium: Chemistry, Analysis, Function and Effects. Royal Society of Chemistry, Cambridge, UK, pp 516-533..
36. Lee YK, Ran X, Lai KWH, Lau VYM, Siu DCW, **Tse HF**. Patient-Specific Induced Pluripotent Stem Cell Models Generation and Characterization. In Turksen K, Nagy A (*eds*). Induced Pluripotent Stem Cells (iPS): Methods and Protocols. Springer, New York, USA, 2015.
37. Hai JJ, **Tse HF**. Interatrial Septal Pacing-technique and Material. In Proietti R, Russo V (*eds*). Pacemakers and ICD: Types, Potential Complications and Long-Term Health Effects. Nova Science Publishers, New York, USA, 2015.
38. Ng KM, Ho JCY, Lee YK, Siu CW, **Tse HF**. Induced pluripotent Stem Cells in Familial Dilated Cardiomyopathy. In Zatz M, Okamoto (*eds*): Stem Cells in Modeling Human Genetic Diseases. Human Press, Springer, New York, USA. pp11-28, 2015.
39. Lau CP, Siu CW, **Tse HF**. Implantable Sensor for Rate Adaptation and Hemodynamic Monitoring In Ellenbogen KA, Kay GN, Lau CP, Wilkoff BL (*eds*): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *4<sup>th</sup> Edition*, Saunders Elsevier, Philadelphia, USA, pp144-176, 2011.
40. Lau CP, Siu CW, **Tse HF**. Sensor for Implantable Cardiac Pacing Devices. In Ellenbogen KA, Wilkoff BL, Kay GN, Lau CP, Angelo Auricchio (*eds*): Clinical Cardiac Pacing, Defibrillation, and Resynchronization Therapy. *5<sup>th</sup> Edition*, Saunders Elsevier, Philadelphia, USA, pp281-312, 2017.
41. **Tse HF**, Schwartz PJ. Neural and Spinal Stimulation. In Ellenbogen KA, Wilkoff BL, Kay GN, Lau CP, Angelo Auricchio (*eds*): Clinical Cardiac Pacing, Defibrillation,



and Resynchronization Therapy. 5<sup>th</sup> Edition, Saunders Elsevier, Philadelphia, USA, pp595-601, 2017.

## II EDITOR OF SCHOLARLY BOOKS AND MONOGRAPHS

1. **Tse HF**, Lee KLF, Lau CP (*eds*): Clinical Cardiac Pacing and Electrophysiology. Monduzzi Editore, Bologna, Italy, 2003.
2. **Tse HF**, Tse TF, Lau CP, Woo KS (*eds*): First Global Conference on Cardiovascular Clinical Trials and Pharmacotherapy - 2nd WHF Global Conference on Cardiovascular Clinical Trials and 13th International Society of Cardiovascular Pharmacotherapy Congress. Monduzzi Editore, Bologna, Italy, 2005.
3. **Tse HF**, Lip GY, Coats AJS (*eds*): Oxford Desk Reference. Oxford. Oxford University Press. 2011.
4. **Tse HF**, Lip GY, Coats AJS (*eds*): Oxford Desk Reference. 2nd Edition Oxford. Oxford University Press. 2017.

## III. PUBLISHED ARTICLES IN INTERNATIONAL JOURNALS

(JIF= Journal Impact Factor, JCI= Journal citation index)

(\*Basic and Clinical Cardiac Electrophysiology;

#Cardiovascular Translational and Regenerative Medicine)

### Original Articles Published in International Journals

1. \***Tse HF**, Lau CP. Exercise-associated cardiac asystole in persons without structural heart disease. *Chest*. 1995; 107: 572-76. (JIF=7.652; No. of cites=13, first author)
2. **Tse HF**, Lau CP, Lai CL, Lau YK. Transesophageal echocardiography in the detection of inferior vena cava and cardiac metastasis in hepatocellular carcinoma. *Clin Cardiol*. 1996;19: 211-213. (JIF=2.733; No. of cites=16, first author).
3. \***Tse HF**, Lau CP, Leung SK, Leung Z, Mehta N. Single lead DDD system: A comparative evaluation of unipolar, bipolar and overlapping biphasic stimulation and the effects of right atrial floating electrode location on atrial pacing and sensing thresholds. *Pacing Clin Electrophysiol*. 1996; 19: 1758-63. (JIF=1.441; No. of cites=19, first author)
4. \***Tse HF**, Lau CP. Long term effect of right ventricular pacing on myocardial perfusion and function. *J Am Coll Cardiol*. 1997; 29: 744-9. (JIF=16.834; No. of cites= 260, first author)
5. \*Lau CP, **Tse HF**, Lok NS, Lee K, Ho SW, Sopher M, Murgatroyd F, Camm A.J. Initial clinical experience with an implantable human atrial defibrillation. *Pacing Clin Electrophysiol*. 1997; 20: 220-5. (JIF=1.441; No. of cites=63)

6. \*Lau CP, **Tse HF**, Cheng G. Effect of atrioventricular asynchrony on platelet activation: Implication of thromboembolism in paced patients. *Heart*. 1997; 78: 358-63. (JIF=5.42; No. of cites=14).
7. \*Lok NS, Lau CP, **Tse HF**, Ayers GM. Clinical shock tolerability and comparison of different atrial electrode locations on the efficacy of low energy human transvenous atrial defibrillation using an implantable lead system. *J Am Coll Cardiol*.1997; 30: 1324-30. (JIF=16.834; No. of cites=68).
8. **Tse HF**, Lau CP, Cheng G. The relationship between mitral regurgitation and platelet activation. *J Am Coll Cardiol*.1997; 30:1813-8. (JIF=16.834; No. of cites=36, first author)
9. \***Tse HF**, Lau CP, Leung SK. Limitation of long term atrial pacing via floating ring electrode using overlapping biphasic impulse stimulation in ambulatory paced patients. *Am J Cardiol*. 1998, 81: 645-7. (JIF=3.171; No. of cites=3, first author).
10. \*Wellens HJJ, Lau CP, Lüderitz B, Akhtar M, Waldo AL, Camm AJ, Timmermans C, **Tse HF**, Jung W, Jordaens L, Ayers G, for the Metrix Investigators. Atrioverter, an implantable device for the treatment of atrial fibrillation. *Circulation*. 1998; 98: 1651-6. (JIF=18.88; No. of cites=185).
11. \*Leung SK, Lau CP, Lam CTF, **Tse HF**, Tang MO, Chung F, Ayers GM. Programmed atrial sensitivity: a critical determinant in atrial fibrillation detection and optimal automatic mode switching. *Pacing Clin Electrophysiol*. 1998; 11: 2214-9. (JIF=1.441; No. of cites=30).
- 1999
12. \***Tse HF**, Lau CP, Ayers GM. Detection of atrial fibrillation during sinus tachycardia induced by exercise in patients with implantable atrial defibrillators. *Pacing Clin Electrophysiol*. 1999; 22: 247-52. (JIF=1.441; No. of cites=3, first author)
13. \*Lam C, Leung SK, Lau CP, **Tse HF**, Ayers GM. Improved efficacy of mode swtiching during atrial fibrillation using automatic atrial sensitivity adjustment. *Pacing Clin Electrophysiol*. 1999; 22: 17-25. (JIF=1.441; No. of cites=12)
14. \***Tse HF**, Lau CP, Ayers GM. Long term outcome in patients with chronic atrial fibrillation after successful internal cardioversion. *Am J Cardiol*. 1999; 83: 607-9. (JIF=3.171; No. of cites=11, first author)
15. \***Tse HF**, Lau CP, Sra JS, Crijns HJGM, Edvardsson N, Kacet S, Wyse GD. Atrial fibrillation detection and R wave synchronization by Metrix implantable atrial defibrillator: Implication for long term efficacy and safety. *Circulation*. 1999; 99: 1446-51. (JIF=18.88; No. of cites=36, first author)
16. \***Tse HF**, Lau CP, Ayers GM. Heterogeneous changes in electrophsiological behaviour in the paroxysmal and chronically fibrillating human atrium. *J Cardiovasc. Electrophysiol*. 1999, 10:125-35. (JIF=2.873; No. of cites= 40, first author)

17. \*Lau CP, **Tse HF**, Ayers GM. Defibrillation guided radiofrequency ablation of atrial fibrillation secondary to an atrial focus. *J Am Coll Cardiol.* 1999; 33: 1217-26. (JIF=16.834; No. of cites=93)
18. \***Tse HF**, Lau CP, Yomtov BM, Ayers GM. Implantable atrial defibrillator with a single pass dual electrode lead. *J Am Coll Cardiol.* 1999; 33: 1974-80. (JIF=16.834; No. of cites= 5, first author)
19. \*Strickberger SA, Tokano T, **Tse HF**, Kim MH, Oral H, Flemming M, Pelosi F, Michaud GF, Knight BP, Goyal R, Morady F. Target temperatures of 48 degrees C versus 60 degrees C during slow pathway ablation: a randomized comparison. *J Cardiovasc Electrophysiol.* 1999; 10: 799-803. (JIF=2.873; No. of cites=5)
20. \*Oral H, Brinkman K, Pelosi F, Flemming M, **Tse HF**, Kim MH, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Effect of electrode polarity on the energy required for transthoracic atrial defibrillation. *Am J Cardiol.* 1999; 84: 228-30. (JIF=3.171; No. of cites=10)
21. Mok MY, **Tse HF**, Lau CS. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. *Lupus* 1999; 8: 328-31. (JIF=2.969; No. of cites= 14)
22. \***Tse HF**, Lau CP, Ayers GM. The incidence and modes of onset of spontaneous re-initiation of atrial fibrillation following successful internal cardioversion and its prevention by intravenous sotalol. *Heart* 1999; 82: 319-24. (JIF=5.42; No. of cites= 63, first author).
23. \***Tse HF**, Lau CP, Yu CM, Lam TF, Leung SK, Ayers GM. Clinical experience with a single pass dual electrode implantable atrial defibrillator lead for maintaining sinus rhythm in patients with recurrent atrial fibrillation. *Am J Cardiol.* 1999; 84: 606-8. (JIF=3.171; No. of cites=2, first author).
24. \***Tse HF**, Lau CP. Safety and efficacy of internal cardioversion of atrial fibrillation in patients with impaired left ventricular systolic function. *Am J Cardiol.* 1999; 84: 1090-2. (JIF=3.171; No. of cites=6, first author)
25. \***Tse HF**, Lau CP, Yu CM, Lee KLF, Michaud GF, Knight BP, Morady F, Strickberger SA. Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation. *J Cardiovasc Electrophysiol.* 1999;10:1200-9. (JIF=2.873; No. of cites=30, first author).
26. \*Flemming MA, Oral H, Kim KH, **Tse HF**, Pelosi F, Michaud GF, Knight BP, Strickberger AS, Morady F. Electrocardiographic predictors of successful ablation of tachycardia or bigeminy arising in the right ventricular outflow tract. *Am J Cardiol.* 1999; 84: 1266-8. (JIF=3.171; No. of cites=21).
- 2000  
27. \*Man KC, Knight B, **Tse HF**, Pelosi F, Michaud GF, Flemming M, Strickberger SA, Morady F. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. *J Am Coll Cardiol.* 2000; 35: 451-7. (JIF=16.834; No. of cites=67)

28. \***Tse HF**, Lau CP, Kou W, Pelosi F, Oral H, Kim M, Michaud GF, Knight BP, Moscucci M, Strickberger SA, Morady F. Comparison of endocardial activation times at effective and ineffective ablation sites within the pulmonary veins. *J Cardiovasc Electrophysiol.* 2000; 11: 155-9. (JIF=2.873; No. of cites=10, first author).
29. \***Tse HF**, Lau CP, Ayers GM. Atrial fibrillation induction and determination of atrial vulnerable period using very low energy synchronized biatrial shock in normal subjects and in patients with atrial fibrillation. *Pacing Clin Electrophysiol.* 2000; 23: 469-76. (JIF=1.441; No. of cites=1, first author)
30. \***Tse HF**, Lau CP, Kou W, Pelosi F, Flemming M, Oral H, Kim M, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Prevalence and significance of exit block during arrhythmias arising in pulmonary veins. *J Cardiovasc Electrophysiol.* 2000; 11: 379-86. (JIF=2.873; No. of cites= 12, first author).
31. \*Leung SK, Lau CP, Lam CTF, **Tse HF**, Lee K, Chan WK, Leung Z. Is automatic mode switching effective for atrial arrhythmias occurring at different rates? a study on efficacy of automatic mode and rate switching for atrial arrhythmias by chest wall stimulation. *Pacing Clin Electrophysiol.* 2000; 23: 824-31. (JIF=1.441; No. of cites= 6).
32. \***Tse HF**, Lau CP, Ayers GM. Failure of coronary sinus pacing in reducing local atrial conduction delay in patients with atrial fibrillation after successful internal cardioversion. *Pacing Clin Electrophysiol.* 2000; 23: 1014-19. (JIF=1.441; No. of cites= 1, first author)
33. \***Tse HF**, Lau CP, Ayers GM. Atrial pacing for suppression of early re-initiation of atrial fibrillation after successful internal cardioversion. *Eur Heart J.* 2000, 21: 1167-76. (JIF=23.425; No. of cites= 29, first author).
34. \***Tse HF**, Wang Q, Yu CM, Ayers GM, Lau CP. Time course of recovery of left atrial mechanical dysfunction after cardioversion of spontaneous atrial fibrillation with the implantable atrial defibrillator. *Am J Cardiol.* 2000; 86: 1023-5. (JIF=3.171; No. of cites=6, first author).
35. \*Lau CP, Chow MSS, **Tse HF**, Tang MO, Fan C. Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. *Am J Cardiol.* 2000;86:1327-32. (JIF=3.171; No. of cites=6).
36. \*Lam CTF, Lau CP, Leung SK, **Tse HF**, Lee KLF, Tang MO, Tsang V. Efficacy and tolerability of continuous overdrive atrial pacing in atrial fibrillation. *Europace.* 2000; 2: 286-91. (JIF=5.231; No. of cites= 27)
37. \*Lau CP, Yu CM, Chau E, Fan K, **Tse HF**, Lee K, Tang MO, Wan SH, Law TC, Lee PY, Lam YM, Hill MRS. Reverse remodeling of the left ventricle by synchronous biventricular pacing for heart failure. *Pacing Clin Electrophysiol.* 2000; 23:1722-25. (JIF=1.441; No. of cites=57)

38. \*Ho PC, **Tse HF**, Lau CP, Hettrick DA, Mehra R. Effects of different atrioventricular intervals during dual site right atrial pacing on left atrial mechanical function. *Pacing Clin Electrophysiol.* 2000; 23: 1748-51. (JIF=1.441; No. of cites=5, corresponding author)
39. \***Tse HF**, Yu C, Lee KLF, Yu CM, Tsang V, Leung SK, Lau CP. Initial clinical experience with a novel self-retaining left ventricular lead for permanent left ventricular pacing. *Pacing Clin Electrophysiol.* 2000; 23: 1738-40. (JIF=1.441; No. of cites= 14, first author)
40. \*Leung SK, Lau CP, Lam CTF, Ho S, **Tse HF**, Yu CM, Lee K, Tang MO, To KH, Renesto F. Automatic optimization of resting and exercise atrioventricular interval using a peak endocardial acceleration sensor: validation with Doppler echocardiography and direct cardiac measurements. *Pacing Clin Electrophysiol.* 2000; 23: 1762-6. (JIF=1.441; No. of cites=22)
41. \*Leung SK, Lau CP, Lam CTF, **Tse HF**, Tang MO, Chung F, Ayers G. A comparative study on the behavior of three different automatic mode switching dual chamber pacemakers to intracardiac recordings of clinical atrial fibrillation. *Pacing Clin Electrophysiol.* 2000; 23: 2086-96. (JIF=1.441; No. of cites= 3)
- 2001
42. \***Tse HF**, Pelosi F, Flemming M, Oral H, Kim M, Michaud GF, Knight BP, Strickberger SA, Morady F. Effects of simultaneous atrioventricular pacing on atrial refractoriness and atrial fibrillation inducibility: Role of atrial mechano-electrical feedback. *J Cardiovasc Electrophysiol.* 2001; 12: 43-50. (JIF=2.873; No. of cites= 31, first author).
43. \***Tse HF**, Lau CP, Leung SK. A cephalic vein cutdown and venography technique to facilitate pacemaker and defibrillator lead implantation. *Pacing Clin Electrophysiol.* 2001; 24: 507-9. (JIF=1.441; No. of cites=16, first author).
44. \***Tse HF**, Wang Q, Yu CM, Ayers GM, Lau CP. Effect of verapamil on prevention of atrial fibrillation in patients implanted with an implantable atrial defibrillator. *Clin Cardiol.* 2001; 7: 503-6. (JIF=2.733; No. of cites= 5, first author)
45. \***Tse HF**, Lau CP, Lee KLF, Pelosi F, Oral H, Michaud GF, Knight BP, Strickberger SA, Morady F. P wave polarity during pacing in pulmonary veins. *J Interv Card Electrophysiol.* 2001; 5: 167-72. (JIF=1.522; No. of cites=6, first author)
46. \***Tse HF**, Lam YM, Lau CP, Cheung BMY, Kumana CR. A comparison of digoxin versus low dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. *Clin Exp Pharm Physiol.* 2001; 28: 446-50. (JIF=2.092; No. of cites=31, first & corresponding author)
47. \*Yu CM, Wang Q, Lau CP, **Tse HF**, Leung SK, Lee KLF, Tsang V, Ayers G. Reversible impairment of left and right ventricular systolic and diastolic function during short-lasting atrial fibrillation in patients with an implantable atrial defibrillator: A tissue Doppler imaging study. *Pacing Clin Electrophysiol.* 2001; 24: 979-88. (JIF=1.441; No. of cites=36)

48. \***Tse HF**, Lau CP, Wang Q, Pelosi F, Oral H, Knight BP, Strickberger SA, Morady F. Effect of diltiazem on the recurrence rate of paroxysmal atrial fibrillation. *Am J Cardiol.* 2001; 88: 568-70. (JIF=3.171; No. of cites=7, first author)
49. \***Tse HF**, Oral H, Pelosi F, Knight BP, Strickberger SA, Morady F. Effect of gender on atrial electrophysiological changes induced by rapid atrial pacing and elevation of atrial pressure. *J Cardiovasc Electrophysiol.* 2001; 12: 986-9. (JIF=2.873; No. of cites= 16, first author)
50. \*Lau CP, **Tse HF**, Yu CM, Teo WA, Kam R, Ng KS, Huang SSK, Lin JL, Tsang V, Fitts SM, Hettrick DA, Hill MRS. Dual-site pacing for atrial fibrillation in patients without bradycardia. *Am J Cardiol.* 2001; 88: 371-75. (JIF=3.171; No. of cites=48)
51. \*Lau CP, **Tse HF**. Early re-initiation of atrial fibrillation: a new electrophysiology phenomenon. *Pacing Clin Electrophysiol.* 2001; 24: 1581-84. (JIF=1.441; No. of cites= 10)
- 2002
52. Lau CP, **Tse HF**, Ng W, Chan KK, Li SK, Keung KK, Lau YK, Chen WH, Tang YW, Leung SK. Comparison of Peridorpil-vs-Captopril for the treatment of acute myocardial infarction. *Am J Cardiol.* 2002; 89: 150-54. (JIF=3.171; No. of cites=11).
53. \***Tse HF**, Lee KLF, Fan K, Lau CP. Non-fluoroscopic magnetic electroanatomic mapping of to facilitate focal pulmonary veins ablation for paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol.* 2002; 25: 57-61. (JIF=1.441; No. of cites= 7, first & corresponding author)
54. \*Xu WC, **Tse HF**, Chan FHY, Lee KLF, Lau CP, Fung PCW. A new bayesian discriminator for detection of atrial tachyarrhythmias. *Circulation.* 2002; 105: 1472-79. (JIF=18.88; No. of cites=17).
55. \***Tse HF**, Lau CP, Daoud EG, Timmermans C, Rodriguez LM, Ayers GM, Wellens HJJ, for the Metrix Investigators. Effect of underlying structural heart disease on the long term efficacy and safety of the Metrix implantable atrial defibrillator. *Pacing Clin Electrophysiol.* 2002; 25: 809-15. (JIF=1.441; No. of cites= 2, first & corresponding author)
56. \***Tse HF**, Yu C, Wong KK, Tsang V, Leung YL, Ho WY, Lau CP. Functional abnormalities in patients with permanent right ventricular pacing: The effect of sites of electrical stimulation. *J Am Coll Cardiol.* 2002; 40: 1451-58. (JIF=16.834; No. of cites= 239, first & corresponding author)
57. \*Rodriguez LM, Geller JC, **Tse HF**, Timmermans C, Reek S, Lee KLF, Ayers GM, Klein HU, Lau CP, Crijns HJGM. Acute results of transvenous cryoablation of supraventricular tachycardia (Atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). *J Cardiovasc Electrophysiol.* 2002; 13: 1082-89. (JIF=2.873; No. of cites=77)
58. \***Tse HF**, Lau CP. Electrophysiological actions of dl-Sotalol in patients with persistent atrial fibrillation. *J Am Coll Cardiol.* 2002; 40: 2150-55. (JIF=16.834; No. of cites=23, first & corresponding author).

59. \***Tse HF**, Lau CP. Bleeding and thromboembolic risk of internal cardioversion for persistent atrial fibrillation. *Pacing Clin Electrophysiol.* 2002; 25: 1752-55. (JIF=1.486; No. of cites= 3, first & corresponding author)
- 2003
60. #**Tse HF**, Kwong YL, Lo G, Ho CL, Chan JKF, Yeung DW, Lau CP. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. *Lancet.* 2003; 361: 47-9. (JIF=53.254; No. of cites=593, first & corresponding author).
61. \***Tse HF**, Yu C, Park E, Lau CP. Impedance cardiography for atrioventricular interval optimization after permanent left ventricular pacing. *Pacing Clin Electrophysiol.* 2003; 26: 189-91. (JIF=1.441; No. of cites= 21, first & corresponding author).
62. \***Tse HF**, Timmermans C, Rodriguez LM, Lau CP, Wellens HJJ. Effect of coronary sinus electrode on the optimal atrial defibrillation pathway for an atrio-ventricular defibrillator. *J Cardiovasc Electrophysiol.* 2003; 14: 32-7. (JIF=2.873; No. of cites= 11, first & corresponding author).
63. \*Li GR, Du XL, Siow YL, O K, **Tse HF**, Lau CP. Calcium-activated transient outward chloride current and phase 1 repolarization of swine ventricular action potential. *Cardiovasc Res.* 2003; 58: 89-98. (JIF=6.29; No. of cites=39).
64. \*Du XL, Lau CP, Chiu SW, **Tse HF**, Gerlach U, Li GR. Effects of chromanol 293B on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. *J Mol Cell Cardiol.* 2003; 35: 293-300. (JIF=5.296; No. of cites=13)
65. **Tse HF**, Cheung BMY, Ng W, Chan JKF, Devereux RB, Lau CP. Regression of left ventricular hypertrophy after treatment of hypertension: comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes. *J Card Fail.* 2003; 9: 122-7. (JIF=3.942; No. of cites=8, first & corresponding author).
66. \***Tse HF**, Lau CP, Ayers GM. Dose-response relationship for successful internal atrial defibrillation. *Pacing Clin Electrophysiol* 2003; 26: 1249-53. (JIF=1.441; No. of cites= 4, first & corresponding author).
67. Ooi GC, Mok MY, Tsang KWT, Wong Y, Khong PL, Fung PCW, Chan S, **Tse HF**, Wong RWS, Lam WK, Lau CS. Interstitial lung disease in systemic sclerosis. An HRCT-clinical correlative study. *Acta Radiol.* 2003; 44: 258-64. (JIF=1.823; No. of cites=27).
68. \***Tse HF**, Lau CP. Recurrence of atrial fibrillation after pulmonary vein isolation. *J Cardiovasc Electrophysiol.* 2003; 14: 691-2. (JIF=2.873; No. of cites= 1, first & corresponding author).
69. \***Tse HF**, Reek S, Timmermans C, Lee KLF, Geller C, Rodriguez LM, Ghaye B, Ayers GM, Crijns HJGM, Klein HU, Lau CP. Pulmonary vein isolation using transvenous catheter cryoablation for atrial fibrillation without the risk of pulmonary vein stenosis. *J Am Coll Cardiol.* 2003; 42: 752-8. (JIF=16.834; No. of cites=137, first & corresponding author).

70. \***Tse HF**, Yu C, Paul VE, Boriani G, Schuchert A, del Ojo JL, Malinowski K, Blanc JJ, Lau CP. Effect of left ventricular function on long-term left ventricular pacing and sensing threshold. *J Interv Card Electrophysiol*. 2003; 9: 21-4. (JIF=1.522; No. of cites=16, first & corresponding author).
71. \***Tse HF**, Lau CP. Clinical predictors and time course of arrhythmia recurrence in patients with early reinitiation of atrial fibrillation after successful internal cardioversion. *Pacing Clin Electrophysiol*. 2003; 26: 1809-14. (JIF=1.441; No. of cites=3, first & corresponding author)
72. \*Siu CW, Lau CP, **Tse HF**. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. *Am J Cardiol* 2003; 92: 1343-5. (JIF=3.171; No. of cites=201, corresponding author).
73. \*Geller JC, Reek S, Timmermans C, Kayser T, Wolpert C, **Tse HF**, Seidl KH, Lambert H, Jung W, Lau CP, Camm AJ, Wellens HJJ, Klein HU. Treatment of atrial fibrillation with an implantable atrial defibrillator: Long term results. *Eur Heart J*. 2003; 24: 2083-9. (JIF=23.425; No. of cites=20)
- 2004
74. Ho HH, Lee KLF, Lau CP, **Tse HF**. Clinical characteristics and outcome in Chinese patients with hypertrophic cardiomyopathy. *Am J Med*. 2004; 116: 19-23. (JIF=5.117; No. of cites=24, corresponding author).
75. Ip MSM, **Tse HF**, Lam B, Tsang KWT, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. *Am J Respir Crit Care Med*. 2004; 169: 348-53. (JIF=15.239; No. of cites= 396).
76. Chen WH, Lee PY, Mg W, **Tse HF**, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. *J Am Coll Cardiol*. 2004; 43: 1122-26. (JIF=16.834; No. of cites=356).
77. \*Du XL, Gao Z, Lau CP, Chiu SW, **Tse HF**, Baumgarten CM, Li GR. Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases. *J Gen Physiol*. 2004; 123: 427-39. (JIF=3.68; No. of cites=56)
78. \*Li GR, Sun H, To J, **Tse HF**, Lau CP. Demonstration of calcium-activated transient outward chloride current and delayed rectifier potassium currents in swine atrial myocytes. *J Mol Cell Cardiol*. 2004; 36: 495-504. (JIF=5.296; No. of cites=21).
79. \***Tse HF**, Newman D, Ellenbogen KA, Buhr T, Markowitz T, Lau CP. Effects of ventricular rate regularization pacing on quality of life and symptoms in patients with atrial fibrillation: Atrial Fibrillation Symptoms Mediated by Pacing to Mean Rates (AF SYMPTOMS Study). *Am J Cardiol*. 2004; 94: 938-41. (JIF=3.171; No. of cites=25, first author).
- 2005
80. \*Knight BP, Gersh BJ, Carlson MD, Friedman PA, McNamara RL, Strickberger SA, **Tse HF**, Waldo AL. American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias); Quality of Care and



- Outcomes Research Interdisciplinary Working Group; Heart Rhythm Society; AHA Writing Group. Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. *Circulation*. 2005; 111: 240-3. (JIF=18.88; No. of cites=56).
81. \*Siu CW, Tung HM, Chu KW, Jim MH, Lau CP, **Tse HF**. Prevalence and clinical predictors for new-onset postoperative atrial fibrillation after elective abdominal surgery for colorectal cancer. *Pacing Clin Electrophysiol*. 2005; 28: S120-3. (JIF=1.441; No. of cites=15, corresponding author)
  82. \***Tse HF**, Siu CW, Tsang V, Yu C, Park E, Bornzin GA, Benser ME, Lau CP. Blood pressure response to transition from supine to standing posture using an orthostatic response algorithm. *Pacing Clin Electrophysiol*. 2005; 28: S242-5. (JIF=1.441; No. of cites=5, first & corresponding author).
  83. \***Tse HF**, Lau CP. Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. *Heart*. 2005; 91: 362-4. (JIF=5.42; No. of cites=18, first & corresponding author).
  84. \***Tse HF**, Ripley KL, Lee KLF, Siu CW, Van Vleet JV, Pelkey WL, Lau CP. Effects of temporal application parameters on lesion dimensions during transvenous catheter cryoablation. *J Cardiovasc Electrophysiol*. 2005; 16: 201-4. (JIF=2.873; No. of cites= 31, first & corresponding author).
  85. \***Tse HF**, Sin PY, Siu CW, Tsang V, Lam CLK, Lau CP. Successful pulmonary vein isolation using transvenous catheter cryoablation improves quality-of-life in patients with atrial fibrillation. *Pacing Clin Electrophysiol*. 2005; 28: 421-4. (JIF=1.441; No. of cites=11, first & corresponding author).
  86. Lee PY, Chen WH, Ng W, Cheng X, Kwong JY, **Tse HF**, Lau CP. Low-dose aspirin increase aspirin resistance in patients with coronary artery disease. *Am J Med*. 2005; 118: 723-7. (JIF=5.117; No. of cites=136).
  87. #Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang J, Li KM, Chan JD, Pei D, Pendas A, Lopez-Otin C, **Tse HF**, Hutchison C, Chen J, Cao Y, Cheah KSE, Tryggvason K, Zhou Z. Genomic instability in laminopathy-based premature aging. *Nat Med*. 2005; 11: 780-85. (JIF=32.621; No. of cites=351).
  88. \***Tse HF**, Lee KLF, Wan SH, Yu Y, Walter H, Pastore J, Zhu Q, Kenknight B, Spinelli J, Lau CP. Area of left ventricular regional conduction delay and preserved myocardium predict responses to cardiac resynchronization therapy. *J Cardiovasc Electrophysiol*. 2005; 16: 690-5. (JIF=2.873; No. of cites= 22, first & corresponding author).
  89. #Wang K, Xue T, Tsang SY, Huizen RV, Wong CW, Lai KW, Ye Z, Cheng L, Au KW, Zhang J, Li GR, Lau CP, **Tse HF**, Li RA. Electrophysiological properties of pluripotent human and mouse embryonic stem cells. *Stem Cells*. 2005; 23: 1526-34. (JIF=5.587; No. of cites=61, co-corresponding author).

90. Chen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, **Tse HF**, Lau CP. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. *Am J Cardiol*. 2005; 96: 760-3. (JIF=3.171; No. of cites=34).
91. Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, Lee MK, Li SK, Ng W, Lee PY, Lam KF, **Tse HF**, Lau CP. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. *J Invasive Cardiol*. 2005;17: 534-8. (JIF=1.112; No. of cites= 0).
92. Hu R, Zhang XX, Wang WQ, Lau CP, **Tse HF**. Smoking, homocysteine and degree of arteriolar retinopathy. *Atherosclerosis*. 2005; 183: 95-100. (JIF=4.467; No. of cites= 9, corresponding author).
93. \***Tse HF**, Kwong YL, Lau CP. Transvenous cryoablation reduces platelet activation during pulmonary vein ablation compared with radiofrequency energy in patients with atrial fibrillation. *J Cardiovasc Electrophysiol*. 2005; 16:1064-70. (JIF=2.873; No. of cites= 19, first & corresponding author).
94. \***Tse HF**, Siu CW, Lee KLF, Fan K, Chan HW, Tang MO, Tsang V, Lee SWL, Lau CP. The incremental benefit of rate-adaptive pacing on exercise performance during cardiac resynchronization therapy. *J Am Coll Cardiol*. 2005; 46: 2292-97. (JIF=16.834; No. of cites= 44, first & corresponding author)
- 2006
95. Lau EO, **Tse HF**, Chan RH, Lee PY, Lee SW, Chwang AT, Lau CP. Prediction of aortic augmentation index using radial pulse transmission-wave analysis. *J Hypertens*. 2006; 24: 723-30. (JIF=4.092; No. of cites= 5).
96. \***Tse HF**, Hettrick DA, Mehra R, Lau CP. Improved atrial mechanical efficiency during alternate and multiple site atrial pacing: Implications for selective site pacing to prevent atrial fibrillation. *J Am Coll Cardiol*. 2006; 47: 209-12. (JIF=16.834; No. of cites= 7, first & corresponding author).
97. Yiu KH, Siu CW, Jim MH, **Tse HF**, Fan K, Chau MC, Chow WH. Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin related over-anticoagulation in patients with mechanical heart valves. *Am J Cardiol*. 2006; 97; 409-411. (JIF=3.171; No. of cites=27).
98. Lam JCM, Lam B, Lam CL, Fong D, Wang JKL, **Tse HF**, Lam KSL, Ip MSM. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese Adults in Hong Kong. *Resp Med*. 2006; 100: 980-87. (JIF=3.23; No. of cites=99).
99. #Zhang Q, Ge JB, Chen JZ, Zhu JH, Zhang LH, Lau CP, **Tse HF**. Mast cell contributes to cardiomyocyte apoptosis after coronary microembolization. *J Histochem Cytochem*. 2006; 54: 515-23. (JIF=2.816; No. of cites=17, corresponding author).

100. \*Wang SL, Ooi CGC, Siu CW, Yiu MWC, Pang CBY, Lau CP, **Tse HF**. Endocardial visualization of esophageal-left atrial anatomic relationship by three-dimensional multidetector computer tomographic “navigator imaging”. *Pacing Clin Electrophysiol.* 2006; 29: 502-8. (JIF=1.441; No. of cites=12, corresponding author).
101. Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, **Tse HF**. Effects of oral arsenic trioxide therapy on QT intervals: implications on long-term cardiac safety. *Blood.* 2006; 108: 103-6. (JIF=15.132; No. of cites=38, corresponding author).
102. <sup>#</sup>**Tse HF**, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Bastian B, Chen WH, Chan JFK, Lo G, Ho CL, Lau CP. Safety of catheter-based intramyocardial autologous bone marrow cells implantation for therapeutic angiogenesis. *Am J Cardiol.* 2006;98:60-2. (JIF=3.171; No. of cites=39, corresponding author).
103. <sup>#</sup>Li GR, Deng XL, Sun H, Chung SSM, **Tse HF**, Lau CP. Ion channels in mesenchymal stem cells from rat bone marrow. *Stem Cells.* 2006; 24: 1519-28. (JIF=5.587; No. of cites=56).
104. Ng W, Wong WM, Chen WH, **Tse HF**, Lee PY, Lai KC, Li SW, Ng M, Lam KF, Cheng X, Lau CP. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. *World J Gastroenterol.* 2006; 12: 2923-27. (JIF=3.30; No. of cites=30).
105. 117.\***Tse HF**, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, Tomaselli GF, Akar FG, Li RA. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN channel reduces the dependence on electronic pacemaker in a sick sinus syndrome model. *Circulation.* 2006; 114: 1000-11. (JIF=18.88; No. of cites=97, first author)
106. \*Yiu KH, Lau CP, Lee K, **Tse HF**. Emerging energy sources for catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol.* 2006; 17: S56-61. (JIF=2.873; No. of cites=4, corresponding author).
- 2007
107. \*Siu CW, **Tse HF**, Lee K, Chan HW, Chen WH, Yung C, Lee S, Lau CP. Cardiac resynchronization therapy optimization by ultrasonic cardiac output monitoring (USCOM) device. *Pacing Clin Electrophysiol.* 2007; 30: 50-55. (JIF=1.441; No. of cites=11).
108. \***Tse HF**, Lau CP, Park E, Bornzin GA, Yu C, Benser M, Bloomfield DM, Padeletti L. Transient overdrive pacing upon standing prevents orthostatic hypotension in elderly pacemaker patients with chronotropic incompetence. *Pacing Clin Electrophysiol.* 2007; 30:188-92. (JIF=1.441; No. of cites=3, first and corresponding author).
109. \*White HD, Gruber M, Kaatz S, Cunha L, **Tse HF**, Husted S, Jerábek O, Rasmussen LH, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med.* 2007; 167: 239-45. (JIF=17.333; No. of cites=369).

110. Siu CW, Yeung CY, Lau CP, Kung AWC, **Tse HF**. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. *Heart*. 2007; 93: 483-7. (JIF= 5.42, No. of cites=81, corresponding author)
111. #Xue T, Siu CW, Lieu DK, Lau CP, **Tse HF**, Li RA. Mechanistic role of I<sub>f</sub> revealed by induction of ventricular automaticity by somatic gene transfer of gating-engineered pacemaker (HCN) channels. *Circulation*. 2007; 115:1839-50. (JIF=18.88; No. of cites=28).
112. Ho HH, Jim MH, Siu CW, Miu KM, Chan HW, Lee WL, Lau CP, **Tse HF**. Leukocytosis and clinical outcomes in acute inferior myocardial infarction. *Int J Cardiol. Int J Cardiol*. 2007;118:278-9. (JIF= 4.034, No. of cites=3).
113. Hu R, Siu CW, Wang WQ, Lau EOY, Lau CP, **Tse HF**. Impaired nitrate-mediated dilatation could reflect nitrate tolerance in patients with coronary artery disease. *Int J Cardiol*. 2007;120:351-6. (JIF= 4.034, No. of cites=10, corresponding author).
114. Yiu KH, Siu CW, Lee KLF, Lau CP, Lee S, Fong YT, **Tse HF**. Emerging trends of community acquired infective endocarditis. *Int J Cardiol* 2007; 121:119-22. (JIF= 4.034, No. of cites=13, corresponding author).
115. \*Siu CW, Jim MH, Ho HH, Miu R, Lee SWL, Lau CP, **Tse HF**. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications on future risk for ischemic stroke. *Chest*. 2007; 132: 44-49. (JIF= 7.652, No. of cites=59, corresponding author).
116. Siu CW, Zhang X, Yung C, Kung AWC, Lau CP, **Tse HF**. Hemodynamic changes in hyperthyroidism related pulmonary hypertension: a prospective echocardiographic study. *J Clin Endocr Metab*. 2007;92:1736-1742. (JIF= 5.789, No. of cites=59, corresponding author).
117. #Lau KK, Chan YH, Yiu KH, Li SW, Tam S, Lau CP, Kwong YL, **Tse HF**. Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. *J Hum Hypertens*. 2007; 21:445-51. (JIF= 2.433, No. of cites=60, corresponding author).
118. \*Lee KL, Burnes JE, Mullen TJ, Hettrick DA, **Tse HF**, Lau CP. Avoidance of right ventricular pacing in cardiac resynchronization therapy improves right ventricular hemodynamics in heart failure patients. *J Cardiovas Electrophysiol* 2007;18:497-504. (JIF= 2.873, No. of cites=33)
119. \*Ripley KL, Gage AA, Olsen DB, Van Vleet JF, Lau CP, **Tse HF**. Time course of esophageal lesions and ulceration after catheter ablation with cryotheraml and radiofrequency ablation: Implication on atrio-esophageal fistula formation after catheter ablation for atrial fibrillation. *J Cardiovasc Electrophysiol* 2007; 18: 642-646. (JIF= 2.873, No. of cites=51, corresponding author).

120. #**Tse HF**, Siu CW, Zhu SG, Liao S, Zhang QY, Lai WH, Kwong YL, Nicholls J, Lau CP. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells for enhancement of neovascularization in chronic ischemic myocardium. *Eur J Heart Fail.* 2007;9:747-53. (JIF= 10.683, No. of cites=74, first and corresponding author).
121. \*Lee KL, Lau CP, **Tse HF**, Echt DS, Heaven D, Smith W, Hood M. First human demonstration of cardiac stimulation with transcutaneous ultrasound energy delivery: Implications for wireless pacing with implantable devices. *J Am Coll Cardiol* 2007;50: 877-83. (JIF=16.834, No. of cites=45)
122. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, **Tse HF**, Lau CP. Aspirin resistance and adverse clinical events in patients with coronary artery disease. *Am J Med.* 2007;120:631-5. (JIF=5.117; No. of cites=114).
123. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, Shu XO, Lau CP, **Tse HF**. Dietary isoflavane intake in high risk patients for cardiovascular events: implications on vascular endothelial function and carotid atherosclerotic burden. *Am J Clin Nutr.* 2007;86:938-45. (JIF=6.549; No. of cites=43, corresponding author).
124. Tan KCB, Chow WS, Tso AWK, Xu A, **Tse HF**, Hoo RLC, Betteridge DJ, Lam KSL. Thiazolidinedione increases serum soluble receptor for advanced glycation end products in type 2 diabetes. *Diabetologia* 2007;50:1819-1825.(JIF=6.023; No. of cites=55).
125. #**Tse HF**, Kwong YL, Chan JKF, Lo G, Ho CL, Parker A, Hauser T, Lau CP. Comparative evaluation of long-term clinical efficacy with catheter-based percutaneous intramyocardial autologous bone marrow cells implantation versus laser myocardial revascularization in patients with severe coronary artery disease. *Am Heart J.* 2007;154:982.e1-6. (JIF=4.171; No. of cites=4; first & corresponding author).
126. #Lee MYK, **Tse HF**, Siu CW, Zhu S, Man RYK, Vanhoutte PM. Genomic and proteomic changes in regenerated porcine coronary artery endothelial cells. *Arterioscler Thromb Vasc Biol.* 2007;27:2443-9. (JIF=6.086; No. of cites=37)
127. #Tao R, Lau CP, **Tse HF**, Li GR. Functional ion channels in mouse bone marrow mesenchymal stem cells. *Am J Physiol Cell Physiol.* 2007; 293: C1561-C1567. (JIF=3.454; No. of cites=31).
128. Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, **Tse HF**, Fong CH, Tam S, Chan L, Lam KS. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. *Arterioscler Thromb Vasc Biol.* 2007;27:2777-82. (JIF=6.086; No. of cites=26)
129. #Wu EX, Wu Y, Nicholls JM, Wang J, Liao S, Zhu S, Lau CP, Tse HF. MR diffusion tensor imaging study of postinfarct myocardium structural remodeling in a porcine model. *Magn Reson Med.* 2007;58:687-95. (JIF=4.082, No. of cites=78).
130. \*de Voogt W, Van Hemel N, de Vusser P, Mairesse G, van Mechelen R, Koistinen J, van den Bos A, Roose I, Voitek J, Yli-Mayry S, Stockman D, Allaf DE, **Tse HF**, Lau

- CP. No evidence of automatic atrial overdrive pacing efficacy on reduction of paroxysmal atrial fibrillation. *Europace*. 2007;9:798-804. (JIF=5.231, No. of cites=19).
131. #Wu EX, Wu Y, Tang H, Wang J, Yang J, Ng MC, Yang ES, Chan CW, Zhu S, Lau CP, **Tse HF**. Study of myocardial fiber pathway using magnetic resonance diffusion tensor imaging. *J Magn Reson Imaging* 2007; 25:1048-57. (JIF= 2.564, No. of cites=37).
132. #**Tse HF**, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Thomas P, Bastian B, Chan JFK, Lo G, Ho CL, Chan WS, Kwong RY, Parker A, Hauser T, Chan J, Fong YT, Lau CP. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). *Eur Heart J*. 2007; 28: 2998-3005. (JIF=23.425; No. of cites=116, first and corresponding author).
- 2008
133. Mok MY, Fung CW, Ooi GC, **Tse HF**, Wong Y, Lam TM, Wong R, Lau CS. Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. *Clin Rheumatol*. 2008;27:315-22. (JIF= 2.141, No. of cites=9).
134. #Shantsila E, Watson T, **Tse HF**, Lip GY. New insights on endothelial progenitor cell subpopulations and their angiogenic properties. *J Am Coll Cardiol* 2008;51:669-71.(JIF=16.834, No. of cites=64).
135. \*Zhang XH, Chan H, Siu CW, Lee KLF, Chan HW, Lee SWL, Fu GS, Lau CP, **Tse HF**. Prevalence and clinical predictors for new-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block. *J Cardiovas Electrophysiol* 2008;19:136-41. (JIF=2.873, No. of cites= 117, corresponding author).
136. #Au KW, Siu CW, Lau CP, **Tse HF**, Li RA. Structural and functional determinants in the S5-P region of HCN-encoded pacemaker channels revealed by cysteine-scanning substitutions. *Am J Physiol Cell Physiol*. 2008;294:C136-44. (JIF=3.454; No. of cites=7).
137. #Wong KK, Yang ES, Wu EX, **Tse HF**, Wong ST. First-pass myocardial perfusion image registration by maximization of normalized mutual information. *J Magn Reson Imaging*. 2008 Mar; 27; 529-37. (JIF=3.612, No. of cites=13).
138. Lau KK, Chan YH, Yiu KH, Tam S, Li SW, LJ Mau CP, **Tse HF**. Incremental predictive value of vascular assessments with Framingham risk score for prediction of coronary events in low-intermediate risk subjects. *Postgrad Med J* 2008;84:153-7. (JIF= 2.078, No. of cites=19, corresponding author).
139. \*Lim HS, Lip GY, Tse HF. Implantable cardioverter defibrillator following acute myocardial infarction: the '48-hour' and '40-day' rule. *Europace*. 2008;10:536-9. (JIF=5.231, No. of cites=1).
140. \*Li GR, Qin GW, Wang HB, Jin MW, Qiang T, Deng XL, Du XL, Sun HY, Zhang XH, Chen JB, Cheng LC, Chiu SW, **Tse HF**, Lau CP. The natural flavone acacetin

selectively inhibits atrial repolarization potassium currents and prevents atrial fibrillation. *Circulation*; 2008;117; 2449-57 (JIF=18.88; No. of cites=61).

141. #Moore JC, Fu J, Chan YC, Lin D, Tran H, Tse HF, Li RA. Distinct cardiogenic preferences of two human embryonic stem cell (hESC) lines are imprinted in their proteomes in the pluripotent state. *Biochem Biophys Res Commun*. 2008; 372:553-8 (JIF=2.559; No. of cites=58).
142. Hu R, Wang WQ, Lau CP, Tse HF. Gender differences on brachial flow mediated dilation and carotid intima-media thickness for prediction of spontaneous cardiovascular events. *Clin Cardiol*. 2008;31:525-530. (JIF=2.733, No. of cites=20, corresponding author).
143. #Lieu DK, Chan YC, Lau CP, Tse HF, Siu CW, Li R. Over-expression of HCN-encoded pacemaker current silences bio-artificial pacemaker. *Heart Rhythm* 2008;5:1310-7. (JIF= 4.743, No. of cites=22)
144. Cheung BM, Wat MS, Tso AW, Tam S, Thomas GN, Leung GM, Tse HF, Woo J, Janus ED, Lau CP, Lam TH, Lam KS. Association between raised blood pressure and dysglycemia in Hong Kong Chinese. *Diab Care* 2008;31:1889-91. (JIF= 13.397, No. of cites=28).
145. \*Tang Q, Li ZQ, Li W, Gou J, Sun HY, Zhang XH, Lau CP, Tse HF, Zhang S, Li GR. The 5-HT<sub>2</sub> antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go related gene (hERG) potassium channels. *Brit J Pharmacol* 2008;155:365-73. (JIF= 6.841, No. of cites=15).
146. #Zhang DY, Lau CP, Wang Y, Tse HF, Li GR. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go related gene potassium channels. *Cell Signal*. 2008;20:1815-1821 (JIF= 3.487, No. of cites=39).
147. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Fong YT, Tam S, Lau CP, Tse HF. Reduction of C-Reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. *Eur Heart J* 2008;29:2800-2807. (JIF=23.425; No. of cites=55, corresponding author).
148. \*Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. *Ann Med*. 2008;40:428-36. (JIF=3.007; No. of cites=95).
149. #Moore JC, Tsang SY, Rushing SN, Lin D, Tse HF, Chan CW, Li RA. Functional consequences of overexpressing the gap junction Cx43 in the cardiogenic potential of pluripotent human embryonic stem cells. *Biochem Biophys Res Commun*. 2008;377:46-51. (JIF=2.559; No. of cites=15).

150. #Tao R, Lau CP, **Tse HF**, Li GR. Regulation of cell proliferation by intermediate-conductance Ca<sup>2+</sup>-activated potassium and volume-sensitive chloride channels in mouse mesenchymal stem cells. *Am J Physiol Cell Physiol*. 2008;295:1409-16. (JIF=3.454; No. of cites=63).
151. #Wong CY, Qiuwaxi J, Chen H, Li SW, Chan HT, Tam S, Shu XO, Lau CP, **Tse HF**. Daily intake of thiamine correlates with the circulating level of endothelial progenitor cells in patients with type II diabetes. *Mol Nutr Food Res* 2008;52:1421-7.(JIF= 5.151, No. of cites=18, corresponding author).
152. #Hu H, He ML, Tao R, Sun HY, Hu R, Zang WJ, Yuan BX, Lau CP, **Tse HF**, Li GR. Characterization of ion channels in human preadipocytes. *J Cell Physiol*. 2008;218:427-435. (JIF= 3.923, No. of cites=25).
153. \*Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, **Tse HF**, Lau CP. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K<sup>+</sup> currents and Na<sup>+</sup> current in human atrial myocytes. *Cardiovas Res* 2008;81:286-93 (JIF=6.29, No. of cites=76).
154. \*Yiu KH, Lau CP, Lee KL, Miu KM, Siu CW, Lam B, Lam J, Ip MS, **Tse HF**. Alleviation of pulmonary hypertension by cardiac resynchronization therapy improves central sleep apnea in patients with heart failure. *Pacing Clin Electrophysiol*; 2008;31:1522-7 (JIF=1.441; No. of cites=16)
155. Erdine S, Ro YM, **Tse HF**, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM; Gemini-AALA Investigators. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity to attain recommended goals for blood pressure and lipids (The Gemini-AALA study). *J Hum Hypertens*. 2009;23:196-210. (JIF= 2.433, No. of cites=22).
156. \*Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, Shea YF, Lee WL, Fan K, **Tse HF**, Chow WH. Amiodarone induced thyrotoxicosis is an predictor of adverse cardiovascular outcome. *J Clin Endocr Metab*. 2009;94:109-14. (JIF= 5.789, No. of cites=28).
157. #Au KW, Liao SY, Lee YK, Lai WH, Ng MK, Chan YC, Yip MC, Ho CY, Wu EX, Li RA, Siu CW, **Tse HF**. Effects of iron oxide nanoparticles on cardiac differentiation of embryonic stem cells *Biochem Biophys Res Commun*. 2009;379:898-903. (JIF=2.559; No. of cites=52, corresponding author)
158. #Wu Y, Chan CW, Nicholls JM, Liao S, **Tse HF**, Wu EX. MR study of the effect of infarct size and location on left ventricular functional and structural remodeling in porcine models. *J Magn Reson Imaging*. 2009;29:305-312. (JIF=3.612; No. of cites=31).
159. \*Siu CW, Jim MH, Zhang X, Chan YH, Pong V, Kwok J, Kung AW, Lau CP, **Tse HF**. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced vs non-hyperthyroidism-induced atrial fibrillation. *Am J Cardiol*. 2009;103:540-3. (JIF=3.171; No. of cites=22, corresponding author).



160. \*Siu CW, Zhang X, Jim MH, Chan YH, Kwok J, Kung AW, Lau CP, **Tse HF**. Risk of ischemic stroke following new onset atrial fibrillation in patients with hyperthyroidism. *Heart Rhythm* 2009;6:169-73. (JIF= 4.743, No. of cites=31, corresponding author).
161. \*Lim HE, **Tse HF**, Pak HN, Kim YH. Catheter ablation of atrial fibrillation via superior approach in patients with interruption of the inferior vena cava. *Heart Rhythm*. 2009; 6:174-9. (JIF= 4.743, No. of cites=19).
162. \***Tse HF**, Liao S, Siu CW, Liu Y, Zhu SG, Nicholls J, Leung G, Ormsby T, Feld GK, Lau CP. Determinants of lesion dimensions during transcatheter microwave ablation. *Pacing Clin Electrophysiol*. 2009; 32: 201-8. (JIF=1.441; No. of cites=4, first and corresponding authors).
163. \*Siu CW, Lau CP, Lam KF, **Tse HF**. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation *Crit Care Med* 2009;37:2174-9 (JIF=6.63; No. of cites=39, corresponding author).
164. \***Tse HF**, Wong KK, Siu CW, Tang MO, Tsang V, Ho WY, Lau CP. Ventricular rate regularization by right ventricular septal pacing preserves left ventricular function and improves exercise capacity in patients with permanent atrial fibrillation. *Europace* 2009;11:594-600. (JIF=5.231, No. of cites=6, first and corresponding author).
165. \*Lee KL, **Tse HF**, Echt DS, Lau CP. Temporary leadless pacing in heart failure patients with ultrasound mediated stimulation energy and effects on the acoustic window. *Heart Rhythm* 2009;6:742-8. (JIF= 4.743, No. of cites=24).
166. #Hu R, He M, Hu H, Yuan BX, Zang WJ, Lau CP, **Tse HF**, Li GR, Characterization of calcium signaling pathways in human preadipocytes. *J Cell Physiol*. 2009;220:765-770. (JIF=3.923; No. of cites=26).
167. \*Xu D, Yang B, Shan Q, Zou J, Chen M, Chen C, Hou X, Zhang F, Li W, Cao K, **Tse HF**. Initial clinical experience of remote magnetic navigation system for catheter mapping and ablation of supraventricular tachycardias. *J Interv Card Electrophysiol* 2009;25:171-4. (JIF=1.522; No. of cites=18, \*corresponding author).
168. #Chan YH, Siu CW, Lau VY, Lau CP, Li RA, **Tse HF**. Synergistic effects of inward rectifier ( $I_{K1}$ ) and pacemaker ( $I_f$ ) currents on the induction of bioengineered cardiac automaticity. *J Cardiovas Electrophysiol* 2009;20:1048-54. (JIF= 2.873, No. of cites=22, corresponding author).
169. \***Tse HF**, Zhang XH, Siu CW, Wang M, Kaiser DR, Lau CP. Upgrading of pacemaker patients with right ventricular apical pacing to right ventricular septal pacing improves left ventricular performance and functional capacity. *J Cardiovas Electrophysiol*. 2009;20:901-5 (JIF= 2.873, No. of cites=16, first and corresponding author).

170. Wang S, Yiu KH, Mok MY, Ooi GC, Khong PL, Mak KF, Lau CS, **Tse HF**. Lo of calcification over thoracic aorta, coronary and carotid arteries in patients with rheumatoid arthritis. *J Intern Med*. 2009;266:445-52 (*JIF*=6.754, *No. of cites*=44, corresponding author).
171. \*Lau CP, Wang CC, Ngarmukos T, Kim YH, Kong CW, Sriratanasathavorn C, Munawar H, Kam R, Lau EO, **Tse HF**. A prospective randomized study to assess the efficacy of rate and site of atrial pacing on long-term development of atrial fibrillation. *J Cardiovas Electrophysiol*. 2009;20:1020-5. (*JIF*= 2.873, *No. of cites*=9).
172. #Lieu DK, Liu J, Siu CW, McNERNEY GP, Abu-Khalil A, Huser T, **Tse HF**, Li RA. Absence of transverse tubules contributes to non-uniform Ca<sup>2+</sup> wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. *Stem Cell Dev* 2009;18:1493-500. (*JIF*= 3.315, *No. of cites*=83).
173. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, KF Henry Ma, Lam KF, Lau CS, **Tse HF**. Pattern of arterial calcification in patients with systemic lupus erythematosus. *J Rheumatol*. 2009;36:2212-7. (*JIF*= 3.47, *No. of cites*=30, corresponding author).
174. #Luk TH, Dai YL, Siu CW, Yiu KH, Chan HT, Lee SWL, Li SW, Tam S, Lau CP, **Tse HF**. Habitual physical activity improves endothelial function and endothelial progenitor cells in coronary artery disease patients. *Eur J Cardiovasc Prev Rehabil*. 2009;16:464-71 (*JIF*= 3.691, *No. of cites*=32, corresponding author).
175. #Liu J, Lieu DK, Siu CW, Fu J, **Tse HF**, Li RA. Facilitated maturation of Ca<sup>2+</sup> handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression. *Am J Physiol Cell Physiol*. 2009;297:C152-9. (*JIF*=3.454; *No. of cites*=62).
176. #Siu CW, Azene EM, Au KW, Lau CP, **Tse HF**, Li RA. State-dependent accessibility of the P-S6 linker of pacemaker (HCN) channels supports a dynamic pore-to-gate coupling model. *J Membr Biol*. 2009;230:35-47. (*JIF*=1.638; *No. of cites*=1).
177. \*Wang M, Zhang X, Lau CP, Lee K, Siu CW, **Tse HF**. Differential in inter-atrial dyssynchrony and atrial mechanical function in sick sinus syndrome with or without paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol*. 2009;20:1237-43 (*JIF*= 2.873, *No. of cites*=7, corresponding author).
178. #Li X, **Tse HF**, Yiu KH, Jia N, Chen H, Li LSW, Jin LJ. Increased levels of circulating endothelial progenitor cells in subjects with moderate to severe periodontitis. *J Clin Periodontol* 2009;36:933-9. (*JIF*= 4.046, *No. of cites*=24).
179. \*Zhang F, Chen M, Yang B, Shan Q, Zou J, Jian Y, Chen H, Lau CP, Cao K, **Tse HF**. Electrocardiographic algorithm to identify the optimal target ablation site for idiopathic right ventricular outflow tract premature ventricular contraction. *Europace* 2009;11:1214-20 (*JIF*=5.231, *No. of cites*=40, corresponding author).

180. #Li GR, Sun HY, Chen JB, Zhou Y, **Tse HF**, Lau CP. Characterization of multiple ion channels in cultured human cardiac fibroblasts. *PLoS ONE* 2009;4:e7307. (JIF=2.766, No. of cites=64).
181. #Chen JB, Tao R, Sun HY, **Tse HF**, Lau CP, Li GR. Multiple Ca(2+) signaling pathways regulate intracellular Ca(2+) activity in human cardiac fibroblasts. *J Cell Physiol.* 2009;223:68-75. (JIF=3.923; No. of cites=26).
182. \***Tse HF**, Siu CW, Lau CP. Impact of right ventricular pacing sites on exercise capacity during ventricular rate regularization in patients with permanent atrial fibrillation. *Pacing Clin Electrophysiol.* 2009;32:1536-42. (JIF=1.441; No. of cites=1, first and corresponding authors).
183. Jim MH, Chan AO, Tse HF, Lau CP. Predictors of inhospital outcome after acute inferior wall myocardial infarction. *Singapore Med J.* 2009;50:956-61 (JIF=1.081; No. of cites=4)
- 2010
184. #Chan YC, Wang K, Lau CP, **Tse HF**, Li RA. Probing the bradycardic drug binding receptor of HCN-encoded pacemaker channels. *Pflugers Arch.* 2010;459:25-38 (JIF=2.765; No. of cites=9).
185. Li M, Ong KL, Wong LY, **Tse HF**, Cheung B. Utilization of lipid lowering medications among adults in the United States 1999-2006. *Atherosclerosis* 2010;208:456-460. (JIF= 4.467, No. of cites=25).
186. #Chan WS, Kwong YL, Kwong RY, Lau CP, **Tse HF**. Therapeutic angiogenesis with direct endomyocardial implantation of autologous bone marrow cells in patients with severe coronary artery diseases: Insight from cardiac magnetic resonance imaging. *J Cardiovasc Magn Reson.* 2010;12:6. (JIF= 5.457, No. of cites=9, corresponding author).
187. #Siu CW, Watson T, Lai WH, Lee YK, Chan YH, Ng KM, Lau CP, Lip GY, **Tse HF**. Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation after successful conversion and maintenance of sinus rhythm. *Europace.* 2010;12:517-21.(JIF=5.231, No. of cites=10, corresponding author).
188. #Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak HA, Lau CP, Lau CS, **Tse HF**. Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. *J Rheumatol.* 2010;37:529-35. (JIF= 3.47, No. of cites=20, corresponding author).
189. \*Siu CW, Pong V, Lam KB, Li SW, Lau CP, **Tse HF**. Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function. *Pacing Clin Electrophysiol.* 2010;33:675-80. (JIF=1.441; No. of cites=9, corresponding authors).
190. Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, **Tse HF**. Fish-oil supplement has neutral effects on vascular and metabolic functions but improves renal functions in

patients with type 2 diabetes mellitus. *Diabetic Med* 2010;27:54-60 (JIF= 3.132, No. of cites=39, corresponding author).

191. #Ng KM, Lee YK, Lai WH, Fung ML, Siu CW, Li RA, **Tse HF**. Exogenous expression of HIF-1 $\alpha$  promotes cardiac differentiation of embryonic stem cells. *J Moll Cell Cardiol* 2010;48:1129-37. (JIF= 5.296; No. of cites=29, corresponding authors).
192. #Dong MQ, Sun HY, Tang Q, **Tse HF**, Lau CP, Li GR. Regulation of human cardiac KCNQ1/KCNE1 channel by epidermal growth factor receptor kinase. *Biochim Biophys Acta*. 2010;1798:995-1001. (JIF= 3.438, No. of cites=18).
193. #Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FY, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, **Tse HF**. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. *Circulation* 2010;121:1113-23. (JIF=18.88; No. of cites=241, corresponding author).
194. \*Jim MH, Chan AO, **Tse HF**, Barold SS, Lau CP. Clinical and Angiographic findings of complete atrioventricular block in acute inferior myocardial infarction. *Ann Acad Med Singap*. 2010;39:185-90. (JIF= 0.819, No. of cites=10).
195. #Liao SY, Siu CW, Liu Y, Zhang Y, Chan WS, Wu EX, Wu Y, Nicholls JM, Li R, Benser M, Stuart R, Park E, Lau CP, **Tse HF**. Attenuation of left ventricular remodelling with passive epicardial patch in porcine model of chronic myocardial infarction. *J Cardiac Fail* 2010;16:590-598 (JIF=3.942; No. of cites=14, corresponding author).
196. #Huang XR, Chung ACK, Yang F, Yue WS, Deng C, Lau CP, **Tse HF**, Lan HY. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. *Hypertension*. 2010;55:1165-71. (JIF=6.823, No. of cites=74).
197. Dai YL, Luk TH, Siu CW, Yiu KH, Chan HT, Lee SW, Li SW, Fong B, Wong WK, Tam S, Lau CP, **Tse HF**. Mitochondrial dysfunction induced by statin contributes to endothelial dysfunction in patients with coronary artery disease. *Cardiovasc Toxicol*. 2010 ;10:130-8.(JIF=2.989, No. of cites=17, corresponding author).
198. \*Siu CW, Pong V, Ho HH, Liu S, Lam BK, Lau CP, Li SW, **Tse HF**. Does MADIT II criteria for implantable cardioverter defibrillator implantation applicable to Chinese patients? *J Cardiovasc Electrophysiol*. 2010;21:231-5. (JIF= 2.873, No. of cites=15, corresponding author).
199. #Chan YC, **Tse HF**, Siu CW, Wang K, Lau CP, Li RA. Automaticity and conduction properties of bio-artificial pacemakers assessed in an in vitro monolayer model of neonatal rat ventricular myocytes. *Europace* 2010;12:1178-87. (JIF=5.231, No. of cites=3, co-corresponding author).
200. \*Hai JJ, Siu CW, Ho HH, Li SW, Lee S, **Tse HF**. Relationship between changes in heart rate recovery after cardiac rehabilitation on cardiovascular mortality in patients

with myocardial infarction. *Heart Rhythm* 2010;7:929-936 (JIF= 4.743, No. of cites=17, co-corresponding author).

201. \*Ho LY, Siu CW, Lau CP, Lip GY, **Tse HF**. Safety and efficacy of oral anticoagulation therapy in chinese patients with concomitant atrial fibrillation and hypertension. *J Hum Hypertens*. 2010;47:304-310. (JIF= 2.433, No. of cites=25, corresponding author.)
202. Yan GH, Wang M<sup>†</sup>, Yue WS, Yiu KH, Siu CW, Chan HT, Lee S, Li SW, Lau CP, Tam S, **Tse HF**<sup>†</sup>. Pulmonary arterial hypertension in patients with coronary artery disease and left ventricular dyssynchrony. *Eur J Heart Fail*. 2010;12:1067-75. (JIF=6.968, No. of cites=4, <sup>†</sup>co-corresponding author).
203. Lee CH, **Tse HF**, Tai BC, Chen Z, Chan MY, Tan HC. Procedure-related myonecrosis after bare and drug-eluting stent implantation. *Asian Cardiovasc Thorac Ann*. 2010;18:272-8.
204. Ho HH, Pong V, Siu CW, Jim MH, Miu R, Yiu KH, Ko R, **Tse HF**, Kwok OH, Chow WH. Long-term clinical outcomes of drug-eluting stents versus bare-metal stents in Chinese patients. *Clin Cardiol*. 2010;33:E22-E29. (JIF=2.757, No. of cites=4).
205. #Yue WS, Wang M, Yan GH, Yiu KH, Yin L, Siu CW, **Tse HF**. Smoking is associated with depletion of circulating endothelial progenitor cells and pulmonary hypertension in patients with coronary artery disease. *Am J Cardiol*. 2010;106:1248-54 (JIF=3.171; No. of cites=23, corresponding author).
206. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, **Tse HF**, Lam TH, Cheung B, Lam K. Association of genetic variants in the adiponectin gene with adiponectin level and hypertension in Hong Kong Chinese. *Eur J Endocrinol*. 2010; 163:251-7. (JIF=4.333; No. of cites=43).
207. # Lee YK, Ng KM, Lai WH, **Tse HF**, Siu CW. Enhancement of cardiac differentiation from embryonic stem cells with triiodothyronine. *Mol Endocrinol*. 2010;24:1728-36. (JIF=3.678, No. of cites=38).
208. #Liao SY, Liu Y, Siu CW, Lai WH, Wu Y, Yip P, Wu Y, Wu EX, Lau CP, Li RA, **Tse HF**. Proarrhythmic risk of transplantation of embryonic stem cell derived cardiomyocyte in infarcted myocardium. *Heart Rhythm*. 2010;7:1852-9. (JIF= 4.743, No. of cites=42, corresponding author).
209. #Lai WH, Ho CY, Lee YK, Ng KM, Au KW, Chan YC, Lau CP, **Tse HF**, Siu CW. ROCK inhibition facilitates the generation of patient-specific induced pluripotent stem cells in a defined, feeder- and serum-free system. *Cell Reprogram*. 2010;12:641-653 (JIF= 1.43, No. of cites=27).
210. #Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, **Tse HF**, Lau CS. Low level of circulating endothelial progenitor cells in patients with systemic sclerosis. *Clin Exp Rheumatol*. 2010;28(5 Suppl 62):S19-25. (JIF=3.201; No. of cites=17).

211. Ho HH, Siu CW, Yiu KH, **Tse HF**, Chui WH, Chow WH. Prosthetic valve endocarditis in a multicenter registry of Chinese patients. *Asian Cardiovasc Thorac Ann.* 2010;18:430-4. (JIF=NA; No. of cites=0).

2011

212. \*Chen H, Yang B, Ju W, Zhang F, Hou X, Chen C, Zhai L, Wang J, Cao K, †Chen M, †**Tse HF**. Long-term clinical implication of the occurrence of dissociated pulmonary vein activities after circumferential left atrial ablation in patients with paroxysmal atrial fibrillation. *Cir J* 2011.;75:73-9. (JIF=2.859, No. of cites= 6, †co-corresponding author).

213. Yiu KH, Yeung CK, Chan HT, Wong RM, Tam S, Lam KF, Yan GH, Yue WS, Chan HH, **Tse HF**. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. *Brit J Derm* 2011;164:514-520. (JIF= 6.129, No. of cites=43, corresponding authors).

214. #Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, Abdul Mutalif R, Navasankari R, Zhang Y, **Tse HF**, Stewart CL, Colman A. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. *Cell Stem Cell.* 2010;8:31-45. (JIF= 23.29, No. of cites=247).

215. #Lee YK, Ng KM, Lai WH, Lieu DK, †**Tse HF**, †Siu CW. Ouabain facilitates cardiac differentiation of mouse embryonic stem cells through ERK1/2 pathway. *Acta Pharmacol Sin.* 2011;32:52-61. (JIF= 3.562, No. of cites=11, †co-corresponding authors).

216. #Li X, **Tse HF**, Yiu KH, Li LS, Jin L. Effect of periodontal treatment on circulating CD34<sup>+</sup> cells and peripheral vascular endothelial function: a randomized controlled trial. *J Clin Periodontol.* 2010;38:148-56. (JIF= 4.046, No. of cites=19).

217. \***Tse HF**, Saha S, Garg A, Bohn D, Lee YL, Lau CP. Muscle noise effects on atrial evoked response sensing: implications on atrial auto-threshold and auto-capture determination. *Pacing Clin Electrophysiol.* 2011;34:460-6 (JIF=1.441; No. of cites=0, first and corresponding authors).

218. #Li M, Ho JC, Lai KW, Au KK, Xu A, Cheung BM, Lam KS, **Tse HF**. The decrement in circulating endothelial progenitor cells (EPC) in type 2 diabetes is independent of the severity of hypoadiponectemia. *Diabetes Metab. Res. Rev.* 2011;27:185-94. (JIF=3.904, No. of cites=10, corresponding author).

219. \*Yiu KH, Zhang XH, Siu CW, Lau CP, Tse HF. Left ventricular apical akinetic aneurysmatic area associated with permanent right ventricular apical pacing for advanced atrioventricular block: clinical characteristics and long-term outcome. *Europace.* 2011;13:514-9. (JIF=5.231, No. of cites=1, corresponding author).

220. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Lau CS, **Tse HF**. Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. *J Rheumatol.* 2011;38:621-7. (JIF =3.47, No. of cites=13, corresponding author).

221. Tso AW, Lam KY, Xu A, Yiu KH, **Tse HF**, Li LS, Law LS, Cheung BM, Cheung TF, Lam KS. Serum adipocyte fatty acid-binding protein is associated with ischemic stroke and predictive of early mortality. *Neurology*. 2011;76:1968-75. ((*JIF* =7.609, *No. of cites*=31).
222. \*Chung N, Jeon HK, Lien LM, **Tse HF**, Chung WS, Lee TH, Chen SA. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. *Thromb Haemost*. 2011;105:535-44. (*JIF*=4.952, *No. of cites*=66).
223. #Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, Lau CP, **Tse HF**. Dietary intake of phytoestrogen is associated with increased circulating endothelial progenitor cells in patients with cardiovascular disease. *Eur J Cardiovasc Prev Rehabil*. 2011 18:360-8 (*JIF*= 3.691, *No. of cites*=15, *corresponding author*).
224. #Yiu YF, Chan YH, Yiu KH, Siu CW, Li SW, Wong LY, Tam S, Lee S, Cheung BM, **Tse HF**. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type II diabetes. *J Clin Endocr Metab*. 2011;96:E830-5. (*JIF*= 5.789, *No. of cites*=71, *corresponding author*).
225. Dai YL, Luk TH, Wang M, Yip PC, Lee SW, Li SW, Tam S, Fong B, Lau CP, Siu CW, **Tse HF**. Effect of coenzyme Q10 supplementation on vascular function in patients with ischemic heart failure. *Atherosclerosis*. 2011;216:395-401. (*JIF*=4.467, *No. of cites*=42, *corresponding author*).
226. \*Wang M, Yan GH, Yue WS, Siu CW, Lee S, Lau CP, **Tse HF**. Effects of low right atrial septal versus right atrial appendage pacing on atrial mechanical function in patients with sinus node dysfunction and atrial fibrillation. *Europace*. 2011 13:1286-74. (*JIF*=5.231, *No. of cites*=11, *corresponding author*).
227. Yue WS, Liao SY, Zhang XH, Lau CP, Kung AW, **Tse HF**, Siu CW. Left ventricular diastolic dysfunction in hyperthyroidism: a prospective echocardiographic study. *Clin Endocrinol (Oxf)*. 2011;74:636-43 (*JIF*=3.077, *No. of cites*=18).
228. \*Chen M, Yang B, Chen H, Ju W, Zhang F, **Tse HF**<sup>†</sup>, Cao K<sup>†</sup>. Randomized comparison between pulmonary vein antral isolation versus complex fractionated electrogram ablation for paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol* 2011; 22:973-81 (*JIF*= 2.873, *No. of cites*=17, <sup>†</sup>*co-corresponding author*).
229. #Tao R, Sun HY, Lau CP, **Tse HF**, Lee HC, Li GR. Cyclic ADP ribose is a novel regulator of intracellular Ca<sup>2+</sup> oscillations in human bone marrow mesenchymal stem cells. *J Cell Mol Med* 2011;15:2684-96. (*JIF*= 4.302, *No. of cites*=18).
230. \*Yan GH, Wang M, Yue WS, Yiu KH, Lau CP, Lee S, Siu CW, **Tse HF**. Relationship between ventricular dyssynchrony and T-wave alternans in patients with coronary artery disease. *Pacing Clin Electrophysiol*. 2011;34:1503-10. (*JIF*=1.441; *No. of cites*=3, *corresponding authors*).
231. Ho HH, Cheung CW, Jim MH, Miu R, Siu CW, Lam YM, Chan HW, Lee WL, Lau CP, **Tse HF**. Type A aortic intramural hematoma: clinical features and outcomes in Chinese patients. *Clin Cardiol* 2011;34:E1-5. (*JIF*=2.733, *No. of cites*=7).

232. \*Chan HT, So J, Li SW, Siu CW, Lau CP, **Tse HF**. Effect of herbal consumption on clinical efficacy of warfarin therapy in patients with atrial fibrillation. *J Cardiovasc Pharmacol*. 2011; 58:87-90 (JIF=2.227; No. of cites=21, corresponding authors).
233. #Ng KM, Lee YK, Lai WH, Fung ML, **Tse HF**, Siu CW. Exogenous expression of human apoA-I enhances cardiac differentiation of pluripotent stem cells. *PLoS One*. 2011;6:e19787. (JIF=2.766, No. of cites=18).
234. #Wu Y, Zhang LJ, Zou C, **Tse HF**, Wu EX. Transmural heterogeneity of left ventricular myocardial remodeling postinfarct porcine model revealed by MR diffusion tensor imaging. *J Magn Reson Imaging* 2011;34:43-9. (JIF=3.612; No. of cites=14).
235. \*Siu CW, Jim MH, Lau CP, **Tse HF**. Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: a randomized control trial. *Acute Cardiac Care*. 2011;13:196-8 (JIF=NA, No of cites=0).
236. #Zhou T, Benda C, Duzinger S, Huang Y, Li X, Li Y, Guo X, Chen S, Chan YC, Ng KM, Ho JC, Wieser M, Yu J, Rddl H, **Tse HF**, Grillari-Voglauer R, Grillari J, Pei D, Esteban MA. Reprogramming of human urine cells to induced pluripotent stem cells. *J Am Soc Nephrol*. 2011;22:1221-8. (JIF =8.655, No of cites=135).
237. #Ho JC, Zhou T, Lai WH, Huang Y, Chan YC, Li X, Wong NL, Li Y, Au KW, Guo D, Xu J, Siu CW, Pei D, †**Tse HF**, †Esteban MA. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in Lamin A/C. *Aging* 2011;3: 380-90. (JIF =5.179, No. of cites=57, †co-corresponding author).
238. #Lee YK, Ng KM, Lai WH, Chan YC, Lian Q, Lau CP, **Tse HF**, Siu CW. Calcium handling in human induced pluripotent stem cell-derived cardiomyocytes. *Stem Cell Rev. & Report* 2011;7:976-86. (JIF=3.612, No of cites=74).
239. \*Wu W, Dong MQ, Wu XG, Sun HY, **Tse HF**, Lau CP, Li GR. Human ether-à-go-go gene potassium channels are regulated by EGFR. *Biochim Biophys Acta*. 2011;1823:282-289. (JIF =4.651, No. of cites=6).
240. #He ML, Liu WJ, Sun HY, Wu W, Liu J, **Tse HF**, Lau CP, Li GR. Effects of ion channels on proliferation in cultured human cardiac fibroblasts. *J Mol Cell Cardiol*. 2011;51:198-206. (JIF=5.296; No. of cites=15)
241. Li M, Xu A, Lam KS, Cheung BM, **Tse HF**. Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease. *Postgrad Med J* 2011;123:66-71. (JIF= 2.057, No. of cites=7, corresponding author).
242. #Chen H, Yiu KH, **Tse HF**. Relationships between endothelial dysfunction, circulating endothelial progenitor cells and psychological status in healthy subjects.



*Depress Anxiety*. 2011;28:719-27. (JIF=5.043; No. of cites=17, corresponding author).

243. Yiu KH, Pong V, Siu CW, Lau CP, **Tse HF**. Long-term oral nitrate therapy is associated with adverse outcome in diabetic patients after elective percutaneous coronary intervention. *Cardiovasc Diabetol*. 2011;10:52. (JIF =5.235, No. of cites=3, corresponding author).
244. #Ng KM, Chan YC, Lee YK, Lai WH, Fung ML, Siu CW, Li RA, **Tse HF**. Cobalt chloride pre-treatment enhances cardiac differentiation of human embryonic stem cells. *Cell Reprogram*. 2011;13:527-37. (JIF= 1.43, No. of cites=8, corresponding author).
245. \*Wu HJ, Wu W, Wang HB, Qin GW, **Tse HF**, Lau CP, Vanhoutte PM, Li GR. Acacetin causes a frequency- and use-dependent blockade of hKv3.691 channels by binding to the S6 domain. *J Mol Cell Cardiol*. 2011 51:966-73. (JIF=5.296; No. of cites=20).
246. Chan YH, Siu CW, Yiu KH, Li SW, Lau KK, Lam TH, Lau CP, **Tse HF**. Abnormal vascular function in PR interval prolongation. *Clin Cardiol* 2011.;34:628-32. (JIF=2.733, No. of cites=8, corresponding author).
247. Yiu KH, Schouffoer AA, Marsan NA, Ninaber MK, Stolk J, Vlieland TV, Scherptong RW, Delgado V, Holman ER, **Tse HF**, Huizinga TW, Bax JJ, Schuerwegh AJ. Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: Relationship to functional capacity and ventricular arrhythmias. *Arthritis Rheum*. 2011;63:3969-78. (JIF=8.955, No. of cites=34).
248. Yiu KH, **Tse HF**, Mok MY, Lau CS. Ethnic difference in the cardiovascular risk in patients with rheumatic disease: Focus on Asians. *Nat Rev Rheumatol*. 2011;7:609-18. (JIF= 15.661, No. of cites=6).
249. \*Connolly SJ, Camm AJ, Halperin J, Joyner C, Hart R, Alings M, Amerena J, Atar D, Avezum A, Blomström P, Borggreffe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Marc Davy J, Delacrétaiz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger C, Heidbüchel H, Kautzner J, Kim JS, Lanan F, Lewis B, Merino JL, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles M, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, **Tse HF**, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, on behalf of the PALLAS Investigators. Effects of Dronedarone in Permanent Atrial Fibrillation. *N Engl J Med*. 2011;365:2268-76. (JIF= 79.258, No. of cites=320).
- 2012
250. Liu J, Song E, Xu A, Berger T, Mak T, **Tse HF**, Law I, Huang B, Liang Y, Vanhoutte P, Wang Y. Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. *Br J Pharmacol*. 2012;165:520-31. (JIF= 6.81, No. of cites=26).
251. Luk TH, Dai YL, Siu CW, Yiu KH, Chan HT, Lee SW, Li SW, Fong B, Wong WK, Tam S, Lau CP, **Tse HF**. Effect of exercise training on vascular endothelial function

- in patients with stable coronary artery disease: A randomized controlled trial. *Eur J Prev Cardiol.* 2012;19:830-9 (JIF= 4.542, No. of cites=45, corresponding author).
252. Chan YH, Lau KK, Yiu KH, Siu CW, Chan HT, Li SW, Tam S, Lam TH, Lau CP, **Tse HF**. Prospective study of isoflavone and the risk of stroke recurrence: clinical implications beyond vascular function. *J Nutr Health Aging* 2012;16:383-388. (JIF= 2.868, No. of cites=3, corresponding author).
253. #Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, **Tse HF**. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol.* 2011 Dec 20;10:113. (JIF=5.235, No. of cites=45, corresponding author).
254. #Li W, Wang X, Fan W, Zhao P, Chan YC, Chen S, Zhang S, Guo X, Zhang Y, Li Y, Cai J, Qin D, Li X, Yang J, Peng T, Zychinski D, Hoffmann D, Zhang R, Deng K, Ng KM, Menten B, Zhong M, Wu J, Li Z, Chen Y, Schambach A, **Tse HF**, Pei D, Esteban MA. Modeling abnormal early development with induced pluripotent stem cells from aneuploidy syndromes. *Hum Mol Genet* 2012;21:32-45.(JIF= 4.902, No. of cites=37).
255. \*Stolen CM, Siu CW, Lam YM, **Tse HF**. Pacing to reduce angina in patients with severe coronary artery disease. *J Cardiovasc Transl Res.* 2012;5:84-91. (JIF=2.337, No. of cites=0, corresponding author).
256. \*Wang M, Yan GH, Yue WS, Siu CW, Yiu KH, Lee SW, **Tse HF**. Left ventricular mechanical dyssynchrony predicts exercise capacity in patients with coronary artery disease and narrow QRS duration. *Cir J* 2012;76:682-8. (JIF=2.895, No. of cites=3, \*co-corresponding author).
257. \*Yan GH, Wang M, Yiu KH, Lau CP, Zhi G, Lee SW, Siu CW, **Tse HF**. Subclinical left ventricular dysfunction revealed by circumferential 2D strain imaging in patients with coronary artery disease and fragmented QRS complex. *Heart Rhythm* 2012;9:928-35.(JIF= 4.743, No. of cites=18, corresponding author).
258. \*Amerena J, Chen SA, Sriratanasathavorn C, Cho JG, Dejjia H, Omar R, **Tse HF**, King A. Insights into the management of atrial fibrillation in Asoa Pacific: baseline data from the RecordAF-AP Registry. *Am J Cardiol.* 2012;109:378-82. (JIF=3.171; No. of cites=12).
259. \*Chong BH, Lau KK, Chan KH, Lui WM, Leung GK, Lau CP, **Tse HF**; Pu JK, Siu CW. Use of aspirin in chinese after recovery from primary intracranial hemorrhage *Thromb Haemost.* 2012;107:241-7. (JIF=4.952, No. of cites=22).
260. \*Siu CW, Wong MP, Ho CM, Lam CL, **Tse HF**. Fatal lung toxic effects related to dronedarone. *Arch Intern Med.* 2012;172:516-7. (JIF=17.333; No. of cites=5, corresponding author).
261. \*Liu Y, Yue WS, Liao SY, Zhang Y, Au KW, Shuto C, Cary H, Park E, Chen P, Siu CW, **Tse HF**. Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. *J*

*Cardiovasc Electrophysiol* 2012;23:534-40. (JIF= 2.873, No. of cites=26, corresponding author).

262. Yiu KH, Mok MY, Wang S, Ooi G, Khong PL, Lau CS, **Tse HF**. Prognostic role of coronary calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. *Clin Exp Rheumatol*. 2012;30:345-50. (JIF=3.201; No. of cites=18, corresponding author)
263. Chan YH, Siu CW, Yiu KH, Chan HT, Li SW, Tam S, Cheung B, Lam TH, Lau CP, **Tse HF**. Adverse systemic arterial function in patients with selenium deficiency. *J Nutr Health Aging* 2012;16:85-8. (JIF= 2.868, No. of cites=8, corresponding author).
264. \*Zhang YH, Wu W, Sun HY, Deng XL, Cheng LC, Li X, **Tse HF**, Lau CP, Li GR. Modulation of human cardiac transient outward potassium current by EGFR tyrosine kinase and Src-family kinases. *Cardiovasc Res*. 2012;93:424-33. (JIF=6.29, No. of cites=14).
265. #Liu Y, Liao SY, Lai WH, Siu CW, Yang YL, **Tse HF**. Lack of cardiac nerve sprouting after direct intramyocardical transplanted ion of bone marrow derived stem cells in swine model of chronic ischemic myocardium. *J Cardiovasc Transl Res*. 2012;5:359-64. (JIF= 2.337, No. of cites=5, corresponding author).
266. #Ho JC, Lai WH, Li M, Yip MC, NL Wong, Chan HT, Ng ES, Lam FF, Au KW, Siu CW, **Tse HF**. Reversal of endothelial progenitor cell dysfunction in patients with type 2 diabetes using a conditioned medium of human embryonic stem cell-derived endothelial cells. *Diabetes Metab Res Rev*. 2012;28:462-73. (JIF= 3.904, No. of cites=13, corresponding author).
267. #Zhang J, Chan YC, Ho JC, Siu CW, Lian Q, **Tse HF**. Regulation of cell proliferation of human induced pluripotent stem cell-derived mesenchymal stem cells via Ether à go-go 1 (hEAG1) potassium channel. *Am J Physiol Cell Physiol*. 2012;303:C115-25. (JIF=3.454; No. of cites=17, corresponding author).
268. Yang B, Fan P, Xu A, Lam KS, Berger T, Mak TW, **Tse HF**, Yue JW, Song E, Vanhoutte PM, Sweeney G, Wang Y. Improved functional recovery to I/R injury in hearts from lipocalin-2 deficiency mice: restoration of mitochondrial function and phospholipids remodeling. *Am J Transl Res*. 2012;4:60-71. (JIF=3.061; No. of cites=17)
269. Pong V, Chan KH, Chong BH, Lui WM, Leung GK, **Tse HF**, Pu JK, Siu CW. Long-term outcome and prognostic factors after spontaneous cerebellar hemorrhage. *Cerebellum*. 2012;11:939-945 (JIF=3.199; No. of cites=15).
270. Lee MY, Cai Y, Wang Y, Liao SY, Liu Y, Zhang Y, Bai B, **Tse HF**, Vanhoutte PM. Differential genomic changes caused by cholesterol and PUFA rich diets in regenerated porcine coronary endothelial cells. *Physiological Genomics* 2012;44:551-561. (JIF=2.782; No. of cites=7).
271. #Zhou T, Benda C, Duzinger S, Huang Y, Li X, Li Y, Wang Y, Zhunag Q, Bao X, **Tse HF**, Brillari J, Grillari-Voglauer R, Pei D, Esteban A. A protocol for generating

- human induced pluripotent stem cells from urine samples. *Nat Protoc.* 2012;7:2080-9 (JIF=12.423; No. of cites=174)
272. \*Chong BH, Pong V, Lam KF, Liu S, Zuo ML, Lau YF, Lau CP, **Tse HF**, Siu CW. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. *Europace.* 2012;14:942-7. (JIF=5.231, No. of cites=54).
273. Ambegaonkar B, Chirovsky D, **Tse HF**, Lau YK, Tomlinson B, Li SK, Yue CS, Wong TH, Choi MC, Tunggal P, Sazonov V. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong. *Adv Ther.* 2012; 29:427-41. (JIF=3.085, No. of cites=3).
274. Yiu KH, Atsma DE, Delgado V, Ng AC, Witkowski TG, Ewe SH, Auger D, Holman ER, van Mil AM, Breuning MH, **Tse HF**, Bax JJ, Schalij MJ, Marsan NA. Myocardial structural alteration and systolic dysfunction in preclinical hypertrophic cardiomyopathy mutation carriers. *PLoS One.* 2012;7:e36115. (JIF=2.766, No. of cites=20).
275. Yeung CY, Lam KS, Li WS, **Tse HF** <sup>†</sup>, Siu CW <sup>†</sup>. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes mellitus. *Diabetes Care.* 2012;35:2564-2569 (JIF= 13.397, No. of cites=12, <sup>†</sup>co-corresponding author).
276. Luk TH, Dai YL, Siu CW, Yiu KH, Li SW, Fong B, Wong WK, Tam S, **Tse HF**. Lower habitual physical activity was associated with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease. *Cir J.* 2012;76:2572-2578 (JIF=2.895, No. of cites=5, corresponding author).
277. Lee SW, William Kong To Hau WK, Kong SL, Chan KK, Chan PH, Lam SC, Tam FC, Wong MK, Chan CW, Lam YM, **Tse HF**, Chan RH. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naïve patients: The VENUS Study. *Cir J.* 2012;76:2662-2672 (JIF=2.895, No. of cites=12).
278. #Zhang Y, Lian Q, Wu X, Yang M, Liao S, Kang S, Wong CY, Wang J, Cheong SK, <sup>†</sup>**Tse HF**, <sup>†</sup>Lian Q. Improved cell survival and paracrine capacity of human embryonic stem cells-derived mesenchymal stem cells promote therapeutic potential for pulmonary arterial hypertension. *Cell Transplant* 2012;21:2225-2239 (JIF=2.885, No. of cites=28, <sup>†</sup>co-corresponding author).
279. Lau KK, Wong YK, Chan YH, Yiu KH, Ho SL, Chan KH, Siu CW, **Tse HF**. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. *Cardiovasc Diabetol.* 2012;11:101.(JIF =5.235, No. of cites=23, corresponding author).
280. #Sun YQ, Deng MX, He J, Zeng QX, Wen W, Wong DS, **Tse HF**, Xu G, Lian Q, Shi J, Fu QL. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice. *Stem Cells.* 2012;30:2692-2699 (JIF=5.587; No. of cites=72).

281. Li FY, Lam KS, **Tse HF**, Chen C, Wang Y, Vanhoutte PM, Xu A. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes induced impairment in vascular function and re-endothelialization via induction of heme oxygenase-1 in mice. *Circulation* 2012;126:1267-77. (JIF=18.88; No. of cites=40).
282. #Fu QL, Chow YY, Sun SJ, Zeng QX, Li HB, Shi JB, Sun YQ, Wen W, **Tse HF**, Lian Q, Xu G. Mesenchymal stem cells derived from human induced pluripotent stem cells modulate T-cell phenotypes in allergic rhinitis. *Allergy* 2012;67:1215-1222 (JIF=6.048, No. of cites=50).
283. Li X, **Tse HF**, Yiu KH, Zhang C, Jin L. Periodontal therapy decreases serum levels of adipocyte fatty acid-binding protein in systemically healthy subjects: A pilot clinical trial. *J Periodont Res* 2012; 48:308-314 (JIF= 2.878, No. of cites=1)
284. \*Lau CP, **Tse HF**, Siu CW, Gbadebo. Atrial electrical and structural remodeling: Implication for racial differences in atrial fibrillation. *J Cardiovasc Electrophysiol.*2012;23:s36-s40 (JIF= 2.873, No. of cites=10).
285. #Siu CW, Lee YK, Ho JC, Lai KW, Chan YC, Ng KM, Wong LY, Au KW, Lau YM, Lau CP, Lay K, Zhang J, Colman A, **Tse HF**. Modeling of familial dilated cardiomyopathy caused by mutation in lamin A/C gene using patient-specific induced pluripotent stem cells. *Aging* 2012;4:803-822. (JIF =5.179, No. of cites=43, corresponding author).
286. #Zhao CT, Wang M, Siu CW, Hou YL, Wang T, **Tse HF**<sup>†</sup>, Yiu KH<sup>†</sup>. Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. *Cardiovasc Diabetol.* 2012 Dec 5;11:147.(JIF =5.235, No. of cites=30, <sup>†</sup>co-corresponding author)
- 2013**
287. Chan C, Zhou YZ, Ying Z, Liao SY, Zhang YL, Yue L, Lee M, Xu A, **Tse HF**, Vanhoutte P. A-FABP and oxidative stress underlie the impairment of endothelium-dependent relaxations to serotonin and the intima-medial thickening in the porcine coronary artery with regenerated endothelium. *ACS Chemical Neuroscience* 2013;4:122-9. (JIF= 4.211, No. of cites=10).
288. Chan HT, Yiu KH, Li SW, Wong CY, Lam S, **Tse HF**. Increased dietary fruit intakes was associated with lower burden of carotid atherosclerosis in patients with Type 2 diabetes mellitus. *Diabetic Med.* 2013;30:100-108 (JIF=3.132; No. of cites=11, corresponding author).
289. #Benda C, Zhou T, Wang X, Tian W, Grillari J, **Tse HF**, Grillari-Voglauer R, Pei D, Esteban MA. Urine as a source of stem cells. *Adv Biochem Eng Biotechnol.* 2013;129:19-32 (JIF=2.795; No. of cites=7).
290. Yiu KH<sup>†</sup>, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, Wong CS, Yan GH, YueWS, Khong PL, Cha H, **Tse HF**<sup>†</sup>. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. *J Intern Med.* 2013;3:273-282 (JIF=6.754, No. of cites=35, <sup>†</sup>corresponding author).

291. Lui MM, **Tse HF**, Mak JC, Lam JC, Lam DC, Tan KC, Ip MS. Altered profile of circulating endothelial progenitor cells in obstructive sleep apnea. *Sleep Breath* 2013;17:937-42. (JIF= 2.03, No. of cites=7).
292. Yiu YF, Yiu KH, Siu CW, Chan YH, Li SW, Wong LY, Lee SW, Tam S, Wong EW, Lau CP, Cheung BM, **Tse HF**. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. *Atherosclerosis*. 2013;227:140-146. (JIF=4.467, No. of cites=91, corresponding author).
293. \*Zuo ML, Liu S, Chan KH, Lau KK, Chong BH, Lam KF, Chan YH, Lau YF, Lip GY, Lau CP, **Tse HF**, Siu CW. CHADS<sub>2</sub> score and CHA<sub>2</sub>DS<sub>2</sub>-VASc score predict new occurrence of atrial fibrillation and ischemic stroke. *J Interv Card Electrophysiol* 2013;37:47-54 (JIF=1.522, No. of cites=23).
294. \*Lau CP, Gbadebo DT, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, Israel CW, Morillo CA, Siu CW, Abe H, Carlson M, **Tse HF**, Hohnloser SH, Healey JS, for the ASSERT investigators. Ethnic difference in atrial fibrillation identified using implanted cardiac devices. *J Cardiovasc Electrophysiol*. 2013;24:381-387(JIF= 2.873, No. of cites=21).
295. #Liao SY, **Tse HF**, Liu Y, Yip MC, Chan YC, Zhang Y, Li RA. Over-expression of Kir2.1 channel in embryonic stem cells derived cardiomyocytes reduces their post-transplantation proarrhythmic risk in myocardial infarction. *Heart Rhythm* 2013;10:273-82 (JIF=4.743, No. of cites=12, corresponding author).
296. #Lau KK, Chan YH, Wong YK, Yiu KH, Teo KC, Li LS, Shu XO, Cheung RT, Ho SL, Chan KH, Siu CW, **Tse HF**. Garlic intake is an independent predictor of endothelial function in patients with ischemic stroke. *J Nutr Health Aging* 2013;17:600-604 (JIF= 2.868, No. of cites=14, corresponding author).
297. Chow WS, Tso AW, Xu A, Yuen MM, Fong CH, Lam TH, Lo SV, **Tse HF**, Cheung BM, Lam KS. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: A 12-year prospective study. *Journal of the American Heart Association* 2013;2:e004176 (JIF= 4.45, No. of cites=40).
298. \*Zhang YH, Wu HJ, Che H, Sun HY, Cheng LC, Li X, Au WK, **Tse HF**, Li GR. Functional transient receptor potential canonical type 1 channels in human atrial myocytes. *Pflugers Arch*. 2013;465:1439-49 (JIF =2.765, No. of cites=10).
299. #**Tse HF**, Ho JC, Buter AW, Lee YK, Choi SW, Ng KM, Siu CW, Simpson MA, Lai WH, Chan YC, Zhang J, Lay KW, Esteban MA, Colman A, Sham PC. Patient-specific induced pluripotent stem cells derived cardiomyocytes recapitulates the pathogenic phenotypes of dilated cardiomyopathy due to a novel desmin gene mutation identified by whole exome sequencing. *Hum Mol Genet* 2013;22:1395-1403 (JIF= 4.902, No. of cites=40, \*first and corresponding author).
300. Chan YH, Lau KK, Yiu KH, Yiu YF, Li SW, Lam TH, Lau CP, Siu CW, **Tse HF**. Prolongation of PR Interval is associated with endothelial dysfunction and activation

of vascular repair in high risk cardiovascular patients. *J Interv Card Electrophysiol* 2013;37:55-61 (JIF=1.522, No. of cites=4, corresponding author).

301. \*Lau CP, Tachapong N, Wang CC, Wang JF, Abe H, Kong CW, Liew R, Shin DG, Padeletti L, Kim YH, Omar R, Jirarojanakorn K, Kim YM, Chen MC, Sriratanasathavorn C, Munawar M, Kam R, Chen JY, Cho YK, Li YG, Wu SL, Bailleul C, **Tse HF**, for SAFE Study Prospective Randomized Study to Assess the Efficacy of Site and Rate of Atrial Pacing on Long-term Progression of Atrial Fibrillation in Sick Sinus Syndrome- Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) study. *Circulation* 2012;128:687-93 (JIF=18.88; No. of cites=21, corresponding author).
302. #Chan YC, Ting S, Lee YK, Ng KM, Zhang J, Chen Z, Siu CW, Oh SK, **Tse HF**. Electro-stimulation promotes maturation of cardiomyocytes derived from pluripotent human embryonic stem cells. *J Cardiovasc Transl Res*. 2013;6:989-99. (JIF= 2.337, No. of cites=45, corresponding author).
303. Chan KH, Leung GK, Lau KK, Liu S, Lui WM, Lau CP, **Tse HF**, Pu JK, Siu CW. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. *World Neurosurg*. 2013;82:1-2 (JIF= 1.924, No. of cites=13).
304. Yiu KH, de Graaf FR, van Velzen JE, Marsan NA, Roos CJ, de Bie MK, **Tse HF**, van der Wall EE, Schalij MJ, Bax JJ, Schuijff JD, Jukema JW. Different value of coronary calcium score to predict obstructive coronary artery disease in patients with and without moderate chronic kidney disease. *Neth Heart J*. 2013;21:347-53 (JIF= 1.476, No. of cites=7).
305. #Lai WH, Ho JC, Ng JH, Chan YC, Au KW, Wong NL, Lee YK, Ng KM, Siu CW, **Tse HF**. Attenuation of critical hindlimb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. *PLoS One*. 2013;8(3):e57876 (JIF=2.766, No. of cites=26, corresponding author).
306. Zuo ML, Yue WC, Yip Terence, Ng Flora, Lam KF, Yiu KH, Lui SL, **Tse HF**, Siu CW, Lo WK. Prevalence of and association with reduced exercise capacity in peritoneal dialysis patients. *Am J Kidney Dis*. 2013.62:939-46. (JIF=7.129, No. of cites=6).
307. Yiu KH, Zhao CT, Chen Y, Siu CW, Chan YH, Lau KK, Liu S, Lau CP, **Tse HF**. Association of subclinical myocardial injury with arterial stiffness in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2013;12:94.(JIF =5.235; No. of cites=19, Corresponding author).
308. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, **Tse HF**, Chau MT, Cheung BM, Lam KS. Serum fibroblast growth factor-21 levels were associated with carotid atherosclerosis independent of established cardiovascular risk factors. *Arterioscler Thromb Vasc Biol*. 2013;33:2454-9 (JIF=6.086; No. of cites=71).

309. #Ting S, Lecina M, Chan YC, **Tse HF**, Reuveny S, Oh SK. Nutrient supplemented serum-free medium increases cardiomyogenesis efficiency of human pluripotent stem cells. *World J Stem Cells*. 2013;5:86-97. (JIF=NA; No. of cites=0).
310. #Guo Y, Chan KH, Lai WH, Siu CW, Kwan SC, **Tse HF**, Wing-Lok Ho P, Wing-Man Ho J. Human mesenchymal stem cells upregulate CD1dCD5(+) regulatory B cells in experimental autoimmune encephalomyelitis. *Neuroimmunomodulation*. 2013;20:294-303. (JIF=2.238; No. of cites=20).
311. \***Tse HF**, Wang YJ, Ai-Abdullah MA, Pizarro-Borromeo AB, Chiang CE, Krittayaphong J, Singh B, Vora A, Wang CX, Zubaid M, Clemens A, Lim P, Hu D. Stroke prevention in atrial fibrillation – An Asian stroke perspective. *Heart Rhythm* 2013;10:1082-1088 (JIF= 4.743, No. of cites=51, first and corresponding author)
312. Chan PH, Liu SS, Tse HF, Chow WH, Jim MH, Ho HH, Siu CW. Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients. *J Geriatr Cardiol*. 2013;10:330-5. (JIF=1.581; No. of cites=1).
- 2014
313. #Zhang YY, Yue J, Che H, Sun HY, **Tse HF**, Li GR. BK<sub>Ca</sub> and hEag1 channels regulate cell proliferation and differentiation in human bone marrow-derived mesenchymal stem cells. *J Cell Physiol*. 2014;229:202-12 (JIF=3.923, No. of cites=17).
314. Yiu KH<sup>†</sup>, Wong A, Pu L, Chiang R, Sit KY, Chan D, Lee HY, Lam YM, Chen Y, Siu CW, Lau CP, Au WK, **Tse HF**<sup>†</sup>. Prognostic value of preoperative right ventricular geometry and tricuspid valve tethering area in patients undergoing tricuspid annuloplasty. *Circulation* 2014;129:87-92 (JIF=18.88; No. of cites=15, <sup>†</sup>*co-corresponding author*).
315. Zhao CT, Yeung CK, Siu CW, Tam S, Chan J, Chen Y, Chan HH, **Tse HF**, Yiu KH Relationship between parathyroid hormone and subclinical myocardial dysfunction in patients with severe psoriasis. *J Eur Acad Dermatol Venereol*. 2014;28:461-8. (JIF= 4.287, No. of cites=7).
316. Lau KK, Wong YK, Chan KH, Teo KC, Hon FW, Mak W, Cheung TF, Li LS, Siu CW, Ho SL, \* **Tse HF**. \* Outpatient clinic visit-to-visit blood pressure variability predicts cardiovascular mortality after lacunar infarct. *Eur J Neurol*. 2014;21:319-25. (JIF= 4.621, No. of cites=12, co-corresponding author\*).
317. Lau KK, Wong YK, Teo KC, Chang RS, Hon SF, Chan KH, Cheung RT, Li LS, **Tse HF**, Ho SL, Siu CW. Stroke patients with a past history of cancer are at increased risk of recurrent stroke and cardiovascular mortality. *PLoS One*. 2014;9:e88283 (JIF=2.766, No. of cites=5).
318. Chan CK, Liao SY, Zhang YL, Xu A, **Tse HF**, Vanhoutte P. Protective effects of histamine on G<sub>q</sub>-mediated relaxation in regenerated endothelium. *Am J Physiol Heart Circ Physiol*. 2014;306:H286-90 (JIF=3.569, No. of cites=3).
319. #Lo CY, Tjong YW, Ho JC, Siu CW, Yu S, Tse HF<sup>†</sup>, Yao X<sup>†</sup>. An upregulated expression of vanilloid transient potential channels 2 enhances the hypo-osmolarity



- induced cytosolic calcium elevation in human induced pluripotent stem cells model of Hutchinson-Gillford Progeria Syndrome. *PLoS One*. 2014;9:e87273. (JIF=2.766, No. of cites=6, co-corresponding author<sup>†</sup>).
320. #Lee YK, Ho PW, Schick R, Lau YM, Lai WH, Zhou T, Li Y, Ng KM, Ho SL, Esteban MA, Binah O, **Tse HF**, Siu CW. Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. *Pflugers Arch*. 2014;466:1831-44 (JIF=2.765, No. of cites=16)
321. #Che H, Yue J, **Tse HF**, Li GR. Functional TRPV and TRPM channels in human preadipocytes. *Pflugers Arch*. 2014;466:947-59. (JIF=2.765, No. of cites=11).
322. #Wu HJ, Yiu WH, Li RX, Wong DW, Leung JC, Chan LY, Zhang Y, Lian Q, Lin M, **Tse HF**, Lai KN, Tang SC. Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis. *PLoS One*. 2014;9:e90883. (JIF =2.766, No. of cites=21).
323. Chan HT, Chan YH, Yiu KH, Li SW, Tam S, Lau CP, **Tse HF**. Worsened arterial stiffness in high-risk cardiovascular patients with high habitual carbohydrate intake: a cross-sectional vascular function study. *BMC Cardiovasc Disord*. 2014;14:24. (JIF=1.812, No. of cites=3, Corresponding author).
324. Chen Y, Zhao CT, Wong A, **Tse HF**<sup>†</sup>, Yiu KH<sup>†</sup>. Association of myocardial dysfunction with vitamin D deficiency in patients with type 2 diabetes mellitus *J Diabetes Complications*. 2014;28:286-290 (JIF=2.792, No. of cites=8, co-corresponding author<sup>†</sup>).
325. \*Siu CW, **Tse HF**. Net clinical benefit of warfarin therapy in very elderly Chinese patients with atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2014;7:300-306 (JIF =4.712, No. of cites=30).
326. Yiu KH, Lau KK, Zhao CT, Chan YH, Chen Y, Zhen Z, Wong A, Lau CP, **Tse HF**. Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2014 Mar 25;13(1):63. (JIF =5.235, No. of cites=12, Corresponding author).
327. Wong CK, Chen Y, Ho LM, Zhen Z, Siu CW, **Tse HF**, Yiu KH. The effects of hyperuricaemia on flow-mediated and nitroglycerin-mediated dilatation in high-risk patients. *Nutr Metab Cardiovasc Dis*. 2014;24:1012-9. (JIF =3.318, No. of cites=3).
328. #Zhang J, Ho JC, Chan YC, Lian Q, Siu CW, **Tse HF**. Transdifferentiation of human induced pluripotent stem cell-derived mesenchymal stem cells into cardiomyocytes via overexpression of myocardin. *Physiol Report*. 2014;2:e00237. (JIF=NA, No. of cites=4, corresponding author).
329. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-

- Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, **Tse HF**, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med*. 2014;370:1702-11 (JIF=79.258 , No. of cites=198).
330. #Li X, Zhang Y, Yeung SC, Liang Y, Liang X, Ding Y, Ip MS, **Tse HF**, Mak JC, Lian Q. Mitochondrial transfer of induced pluripotent stem cells-derived MSCs to airway epithelial cells attenuates cigarette smoke-induced damage. *Am J Respir Cell Mol Biol*. 2014;51:455-65 (JIF=3.785; No. of cites=57).
331. \*Siu CW, Lip GY, Kwok-Fai Lam P, **Tse HF**. Risk of stroke and intracranial hemorrhage in 9,727 chinese with atrial fibrillation in Hong Kong. *Heart Rhythm*. 2014;11:1401-8. (JIF=4.743, No. of cites=57).
332. Cheung CY, Hui EY, Cheung BM, Woo Y, Xu A, Fong CH, Ong KL, Yeung C, Janus ED, **Tse HF**, Sham PC, Lam KS. Adiponectin gene variants and the risk of coronary heart disease: a 16-year longitudinal study. *Eur J Endocrinol*. 2014;171:107-15.(JIF=4.333, No. of cites=15).
333. Lau KK, Wong YK, Chan YH, Teo KC, Chan KH, Wai Li LS, Cheung RT, Siu CW, Ho SL, **Tse HF**. Visit-to-visit blood pressure variability as a prognostic marker in patients with cardiovascular and cerebrovascular diseases - Relationships and comparisons with vascular markers of atherosclerosis. *Atherosclerosis*. 2014 9;235:230-235. (JIF=4.467, No. of cites=18, corresponding author).
334. Lau KK, Wong YK, Teo KC, Chang RS, Chan KH, Hon SF, Wat KL, Cheung RT, Li LS, Siu CW, **Tse HF**. Long-Term prognostic implications of visit-to-visit blood pressure variability in patients with ischemic stroke. *Am J Hypertens*. 2014; 27:1486-94. (JIF=3.046, No. of cites=15, corresponding author).
335. Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK, Lam KS, **Tse HF**, Yau T, Siu CW. Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. *J Oncol*. 2014;2014:529468. (JIF=4.528, No. of cites=6).
336. \*Huang D, Anguo L, Yue WS, Yin L, **Tse HF**, Siu CW. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA<sub>2</sub> DS<sub>2</sub> -VASc Score of 1. *Pacing Clin Electrophysiol*. 2014;37:1442-7. (JIF=1.441, No. of cites=28).
337. #Santoso T, Siu CW, Irawan C, Chan WS, Alwi I, Yiu KH, Aziz A, Kwong YL, **Tse HF**. Endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic heart failure: a randomized placebo-controlled trial (END-HF). *J Cardiovasc Transl Res*. 2014;7:545-52 (JIF=2.337, No. of cites=9, corresponding author).
338. \*Ho MH, Ho CW, Cheung E, Chan PH, Hai JJ, Chan KH, Chan EW, Leung GK, **Tse HF**, Siu CW. Continuation of dabigatran therapy in "real-world" practice in Hong Kong. *PLoS One*. 2014;9(8):e101245. (JIF=2.766, No. of cites=18).

339. Hui E, Xu A, Chow WS, Lee PC, Fong CH, Cheung SC, **Tse HF**, Chau MT, Cheung BM, Lam KS. Hypoadiponectinemia as an independent predictor for the progression of carotid atherosclerosis: a 5-year prospective study. *Metab Syndr Relat Disord*. 2014;12:517-22. (JIF=1.744, No. of cites=8).
340. #Liu L, Xu Y, He M, Zhang M, Cui F, Lu L, Yao M, Tian W, Benda C, Zhuang Q, Huang Z, Li W, Li X, Zhao P, Fan W, Luo Z, Li Y, Wu Y, Hutchins AP, Wang D, **Tse HF**, Schambach A, Frampton J, Qin B, Bao X, Yao H, Zhang B, Sun H, Pei D, Wang H, Wang J, Esteban MA. Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. *Cell Stem Cell*. 2014;15:574-88. (JIF= 23.29, No. of cites=23).
341. \*Chan YH, Yiu KH, Lau KK, Yiu YF, Li SW, Lam TH, Lau CP, Siu CW, **Tse HF**. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation. *Atherosclerosis*. 2014;237:504-13. (JIF=4.467, No. of cites=20, corresponding author).
342. Yiu KH<sup>†</sup>, Ng WS, Chan D, Sit KY, Wong A, Lee CW, Chum HL, Cheng WY, Pun CT, Ho KL, Chen Y, Ho LM, Kumana CR, Cheung HL, Chung MC, Lau CP, Au WK, **Tse HF**<sup>†</sup>. Improved prognosis following renin-angiotensin-aldosterone system blockade in patients undergoing concomitant aortic and mitral valve replacement. *Int J Cardiol*. 2014;177:680-2. (JIF=4.034, No. of cites=2, <sup>†</sup> co-corresponding author).
- 2015
343. Chen Y, Chung HY, Zhao CT, Wong A, Zhen Z, Tsang HH, Lau CS, **Tse HF**<sup>†</sup>, Yiu KH<sup>†</sup>. Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. *Rheumatology (Oxford)*. 2015;54:292-301 (JIF=5.245, No. of cites=7, <sup>†</sup> co-corresponding author).
344. Cheng Y, Yang C, Zhao J, **Tse HF**, Rong J. Proteomic identification of calcium-binding chaperone calreticulin as a potential mediator for the neuroprotective and neuritogenic activities of fruit-derived glycoside amygdalin. *J Nutr Biochem*. 2015;26:146-54 (JIF= 4.414, No. of cites=6).
345. \*Lau KK, Chan PH, Yiu KH, Chan YH, Liu S, Chan KH, Yeung CY, Li SW, **Tse HF**, Siu CW. Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke. *Cardiol J*. 2014;21:474-483 (JIF=1.339, No. of cites=16).
346. \*Ho CW, Ho MH, Chan PH, Hai JJ, Cheung W, Yeung CY, Lau KK, Chan KO, Lau CP, Lip YH, Leung GK, **Tse HF**, Siu CW. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran. *Stroke* 2015;46:23-30 (JIF=6.239, No. of cites=51).
347. Chan YH, Lau KK, Yiu KH, Li SW, Tam S, Lam TH, Lau CP, Siu CW, Cheung BM, **Tse HF**. Vascular protective effects of statin-related increase in serum 25-hydroxyvitamin D among high-risk cardiac patients. *J Cardiovasc Med (Hagerstown)*. 2015;16:51-8. (JIF=1.67, No. of cites=4, corresponding author).

348. Lau KK, Wong YK, Chan YH, Li OY, Lee PY, Yuen GG, Wong YK, Tong S, Wong D, Chan KH, Cheung RT, Siu CW, Ho SL, **Tse HF**. Mediterranean-style diet Is associated with reduced blood pressure variability and subsequent stroke risk in patients with coronary artery disease. *Am J Hypertens*. 2015;28:501-507 (JIF=3.046, No. of cites=15, corresponding author).
349. <sup>#</sup>**Tse HF**, Turner S, Sanders P, Okuyama Y, Fujiu K, Cheung CW, Russo M, Green MD, Yiu KH, Siu CW. Thoracic Spinal Cord Stimulation for HEART Failure as a Restorative Treatment (SCS HEART Study): First-in-man Experience. *Heart Rhythm*. 2015;12:588-595 (JIF=4.743, No. of cites=34, first and corresponding author).
350. <sup>#</sup>Bao X, Wu H, Zhu X, Guo X, Hutchins AP, Luo Z, Song H, Chen Y, Lai K, Yin M, Xu L, Zhou L, Chen J, Wang D, Qin B, Frampton J, **Tse HF**, Pei D, Wang H, Zhang B, Esteban MA. The p53-induced lincRNA-p21 derails somatic cell reprogramming by sustaining H3K9me3 and CpG methylation at pluripotency gene promoters. *Cell Res*. 2015;25:80-92.(JIF=15.393, No. of cites=54).
351. <sup>\*</sup>Shenthar J, Milasinovic G, Al Fagih A, Götte M, Engel G, Wolff S, **Tse HF**, Herr J, Carrithers J, Cerkenvenik J, Nähle CP. MRI scanning in patients with new and existing CapSureFix<sup>®</sup> Novus 5076 pacemaker leads: randomized trial results. *Heart Rhythm*. 2015;12:759-65 (JIF=4.743, No. of cites=10).
352. Poon MW, Yan LM, Jiang D, Qin P, **Tse HF**, Wong IY, Wong D, Tergaonkar V, Lian Q. Inhibition of RAP1 enhances corneal recovery following alkali injury. *Invest Ophthalmol Vis Sci*. 2015;56:711-721 (JIF=3.388, No. of cites=14).
353. <sup>#</sup>Wu Y, Li Y, Zhang H, Huang Y, Zhao P, Tang Y, Qiu X, Ying Y, Li W, Ni S, Zhang M, Liu L, Xu L, Zhuang Q, Luo Z, Benda C, Song H, Liu B, Lai L, Liu X, **Tse HF**, Bao X, Chan WY, Esteban M, Qin B, Pei D. Autophagy and mTORC1 regulate the stochastic phase of somatic cell reprogramming. *Nat Cell Bio* 2015;17:715-25. (JIF=19.064, No. of cites=25).
354. <sup>#</sup>Liang X, Ding Y, Zhang Y, Chai YH, He J, Chiu SM, Gao F, **Tse HF**<sup>†</sup>, Lian Q<sup>†</sup>. Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction. *Cell Death Dis*. 2015 May 21;6:e1765. doi: 10.1038/cddis.2017.6231. (JIF=5.638, No. of cites=10, <sup>†</sup>co-corresponding author).
355. <sup>#</sup>Hu X, Huang X, Yang Q, Wang L, Sun J, Zhan H, Lin J, Pu Z, Jiang J, Sun Y, Xiang M, Liu X, Xie X, Yu X, Chen Z, **Tse HF**, Zhang J, Wang J. Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow nonnuclear cell administration for acute myocardial infarction patients: The CHINA-AMI Randomized Controlled Trial. *Int J Cardiol*. 2015;184:446-51. (JIF=4.034, No. of cites=16).
356. <sup>\*</sup>Liao SY, Liu Y, Zuo M, Zhang Y, Yue W, Au KW, Lai WH, Wu Y, Shuto C, Chen P, Siu CW, Schwartz PJ, **Tse HF**. Remodeling of cardiac sympathetic re-innervation with thoracic spinal cord stimulation improve left ventricular function in a porcine model of heart failure. *Europace* 2015;17:1875-83. (JIF=5.231, No. of cites=5, corresponding author).

357. \*Dong JZ, Sang CH, Yu RH, Long Y, Tang RB, Jiang CX, Ning M, Liu N, Liu XP, Du X, **Tse HF**, Ma CS. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. *Europace*. 2015;17:1798-806. (JIF=5.231, No. of cites=19).
358. #Zhang Y, Liang X, Liao S, Wang W, Wang J, Li X, Ding Y, Liang Y, Gao F, Yang M, Fu Q, Xu A, Chai YH, He J, **Tse HF**<sup>†</sup>, Lian Q<sup>†</sup>. Potent paracrine effects of human induced pluripotent stem cell-derived mesenchymal stem cells attenuate doxorubicin-induced cardiomyopathy. *Sci Rep*. 2015;5:11235. (JIF=4.122, No. of cites=29, <sup>†</sup>co-corresponding author)
359. \*Chan PH, Li WH, Hai JJ, **Tse HF**, Siu CW. Impact of antithrombotic therapy in atrial fibrillation on the presentation of coronary artery disease. *PLoS One*. 2015;10:e0131479. (JIF =2.766, No. of cites=2)
360. #Poon MW, He J, Fang X, Zhang Z, Wang W, Wang J, Qiu F, **Tse HF**, Li W, Liu Z, Lian Q. Human ocular epithelial cells endogenously expressing SOX2 and OCT4 yield high efficiency of pluripotency reprogramming. *PLoS One*. 2015;10:e0131288. (JIF =2.766, No. of cites=6).
361. \*Hai J, Chan PH, **Tse HF**, Siu CW. Slow heart rate predicts new occurrence of atrial fibrillation. *Heart Lung Circ*. 2015;24:1087-93. (JIF =1.921, No. of cites=0).
362. Cheng Y, Zhao J, **Tse HF**, Chris Le X, Rong J. Plant natural products calycosin and gallic acid synergistically attenuate neutrophil infiltration and subsequent injury in isoproterenol-induced myocardial infarction: a possible role for leukotriene B4 12-hydroxydehydrogenase? *Oxid Med Cell Longev*. 2015;2015:434052. (JIF=4.936, No. of cites=0)
363. Tsoi MF, Cheung CL, Cheung T, Wong I, Kumana C, **Tse HF**, Cheung B. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. *Sci Rep*. 2015;5:13204. (JIF=4.122, No. of cites=7)
364. \*Hai JJ, Lim ET, Chan CP, Chan YS, Chan KK, Chong D, Ho KL, Tan BY, Teo WS, Ching CK<sup>†</sup>, **Tse HF**<sup>†</sup>. First clinical experience on the safety and feasibility of total subcutaneous implantable defibrillator in an Asian population. *Europace* 2015;17 Suppl 2:ii63-ii68. (JIF=5.231, No. of cites=4, <sup>†</sup>co-corresponding author)
365. Chan PH, Hai J, Yeung CY, Lip GY, Lam KS, **Tse HF**, Siu CW. Benefit of Anticoagulation therapy in hyperthyroidism-related atrial fibrillation. *Clin Cardiol*. 2015;38:476-82. (JIF=2.733, No. of cites=6).
366. Sun YQ, Zhang Y, Li X, Deng MX, Gao WX, Yao Y, Chiu SM, Liang X, Gao F, Chan CW, **Tse HF**, Shi J, Fu QL, Lian Q. Insensitivity of human iPS cells-derived mesenchymal stem cells to interferon- $\gamma$  -induced HLA expression potentiates repair efficiency of hind limb ischemia in immune humanized NOD SCID Gamma mice. *Stem Cells*. 2015;33:3452-67. (JIF=5.587, No. of cites=14)

367. Zhang Y, Zhang Z, Gao F, **Tse HF**, Tergaonkar V, Lian Q. Paracrine regulation in mesenchymal stem cells: the role of Rap1. *Cell Death Dis.* 2015;6:e1932. (JIF=5.638, No. of cites=2).
368. Tang CS, Zhang H, Cheung CY, Xu M, Ho JC, Zhou W, Cherny SS, Zhang Y, Holmen O, Au KW, Yu H, Xu L, Jia J, Porsch RM, Sun L, Xu W, Zheng H, Wong LY, Mu Y, Dou J, Fong CH, Wang S, Hong X, Dong L, Liao Y, Wang J, Lam LS, Su X, Yan H, Yang ML, Chen J, Siu CW, Xie G, Woo YC, Wu Y, Tan KC, Hveem K, Cheung BM, Zolner S, Xu A, Chen Y, Jiang CQ, Zhang Y, Lam TH, Ganesh S, Huo Y, Sham PC<sup>†</sup>, Lam KS<sup>†</sup>, Willer CJ<sup>†</sup>, **Tse HF**<sup>†</sup>, Gao W<sup>†</sup>. Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. *Nat Comm* 2015;6:10206. (JIF =12.353, No. of cites=8, <sup>†</sup>co-corresponding author).
369. Chan PH, Li WH, Hai JJ, Chan KH, **Tse HF**, Cheung BM, Chan EW, Wong IC, Leung WK, Hung IF, Lip GY, Siu CW. Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. *Eur Heart J Cardiovasc Pharmacother.* 2015;1:265-72. (JIF =NA, No. of cites=5)
- 2016
370. Lian Q, Zhang Y, Liang X, Gao F, **Tse HF**. Directed Differentiation of Human-Induced Pluripotent Stem Cells to Mesenchymal Stem Cells. *Methods Mol Biol.* 2016;1416:289-98 (JIF=0.429, No. of cites=0)
371. <sup>#</sup>Lee YK, Ran X, Lai KW, Lau VY, Siu DC, **Tse HF**. Generation and characterization of patient-specific iPSC model for cardiovascular disease. *Methods Mol Biol.* 2016;1353:191-213. (JIF=0.429, No. of cites=0, corresponding author)
372. Chen Y, Chan AC, Chan SC, Chok SH, Sharr W, Fung J, Liu JH, Zhen Z, Sin WC, Lo CM, **Tse HF**<sup>†</sup>, Yiu KH<sup>†</sup>. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. *J Cardiol.* 2016;67:140-6. (JIF=2.918, No. of cites=5, <sup>†</sup>co-corresponding author)
373. Chan PH, Huang D, Yip PS, Hai JJ, **Tse HF**, Chan TM, Lip GYH, Lo WK, Siu CW. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. *Europace.* 2016;18:665-71. (JIF=5.231, No. of cites=8).
374. Chan PH, Huang D, Hai JJ, Li WH, Yin LX, Chan EW, Wong IC, Lau CP, Chiang CE, Zhu J, **Tse HF**, Siu CW. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. *Heart Rhythm.* 2016;13:366-73 (JIF=4.743, No. of cites=16).
375. Zhen Z, Chen Y, Shih K, Liu JH, Yuen M, Wong DS, Lam KS, **Tse HF**<sup>†</sup>, Yiu KH<sup>†</sup>. Altered myocardial response in patients with diabetic retinopathy: An exercise echocardiography study. *Cardiovasc Diabetol.* 2015;14:123. (JIF =5.235, No. of cites=5, <sup>†</sup>co-corresponding author).
376. Yiu KH, Ninaber MK, Kroft LJ, Schouffoer AA, Stolk J, Scherer HU, Meijs J, de Vries-Bouwstra J, **Tse HF**, Delgado V, Bax JJ, Huizinga TW, Marsan NA. Impact of

pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. *Rheumatology* (Oxford). 2016;55:504-12. (JIF =5.245, No. of cites=1).

377. Zhen Z, Chen Y, Liu JH, Chan CW, Yuen M, Lam KS, Tse HF<sup>†</sup>, Yiu KH<sup>†</sup>. Increased T-wave alternans is associated with subclinical myocardial structural and functional abnormalities in patients with type 2 diabetes. *J Cardiol*. 2016;68:329-34 (JIF=2.918, No. of cites=2, <sup>†</sup>co-corresponding author)
378. Lee YK, Lau YM, Ng KM, Lai WH, Ho SL, Tse HF, Siu CW, Ho PW. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA. *Int J Cardiol*. 2016;203:964-71.(JIF=4.034, No. of cites=11).
379. Liu JH, Chen Y, Zhen Z, Yeung CK, Chan J, Chan HH, Tse HF, Yiu KH. Relation between endothelial progenitor cells and arterial stiffness in patients with psoriasis. *J Dermatol*. 2016;43:888-93 (JIF =2.788, No. of cites=3).
380. Chen Y, Seto WK, Ho LM, Fung J, Jim MH, Yip G, Fan K, Zhen Z, Liu JH, Yuen MF, Lau CP, Tse HF, Yiu KH. Relation of tricuspid regurgitation to liver stiffness measured by transient elastography in patients with left-sided cardiac valve disease. *Am J Cardiol*. 2016;117:640-6. (JIF =3.171, No. of cites=2).
381. Liu JH, Chen Y, Yuen M, Zhen Z, Chan CW, Lam KS, Tse HF, Yiu KH. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2016;15:22. (JIF =5.235, No. of cites=9, <sup>†</sup>co-corresponding author).
382. Kumana CR, Cheung BM, Siu DC, Tse HF, Lauder IJ. Non vitamin K oral anticoagulants versus warfarin for patients with atrial fibrillation: absolute benefit and harm assessments yield novel insights. *Cardiovasc Ther*. 2016;34:100-6. (JIF =2.245, No. of cites=2).
383. Chan PH, Li WH, Hai JJ, Chan EW, Wong IC, Tse HF, Lip GY, Siu CW. Time in therapeutic range and percentage of international normalized ratio in the therapeutic range as a measure of quality of anticoagulation control in patients with atrial fibrillation. *Can J Cardiol*. 2016;32:1247.e23-1247(JIF =4.524, No. of cites=1).
384. Hai JJ, Chan PH, Huang D, Ho MH, Ho CW, Cheung E, Lau CP, Tse HF, Siu CW. Clinical characteristics, management, and outcomes of hospitalized heart failure in a Chinese population-The Hong Kong Heart Failure Registry. *J Card Fail*. 2016;22:600-8 (JIF =3.942, No. of cites=7).
385. Chan PH, Hai JJ, Chan EW, Li WH, Tse HF, Wong IC, Lip GY, Siu CW. Use of the SAME-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. *PLoS One*. 2016;11:e0150674. (JIF =2.766, No. of cites=11).
386. Chan PH, Huang D, Lau CP, Chan EW, Wong IC, Lip GY, Tse HF, Siu CW. Net Clinical Benefit of Dabigatran Over Warfarin in Patients With Atrial Fibrillation

Stratified by CHA<sub>2</sub>DS<sub>2</sub>-VASc and Time in Therapeutic Range. *Can J Cardiol*. 2016;32:1247.e15-1247. (JIF =4.524, No. of cites=0).

387. Cheng Y, Tse HF, Li X, Han Y, Rong J. Gallic acid-l-leucine (GAL) conjugate enhances macrophage phagocytosis via inducing leukotriene B4 12-hydroxydehydrogenase (LTB4DH) expression. *Mol Immunol*. 2016;74:39-46. (JIF =3.188, No. of cites=4).
388. Bai B, Man AW, Yang K, Guo Y, Xu C, Tse HF, Han W, Bloksgaard M, De Mey JG, Vanhoutte PM, Xu A, Wang Y. Endothelial SIRT1 prevents adverse arterial remodeling by facilitating HERC2-mediated degradation of acetylated LKB1. *Oncotarget*. 2016;7:39065-39081.(JIF =5.168, No. of cites=6).
389. Zhang Y, Yu Z, Jiang D, Liang X, Liao S, Zhang Z, Yue W, Li X, Chiu SM, Chai YH, Liang Y, Chow Y, Han S, Xu A, Tse HF<sup>†</sup>, Lian Q<sup>†</sup>. Human iPSC-MSCs with high intrinsic Miro1 and sensitivity to TNF- $\alpha$  yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy. *Stem Cell Report* 2016;7:749-763. (JIF =6.537, No. of cites=10, <sup>†</sup>co-corresponding author)
390. Xu J, Lee YK, Ran X, Liao SY, Yang J, Au KW, Lai WH, Esteban MA, Tse HF. Generation of induced cardiospheres via reprogramming of skin fibroblasts for myocardial regeneration. *Stem Cells* 2016;34:2693-2706. (JIF =5.587, No. of cites=2, corresponding author)
391. Lee SW, Lam SC, Tam FC, Chan KK, Shea CP, Kong SL, Wong AY, Yung A, Zhang LW, Tse HF, Wu KK, Chan R, Haude M, Mehran R, Mintz GS, Maehara A. Evaluation of early healing profile and neointimal transformation over 24 months using longitudinal sequential optical coherence tomography assessments and 3-Year clinical results of the new dual-therapy endothelial progenitor cell capturing sirolimus-eluting combo stent: The EGO-Combo Study. *Circ Cardiovasc Interv*. 2016;9. pii: e003469. (JIF =6.504, No. of cites=1)
392. Chen Y, Liu JH, Chan D, Sit KY, Wong CK, Ho KL, Ho LM, Zhen Z, Lam YM, Lau CP, Au WK, Tse HF, Yiu KH. Prevalence, predictors and clinical outcome of residual pulmonary hypertension following tricuspid annuloplasty. *J Am Heart Assoc*. 2016;5. pii: e003353. (JIF =4.45, No. of cites=1)
393. Hai JJ, Chan PH, Chan YH, Fong CH, Huang D, Li WH, Yin LX, Lau CP, Tse HF, Siu CW. Prediction of thromboembolic events in heart failure patients in sinus rhythm: The Hong Kong Heart Failure Registry. *PLoS One*. 2016;11:e0169095 (JIF =2.766, No. of cites=0).
394. Cheng YY, Luo D, Xia Z, Tse HF, Li X, Rong J. In Vivo Cardioprotective Effects and pharmacokinetic profile of N-Propyl caffeamide against ischemia reperfusion injury. *Arch Immunol Ther Exp (Warsz)*. 2016 :65:145-156 (JIF =3.018, No. of cites=2)
395. Cheung CYY, Tang CS, Xu A, Lee CH, Au KW, Xu L, FongCHY, Kwok KHM, Chow WS, WooYC, Yuen MMA, Hai JSH, Jin YL, Cheung BMY, Tan KCB, Cherny SS, Zhu F, Zhu T, Thomas GN, Cheng KK, Jiang CQ, Lam TH, Tse HF, Sham PC,



- Lam KSL. Exome-chip association analysis reveals an Asian-specific missense variant in PAX4 associated with type 2 diabetes in Chinese. *Diabetologia* 2017;60:107-115. (JIF =6.023, No. of cites=2)
396. Ng KM, Mok PY, Butler AW, Ho JC, Choi SW, Lee YK, Lai WH, Au KW, Lau YM, Wong LY, Esteban MA, Siu CW, Sham PC, Colman A, **Tse HF**. Amelioration of X-linked related autophagy failure in Danon disease with DNA methylation inhibitor. *Circulation*. 2016;134:1373-1389. (JIF =18.88, No. of cites=2, corresponding author)
397. Chan PH, Hai JJ, Huang D, Ho MH, Chan EW, Cheung BM, Chan AO, Wong IC, **Tse HF**, Hung IF, Siu CW. Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention. *SAGE Open Med*. 2016 Aug 4;4:2050312116662414. doi: 10.1177/2050312116662414. eCollection 2016. (JIF =NA, No. of cites=0)
398. Jiang D, Gao F, Zhang YL, Wong SHD, Li Q, **Tse HF**, Xu G, Yu Z, Lian Q. Mitochondrial transfer of Mesenchymal Stem cells effectively protects corneal epithelial cells from mitochondrial damage. *Cell Death and Diseases* 2016;7:e2467. (JIF=5.938, No. of cites=14)
399. Hsu JC, Akao M, Abe M, Anderson KL, Avezum A, Glusenkamp N, Kohsaka S, Lane DA, Lip GY, Ma CS, Masoudi FA, Potpara TS, Siong TW, Turakhia MP, **Tse HF**, Rumsfeld JS, Maddox TM. International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. *J Am Heart Assoc*. 2016 Nov 2;5(11). pii: e004037 (JIF =4.45, No. of cites=3)
- 2017
400. Li X, Zhang YL, Liang Y, Liang X, Ding Y, Ip MS, **Tse HF**, Lian Q, Mak JC. iPSC-derived mesenchymal stem cells exert SCF-dependent recovery of cigarette smoke-induced apoptosis/proliferation imbalance in airway cells. *J Cell Mol Med* 2017;21:265-277. (JIF =4.302, No. of cites=5)
401. Hai JJ, Tam E, Chan PH, Lau CP, Siu CW, **Tse HF**. Incidence and predictors of sudden arrhythmic death or ventricular tachyarrhythmias after acute coronary syndrome: An asian perspective. *Heart Rhythm*. 2017;14:1:81-87 (JIF =4.743, No. of cites=2, corresponding author).
402. Li L, Zhang Q, Yang H, Zou Q, Lai C, Jiang F, Zhao P, Luo Z, Yang J, Chen Q, Wang Y, Newsome PN, Frampton J, Maxwell PH, Li W, Chen S, Wang D, Siu TS, Tam S, **Tse HF**, Qin B, Bao X, Esteban MA, Lai L. Fumarylacetoacetate hydrolase knockout rabbit model for hereditary tyrosinemia type 1. *J Biol Chem*. 2017 Jan 4. pii: jbc.M116.764787. doi: 10.1074/jbc.M116.764787. (JIF =4.01, No. of cites=1)
403. Poon MW, Jiang D, Qin P, Zhang Y, Qiu B, Chanda S, Tergaonkar V, Li Q, Wong IY, Yu Z, **Tse HF**, Wong DS, Lian Q. Inhibition of NUCKS facilitates corneal recovery following alkali burn. *Sci Rep*. 2017;7:41224 (JIF=4.122, No. of cites=6)
404. Liu JH, Ng MY, Cheung T, Chung HY, Chen Y, Zhen Z, Zou Y, Mak KF, Khong PL, Lau CS, **Tse HF**, Yiu KH. Ten-year progression of coronary artery, carotid artery, and aortic calcification in patients with rheumatoid arthritis. *Clin Rheumatol*. 2017 2017;36:807-816(JIF =2.141, No. of cites=1)

405. Lee CH, Huang G, Chan PH, Hai J, Yeung CY, Fong CH, Woo YC, Ho KL, Yiu MK, Leung F, Lau TW, **Tse HF**, Lam KS, Siu CW. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma. *PLoS One*. 2017;12:e0171495. (JIF =2.766, No. of cites=1).
406. Cao G, Chen C, Lin Q, Chen Y, Zhen Z, Zou Y, Liu J, Wu M, Wang R, Liu M, Zhao C, Lu S, Ng MY, **Tse HF**, Yiu KH. Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese. *Postgrad Med*. 2017;129:187-192. (JIF =2.057, No. of cites=0)
407. Yang J, Wang Y, Zhou T, Wong LY, Tian XY, Hong X, Lai WH, Au KW, Wei R, Liu Y, Cheng LH, Liang G, Huang Z, Fan W, Zhao P, Wang X, Ibañez DP, Luo Z, Li Y, Zhong X, Chen S, Wang D, Li L, Lai L, Qin B, Bao X, Hutchins AP, Siu CW, Huang Y, Esteban MA, † **Tse HF**†. Generation of human liver chimeric mice with hepatocytes from familial hypercholesterolemia induced pluripotent stem cells. *Stem Cell Reports*. 2017;8:603-618. (JIF =6.537, No. of cites=3, †co-corresponding author)
408. Lai FP, Lau ST, Wong JK, Gui H, Wang RX, Zhou T, Lai WH, **Tse HF**, Tam PK, Garcia-Barcelo MM, Ngan ES. Correction of Hirschsprung-associated Mutations in Human Induced Pluripotent Stem Cells, via CRISPR/Cas9, Restores Neural Crest Cell Function. *Gastroenterology*. 2017;153:139 (JIF =20.773, No. of cites=4)
409. Cheung CY, Tang CS, Xu A, Lee CH, Au KW, Xu L, Fong CH, Kwok KH, Chow WS, Woo YC, Yuen M, Cherny SS, Hai J, Cheung BM, Tan K, Lam TH, **Tse HF**, † Sham PC, † Lam KS. † An exome-chip association analysis in Chinese reveals a functional missense variant of *Gckr* that regulates FGF21 levels. *Diabetes*. 2017;6:1723-1728 (JIF =7.273, No. of cites=0, †co-corresponding author).
410. Zhang Y, Chiu S, Liang X, Chai YH, Qin Y, Wang J, Li X, Qiu B, Tergaonkar V, **Tse HF**, Lian Q. Absence of NUCKS augments paracrine effects of mesenchymal stem cells-mediated cardiac protection. *Exp Cell Res*. 2017;356:74-84. (JIF =3.309, No. of cites=0, †co-corresponding author).
411. Agrawal DR, Tanabe Y, Weng D, Ma A, Hsu S, Liao SY, Zhen Z, Zhu ZY, Sun C, Dong Z, Yang F, **Tse HF**, † Poon AS, † Ho JS†. Conformal phased surfaces for wireless powering of bioelectronic microdevices. *Nature Biomedical Engineering* 2017;1, 0043. | DOI: 10.1038/s41551-017-0043 (JIF =NA, No. of cites=9, †co-corresponding author).
412. Lu J, Lee YK, Ran X, Lai WH, Li RA, Keung W, Tse K, **Tse HF**, Yao X. An abnormal TRPV4-related cytosolic Ca<sup>2+</sup> rise in response to uniaxial stretch in induced pluripotent stem cells-derived cardiomyocytes from dilated cardiomyopathy patients. *Biochim Biophys Acta*. 2017 Jul 25;1863(11):2964-2972. [Epub ahead of print] (JIF =5.108, No. of cites=0).
413. Liao S, Zhen Z, Liu Y, Au KW, Lai WH, Tsang A, **Tse HF**. Improvement of myocardial function following catheter-based renal denervation in heart failure. *J Am Coll Cardiol Basic Transl Sci* 2017;2: 270-81 (JIF =NA, No. of cites=NA, corresponding author).

414. Lee CH, Woo YC, Chow WS, Cheung CY, Fong CH, Yuen MM, Xu A, **Tse HF**,<sup>†</sup> Lam KS.<sup>†</sup> Can circulating fibroblast growth factor 21 play a role in primary prevention of coronary heart disease among Chinese patients with type 2 diabetes? *J Am Heart Assoc.* 2017;6. pii: e005344. doi: (JIF =4.45, No. of cites=NA, <sup>†</sup>co-corresponding author)
415. Lee YK, Lau YM, Cai ZJ, Lai WH, Wong LY, **Tse HF**, Ng KM, Siu CW. Modeling treatment response for Lamin A/C related dilated cardiomyopathy in human induced pluripotent stem cells. *J Am Heart Assoc.* 2017;6. pii: e005677. doi (JIF =4.45, No. of cites=0)
416. Liu JH, Chen Y, Zhen Z, Ho LM, Tsang A, Yuen M, Lam K, **Tse HF**, Yiu KH. Relationship of biomarkers of extracellular matrix with myocardial function in Type 2 diabetes mellitus. *Biomark Med.* 2017;11:569-578. (JIF=2.346, No. of cites=0).
417. Tam CC, Chan K, Lam S, Yung A, Lam YM, Chan C, Siu D, **Tse HF**. One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent. *J Int Med Res.* 2018;46:457-463 (JIF=1.323, No. of cites=0).
418. Liang Y, Li X, Zhang Y, Yeung SC, Zhen Z, Ip MSM, **Tse HF**, Lian Q, Mak JCW. Induced pluripotent stem cells-derived mesenchymal stem cells attenuate cigarette smoke-induced cardiac remodeling and dysfunction. *Front Pharmacol.* 2017 Jul 28;8:501. (JIF=3.831, No. of cites=0).
419. Wang Y, Liu HN, Zhen Z, Yiu KH, **Tse HF**, Pelekos G, Tonetti M, Jin L. Periodontal treatment modulates gene expression of endothelial progenitor cells in diabetic patients. *J Clin Periodontol.* 2017 12:1253-1263 (JIF=4.046, No. of cites=0).
420. Chan YH, Hai JJ, Lau KK, Li SW, Lau CP, Siu CW, Yiu KH, **Tse HF**. PR interval prolongation in coronary patients or risk equivalent: excess risk of ischemic stroke and vascular pathophysiological insights. *BMC Cardiovasc Disord.* 2017 Aug 24;17(1):233 (JIF=1.812, No. of cites=0).
421. Chen L, Cui Y, Jiang D, Ma CY, **Tse HF**, Hwu WL, Lian Q. Management of Leigh Syndrome: current status and new insights. *Clin Genet.* 2017;93:1131-1140 (JIF=3.512, No. of cites=0).
422. Chen Y, Liu JH, Zhen Z, Zuo Y, Lin Q, Liu M, Zhao C, Wu M, Cao G, Wang R, **Tse HF**, Yiu KH. Assessment of left ventricular function and peripheral vascular arterial stiffness in patients with dipper and non-dipper hypertension. *J Investig Med.* 2018;66:2:319-324(JIF=2.029, No. of cites=0)
423. Yiu KH, Chen Y, Liu JH, Lin Q, Liu M, Wu M, Wang R, Zhen Z, Zou Y, Lam YM, Ng MY, Lau CP, **Tse HF**. Burden and contributing factors associated with tricuspid regurgitation: a hospital-based study. *Hosp Pract (1995).* 2017 Oct 3:1-6. doi: 10.1080/21548331.2017.1384688. [Epub ahead of print] (JIF=NA, No. of cites=NA).
424. Lu X, Peloso GM, Liu DJ, Wu Y, Zhang H, Zhou W, Li J, Tang CS, Dorajoo R, Li H, Long J, Guo X, Xu M, Spracklen CN, Chen Y, Liu X, Zhang Y, Khor CC, Liu J, Sun

- L, Wang L, Gao Y, Hu Y, Yu K, Wang Y, Cheung CY, Wang F, Huang J, Fan Q, Cai Q, Chen S, Shi J, Yang X, Zhao W, Sheu WH, Cherny SS, He M, Feranil AB, Adair LS, Gondon-Larsen P, Du S, Varma R, Chen YI, Shu X, Lam KS, Wong TY, Ganesh SK, Mo Z, Hveem K, Fritsche L, Nielsen JB, **Tse HF**, Huo Y, Cheng CY, Chen YE, Zheng W, Tai ES, Gao W, Lin X, Huang W, Abecasis G, GLGC Consortium, Kathiresan S, Mohlke KL, Wu T, Sham PC, Gu D, Willer CJ. Exome chip meta-analysis identifies novel loci and East Asian-specific coding variants contributing to lipid levels and coronary artery disease. *Nature Genetic* 2017;49:1722-1730 (*JIF*=27.125, *No. of cites*=3).
425. Tanabe Y, Ho JS, Liu J, Liao S-Y, Zhen Z, Hsu S, Shuto C, Zhu ZY, Ma A, Vassos C, Chan P, Tse HF, Poon ASY. High-performance wireless powering for peripheral nerve neuromodulation systems. *PLoS ONE* 2017;12(10): e0186698. <https://doi.org/10.1371/journal.pone.0186698> (*JIF* =2.766, *No. of cites*=0).
426. Chan YH, Yiu KH, Hai JJ, Chan PH, Lam TH, Cowling BJ, Sham PC, Lau CP, Lam KS, Siu CW, **Tse HF**. Genetically deprived vitamin D exposure predisposes to atrial fibrillation. *Europace*. 2017;19(suppl\_4):iv25-iv31. (*JIF*=5.231, *No. of cites*=0).
427. Wu HJ, Yiu WH, Wong DWL, Li RX, Chan LYY, Leung JCK, Zhang Y, Lian Q, Lai KN, **Tse HF**, Tang SCW. Human induced pluripotent stem cell-derived mesenchymal stem cells prevent adriamycin nephropathy in mice. *Oncotarget*. 2017;8103640-103656. (*JIF* =5.168, *No. of cites*=0).
428. Hai JJ, Un KC, Wong CK, Wong KL, Zhang ZY, Chan PH, Lau CP, Siu CW, **Tse HF**. Prognostic implications of early monomorphic and non-monomorphic tachyarrhythmias in patients discharged with acute coronary syndrome. *Heart Rhythm*. 2018;15:6:822-829: (*JIF* =4.743, *No. of cites*=0, *corresponding author*).
429. Liu FZ, Liao HT, Lin WD, Xue YM, Zhan XZ, Fang XH, Rao F, Deng H, Huang J, Hai JJ, **Tse HF**, Wu SL. Predictive effect of hyperuricemia on left atrial stasis in non-valvular atrial fibrillation patients. *Int J Cardiol*. 2018 May 258:103-108. (*JIF*=4.034, *No. of cites*=0).
430. Ding Y, Liang X, Zhang Y, Yi L, Shum HC, Chen Q, Chan BP, Fan H, Liu Z, Tergaonkar V, Qi Z\*, **Tse HF\***, Lian Q\*. Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. *Cell Death Dis*. 2018 Mar 7;9(3):386. doi: 10.1038/s41419-018-0414-3. (*JIF*=5.638, *No. of cites*=0, *co-corresponding author\**)
431. Zhuang Q, Li W, Benda C, Huang Z, Ahmed T, Liu P, Guo X, Ibañez DP, Luo Z, Zhang M, Abdul MM, Yang Z, Yang J, Huang Y, Zhang H, Huang D, Zhou J, Zhong X, Zhu X, Fu X, Fan W, Liu Y, Xu Y, Ward C, Khan MJ, Kanwal S, Mirza B, Tortorella MD, **Tse HF**, Chen J, Qin B, Bao X, Gao S, Hutchins AP, Esteban MA. NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming. *Nat Cell Biol*. 2018 Apr;20(4):400-412. doi: 10.1038/s41556-018-0047-x. Epub 2018 Mar 12. (*JIF*=19.064, *No. of cites*=0).
432. Huang D, Cheng YY, Chan PH, Hai J, Yiu KH, **Tse HF**, Wong KL, Fan K, Li YW, Ng WL, Yim CW, Wong CJ, Tam LS, Wong PCH, Wong CY, Ho CH, Leung AMH,

Mok CC, Lam H, Lau CS, Cheung T, Ho C, Law SWY, Chan EW, Yin LX, Yue WS, Mok TM, Evora MA, Siu CW. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study. *ERJ Open Res.* 2018 Mar 6;4(1). pii: 00135-2017. doi: (JIF=NA, No. of cites=0).

433. Mura M, Lee YK, Ginevrino M, Zappatore R, Pisano F, Boni M, Dagradi F, Crotti L, Valente EM, Schwartz PJ, **Tse HF**, Gneccchi M. Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene. *Stem Cell Res.* 2018 Apr 7;29:157-161. doi: 10.1016/j.scr.2018.04.002. (JIF=1.829, No. of cites=0).
434. Wu MZ, Chen Y, Au WK, Chan D, Sit KY, Ho KL, Ho LM, Lam YM, Lau CP, Chan TM, **Tse HF**, Yiu KH. Predictive value of acute kidney injury for major adverse cardiovascular events following tricuspid annuloplasty: A comparison of three consensus criteria. *J Cardiol.* 2018 Mar 26. pii: S0914-5087(18)30057-1. doi: 10.1016/j.jjcc.2018.01.018. [Epub ahead of print]

#### **Original Articles Published in International Journals (as Investigator in Multi-center Trials)**

1. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; **ATHENA Investigators**. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med.* 2009;360:668-78. (JIF =79.258, No. of cites=634)
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; **the RE-LY Steering Committee and Investigators**. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med.* 2009;361:1214-20. (JIF =79.258, No. of cites=5089)
3. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; **HEAAL Investigators**. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. *Lancet.* 2009;374:1840-8. (JIF =53.254, No. of cites=268)
4. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; **ASSERT Investigators**. Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med.* 2012;366:120-9. (JIF =79.258, No. of cites=721)
5. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; **SIGNIFY Investigators**. Ivabradine in stable coronary artery disease without clinical heart failure. *N Engl J Med.* 2014;;371:1091-9. (JIF =79.258, No. of cites=198)
6. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; **PARADIGM-HF Investigators** and

Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med.* 2014;371:993-1004. (JIF =79.258, No. of cites=1077)

7. Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, González-Medina A, Haggèe AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; **PARADIGM-HF Investigators** and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation.* 2015;131:54-61. (JIF =18.88, No. of cites=207)
8. Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER 3rd, Siegbahn A, Tarka E, Steg PG, Stewart RA, Weiss R, Östlund O, White HD; **STABILITY Investigators**. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. *J Am Heart Assoc.* 2016;5. pii: e003407. (JIF =4.45, No. of cites=0)
9. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; **PARADIGM-HF Investigators and Committees**. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. *Circ Heart Fail.* 2016;9. pii: e002560. (JIF =5.684, No. of cites=53)
10. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; **GLORIA-AF Investigators**. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. *J Am Coll Cardiol.* 2017;69:777-785. (JIF=16.834, No. of cites=34).
11. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; **EXSCEL Study Group**. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2017;377:1228-1239. (JIF =79.258, No. of cites=97)

### Invited Articles or Review Published in International Journals

1. Lau CP, Tse HF. Electrical remodelling of chronic atrial fibrillation. *Clin Exp Pharm Physiol.* 1997; 24: 982-3. (JIF=2.092; No. of cites=16).

2. **Tse HF**, Lau CP. Electrophysiologic properties of fibrillating atrium: implication for therapy. *Clin Exp Pharm Physiol*. 1998; 25: 293-302. (JIF=2.092; No. of cites=10, first author)
3. **Tse HF**, Lau CP. The current status of single lead dual chamber sensing and pacing. *J Interv Card Electrophysiol* 1998, 2:255-67. (JIF=1.522; No. of cites=11, first author)
4. **Tse HF**, Lau CP, Camm AJ. Transvenous atrial defibrillation: Technique and clinical application. *Clin Cardiol*. 1999; 22:614-22. (JIF=2.733; No. of cites= 9, first author)
5. **Tse HF**, Lam WF. JTV-519 Japan tobacco. Current Option in Investigational Drugs. 2001; 2: 936-939 (JIF=4.883; No. of cites= 1).
6. Lau CP, Leung SK, **Tse HF**, Barold SS. Automatic mode switching of implantable pacemaker I: Principles of instrumentation, clinical and hemodynamics considerations. *Pacing Clin Electrophysiol*. 2002; 25: 967-85. (JIF=1.441; No. of cites= 14).
7. Lau CP, Leung SK, **Tse HF**, Barold SS. Automatic mode switching of implantable pacemaker II: Current algorithms and their programming. *Pacing Clin Electrophysiol*. 2002; 25: 1094-113. (JIF=1.441; No. of cites=12).
8. Lau CP, Barold S, **Tse HF**, Lee KLF, Chan HW, Fan K, Chau E, Yu CM. Advances in devices for cardiac resynchronization in heart failure. *J Interv Card Electrophysiol*. 2003; 9: 167-81. (JIF=1.522; No. of cites=14).
9. Kwok KM, Lee KLF, Lau CP, **Tse HF**. Sudden cardiac death: Prevention and treatment. *Hong Kong Med J*. 2003; 9: 357-62. (JIF=0.872; No. of cites=2, corresponding author). (Review)
10. Mitchell ARJ, Spurrell PAR, Silkee N, **Tse HF**, Lau CP. Reducing atrial defibrillation thresholds in patients with persistent atrial fibrillation. *J Cardiovasc Electrophysiol*. 2003; 14: 899-900. (JIF=2.873; No. of cites=0)
11. **Tse HF**, Lau CP. Future perspective of implantable device for atrial defibrillation. *Cardiol Clin* 2004; 22: 87-100. (JIF=1.064; No. of cites=0, first author)
12. Cheung BMY, Man YB, **Tse HF**, Kumana CR, Lau CP. Advantages of blood pressure optimization. *Adv Ther* 2005; 22: 285-96. (JIF=3.085; No. of cites= 3).
13. **Tse HF**. Catheter ablation for persistent atrial fibrillation: Are we ready for "prime time"? *J Cardiovasc Electrophysiol* 2005; 16: 1148-49. (JIF=2.873; No. of cites= 2, first & corresponding author)
14. \***Tse HF**. Atrial fibrillation: from pathophysiology to catheter ablation. *Heart Rhythm*. 2006; 3: 896-7. (JIF=4.743; No. of cites=0, first author).
15. \***Tse HF**, Lau CP. Clinical trials for cardiac pacing in bradycardia: the end or the beginning? *Circulation*. 2006; 114:3-5. (JIF=18.88; No. of cites=6, first author)

16. \***Tse HF**, Lau CP. Selection of permanent ventricular pacing site: how far should we go? *J Am Coll Cardiol* 2006; 48:1649-51. (JIF=16.834; No. of cites=10, first & corresponding author)
17. \*Lau CP, **Tse HF**, Mond HG. The impact of reimbursement on the usage of pacemakers, implantable cardioverter defibrillators and radiofrequency ablation. *J Interv Card Electrophysiol.* 2007;17: 177-181. (JIF=1.522; No. of cites=6)
18. #**Tse HF**, Yiu KH, Lau CP. Bone marrow stem cell therapy for myocardial angiogenesis. *Curr Vasc Pharmacol* 2007;5:103-112. (JIF= 2.087, No. of cites=21, first and corresponding author).
19. #**Tse HF**, Lau CP. Therapeutic angiogenesis with bone marrow derived stem cells. *J Cardiovasc Pharmacol Ther.* 2007;12:89-97. (JIF=2.936; No. of cites=21, first and corresponding author).
20. \*Lip GY, **Tse HF**. Management of atrial fibrillation. *Lancet* 2007;370:604-18. (JIF=53.254; No. of cites=118)
21. #Shantsila E, Watson T, **Tse HF**, Lip GY. Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell numbers? *Ann Med.* 2007;39:474-9. (JIF=3.007; No. of cites=20)
22. \*Yiu KH, **Tse HF**. Hypertension and cardiac arrhythmias: A review of the epidemiology, pathophysiology and clinical implications. *J Hum Hypertens* 2008; 22:380-8 (JIF= 2.433, No. of cites=21, corresponding author).
23. \*Lau CP, **Tse HF**, Camm AJ, Barold SS. Evolution of pacing for bradycardia: sensor. *Eur Heart J Suppl* 2007; 9: I11-I22 (JIF=0.418 No. of cites=0)
24. \*Siu CW, Wang M, Zhang XH, Lau CP, **Tse HF**. Analysis of ventricular performance as a function of pacing site and mode. *Prog Cardiovasc Dis* 2008; 50:171-182. (JIF=6.754, No. of cites=18, corresponding author).
25. \*Lam SK, **Tse HF**, Lau CP. CRT begets CRT-D: Is one better than the other? *J Cardiovas Electrophysiol* 2008;19:1266-9. (JIF= 2.873, No. of cites=4)
26. Lee CH, **Tse HF**. Microvascular obstruction after percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2010;75:369-77. (JIF=2.602; No. of cites=8).
27. Yiu KH, Cheung BM, **Tse HF**. A new paradigm for managing dyslipidemia with combination therapy: laropirant plus niacin plus simvastatin. *Expert Opin Investig Drugs.* 2010;19:437-49. (JIF=3.883, No. of cites=7, corresponding author).
28. \*Siu CW, **Tse HF**. Predicting recurrence of atrial fibrillation after electrical cardioversion: gauging atrial damage. *Europace.* 2010;12:764-5 (JIF=5.231, No. of cites=2, corresponding author).



29. #Siu CW, Liao SY, Liu Y, Lian Q, **Tse HF**. Stem cells for myocardial repair. *Thromb Haematol* 2010;104:6-12. (JIF=4.952, No. of cites=20, corresponding author).
30. #Lian Q, **Tse HF**. Ischaemic preconditioning and stem cell mobilisation. *Thromb Haemost.* 2010;104:194-5. (JIF=4.952, No. of cites=3, corresponding a233).
31. #Pei D, Xu J, Zhuang Q, **Tse HF**, Esteban MA. Induced pluripotent stem cell technology in regenerative medicine and biology. *Adv Biochem Eng Biotechnol.* 2010;123:127-41 (JIF=2.222; No. of cites=13).
32. #Lian Q, Chow Y, Esteban MA, Pei D, **Tse HF**. Future perspective of induced pluripotent stem cell for diagnosis, drug screening and treatment of human diseases. *Thromb Haemost.* 2010;104:39-44. (JIF=4.952, No. of cites=26, corresponding authors)
33. #Tse HF. New era of regenerative medicine for cardiovascular diseases. *Thromb Haemost.* 2010;104:4-5. (JIF=4.952, No. of cites=1).
34. Ho HH, Lau TW, Leung F, **Tse HF**, Siu CW. Pre-operative management of anti-platelet agents and anti-thrombotic agents in geriatric patients undergoing semi-urgent hip fracture surgery. *Osteoporos Int* 2010; 21 (Suppl 4):S573-577. (JIF=3.856; No. of cites=2).
35. Lo LL, Siu CW, **Tse HF**, Lau TW, Leung F, Wong M. Pre-operative pulmonary assessment for patients with hip fracture. *Osteoporos Int* 2010; 21 (Suppl 4):S579-586. (JIF=3.856; No. of cites=8).
36. Siu CW, Sun NC, Lau TW, Yiu KH, Leung F, **Tse HF**. Pre-operative cardiac risk assessment in geriatric patients with hip fracture. *Osteoporos Int* 2010; 21 (Suppl 4):S587-591. (JIF=3.856; No. of cites=3).
37. \*Siu CW, **Tse HF**, Lau CP. A shock in time saves ablation? *Europace.* 2011;13:155-6. (JIF=5.231; No. of cites=0).
38. #Li X, **Tse HF**, Jin LJ. An update on periodontal infections, endothelial dysfunction and circulating endothelial progenitor cells. *J Dent Res.* 2011;90:1062-9. (JIF= 5.38, No. of cites=13, corresponding author).
39. \*Lip GY, Halperin JL, **Tse HF**. The new 2010 European Society of Cardiology guidelines on atrial fibrillation management- an evolution or revolution? *Chest.* 2011;139:738-41. (JIF= 7.652, No. of cites=6, corresponding author)
40. Liu Y, **Tse HF**. The proarrhythmic risk of cell therapy for cardiovascular diseases. *Expert Rev Cardiovasc Ther.* 2011;9:1593-601
41. \*Lau YF, Yiu KH, Siu CW, **Tse HF**. Hypertension and atrial fibrillation: Epidemiology, pathophysiology and therapeutic implications. *J Hum Hypertens.* 2012;26:563-569. (JIF= 2.433, No. of cites=30, corresponding author)

42. \*Lip GY, **Tse HF**, Lane DA. Management of atrial fibrillation. *Lancet* 2012 18;379:648-61.(*JIF*=53.254; *No. of cites*= 213).
43. \*Siu CW, **Tse HF**. Thromboembolic risk of the hot- and cold- catheter ablation for atrial fibrillation. *Heart Rhythm* 2012;9:197-8. (*JIF*= 4.743, *No. of cites*=0, corresponding author).
44. Lam CC, **Tse HF**, Siu CW. Transient atrial fibrillation complicating acute myocardial infarction: a nuisance or nemesis. *Thromb Haemost.* 2012;107:6-7. (*JIF*=4.952, *No. of cites*=7).
45. \*Chiang CE, Zhang S, **Tse HF**, Teo WS, Omar R, Sriratanasathavorn C. Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. *Int J Cardiol.* 2012; 164:31-32 (*JIF*=4.034, *No. of cites*=6).
46. #Siu CW, **Tse HF**. Cardiac regeneration: messages from CADUCEUS. *Lancet* 2012 2012;379:870-1.(*JIF*=53.254; *No. of cites*=20, corresponding author).
47. \*Lau CP, **Tse HF**, Siu CW, Gbadebo. Atrial electrical and structural remodeling: Implication for racial differences in atrial fibrillation. *J Cardiovasc Electrophysiol.*2012;23:s36-s40 (*JIF*= 2.873, *No. of cites*=10).
48. #Ng KM, **Tse HF**. Modeling hereditary cardiac disease with patient-specific induced pluripotent stem cells: opportunities and concerns. *J Cardiovasc Pharmacol.* 2012;Oct;60:406-7 (*JIF*=2.227; *No. of cites*=1, corresponding authors,).
49. \*Lau CP, **Tse HF**. Linear ablation for atrial fibrillation guided by acoustic imaging: "How does it sound?" *Heart Rhythm.* 2012;9:1863-1864 (*JIF*= 4.743, *No. of cites*=1).
50. \*Lau CP, **Tse HF**, Siu CW, Gbadebo D. Atrial electrical and structural remodeling: implications for racial differences in atrial fibrillation. *J Cardiovasc Electrophysiol.* 2012;23:s36-40. (*JIF*= 2.873, *No. of cites*=10).
51. \*Lau CP, Siu CW, **Tse HF**. Pacing inducibility for atrial fibrillation: A test tested? *J Cardiovasc Electrophysiol.* 2013;24:624-5 (*JIF*= 2.873, *No. of cites*=0)
52. #Zhang Y, Liang X, Lian Q, **Tse HF**. Perspective and challenges of mesenchymal stem cells for cardiovascular regeneration. *Expert Rev Cardiovasc Ther.* 2013;11:505-17. (*JIF*=NA; *No. of cites*=15)
53. #Liao SY, **Tse HF**. Multipotent (adult) and pluripotent stem cells for heart regeneration: What are the Pros and Cons? *Stem Cell Res Ther* 2013;4:151. (*JIF*=4.963; *No. of cites*=8, corresponding author).
54. #Liang X, Ding Y, Zhang Y, **Tse HF**, Lian Q. Paracrine mechanisms of Mesenchymal Stem cell-based therapy: Current status and perspectives. *Cell Transplant.* 2013;23:1045-59. (*JIF*=2.885, *No. of cites*=145).

55. \*Lau CP, Siu CW, **Tse HF**. The future of implantable devices for cardiac rhythm management. *Circulation* 2014;129:811-22 (*JIF*=18.88; *No. of cites*=0).
56. \*Lau CP, **Tse HF**. Response or non-response to cardiac resynchronization therapy in heart failure: Lessons from the real world. *Heart Rhythm*. 2014;11:1417-8 (*JIF*=4.743, *No. of cites*=0).
57. Lau CP, Chun-Wah Siu D, **Tse HF**. Pulmonary vein in pathogenesis of persistent atrial fibrillation: An unsettled controversy. *J Cardiovasc Electrophysiol*. 2014 :25:477-8 (*JIF*= 2.873, *No. of cites*=1).
58. Yiu KH, **Tse HF**. Specific role of impaired glucose metabolism and diabetes in endothelial progenitor cell characteristics and function. *Arterioscler Thromb Vasc Biol*. 2014;34:1136-43. (*JIF*=6.086; *No. of cites*=36, *corresponding author*).
59. \*Chan PH, **Tse HF**. Adoption of cardiac resynchronization therapy in heart failure patients with post-cardiac valve surgery or interventions? *J Cardiovasc Electrophysiol*. 2014;25: 1214-5. (*JIF*=2.873, *No. of cites*=0, *corresponding author*).
60. #Xu JY, Lee YK, Wang Y, **Tse HF**. Therapeutic application of endothelial progenitor cells for treatment of cardiovascular diseases. *Curr Stem Cell Res Ther*. 2014;9:401-14. (*JIF*= 2.168, *No. of cites*=13, *corresponding author*).
61. #Lee YK, Ng KM<sup>†</sup>, **Tse HF**<sup>†</sup>. Modeling of human cardiomyopathy with induced pluripotent stem cells. *J Biomed Nanotechnol*. 2014;10:2562-85. (*JIF*=5.068, *No. of cites*=2, <sup>†</sup>*co-corresponding author*)
62. Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Fu Q, **Tse HF**, Lian Q. Mesenchymal Stem Cells and Immunomodulation: Current Status and Future Prospects. *Cell Death and Disease* 2016;7:e2062. doi: 10.1038/cddis.2015.327 (*JIF*=5.638, *No. of cites*=0, *in press*)
63. Hai JJ, **Tse HF**. Phrenic nerve palsy in cryoballoon ablation: Can it be prevented? *Heart Rhythm*. 2015 Nov 10. pii: S1547-5271(15)01392-2. doi: 10.1016/j.hrthm.2015.11.006. [Epub ahead of print] (*JIF*=4.743, *No. of cites*=0, *corresponding author*)
64. Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, **Tse HF**, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart

- Rhythm Association consensus conference. *Europace*. 2016;18:37-50. (JIF=5.231, No. of cites=3)
65. Lau CP, Siu CW, You KH, Lee KL, Chan YH, **Tse HF**. Subclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices *Europace*. 2015;17 Suppl 2:ii40-ii46. doi: 10.1093/europace/euv235. (JIF=5.231, No. of cites=0)
  66. #Lee YK, Ran X, Lai KW, Lau VY, Siu DC, **Tse HF**. Generation and characterization of patient-specific iPSC model for cardiovascular disease. *Methods Mol Biol*. 2016;1353:191-213. (JIF=0.429, No. of cites=0, corresponding author)
  67. Lip GY, Fauchier L, Freedman SB, Van Gelder I, Natale A, Gianni C, Nattel S, Potpara T, Rienstra M, **Tse HF**, Lane DA. Atrial fibrillation. *Nat Rev Dis Primers*. 2016 Mar 31;2:16016. doi: 10.1038/nrdp.2016.16. (JIF=NA, No. of cites=0)
  68. Lee YK, Jiang Y, Ran XR, Lau YM, Ng KM, Lai WH, Siu CW, **Tse HF**. Recent advances in animal and human pluripotent stem cell modeling of cardiac laminopathy. *Stem Cell Res Ther*. 2016 Sep 20;7(1):139. doi: 10.1186/s13287-016-0401-5. (JIF=4.963, No. of cites=2, corresponding author)
  69. Cheung BM, Cheng CH, Lau CP, Wong CK, Ma RC, Chu DW, Ho DH, Lee KL, **Tse HF**, Wong AS, Yan BP, Yan VW. 2016 Consensus statement on prevention of atherosclerotic cardiovascular disease in the Hong Kong population. *Hong Kong Med J*. 2017;23:191-201. (JIF=1.226, No. of cites=0)
  70. Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, Healey JS, Israel CW, Kudaiberdieva G, Levin LÅ, Lip GYH, Martin D, Okumura K, Svendsen JH, **Tse HF**, Botto GL; Document Reviewers: Christian Sticherling (Reviewer Coordinator), Linde C, Kutiyifa V, Bernat R, Scherr D, Lau CP, Iturralde P, P Morin D, Savelieva I. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). *Europace*. 2017;19:1556-1578. (JIF=5.231, No. of cites=NA).
  71. Wong CX, Brown A, **Tse HF**, Albert CM, Kalman JM, Marwick TH, Lau DH, Sanders P. Epidemiology of Atrial Fibrillation: The Australian and Asia-Pacific Perspective. *Heart Lung Circ*. 2017;26:870-879. (JIF=1.921, No. of cites=NA).
  72. Hai JJ, **Tse HF**. Myths and legends of right ventricular septal pacing. *J Cardiovasc Electrophysiol*. 2017;28:931-932. (JIF= 2.873, No. of cites=0)
  73. Zhang Z, Zhang Y, Gao F, Han S, Cheah KS, **Tse HF**, Lian Q. CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects. *Mol Ther Nucleic Acids*. 2017 Dec 15;9:230-241. (JIF= 5.66, No. of cites=3)
  74. Yiu KH, **Tse HF**. Editorial commentary for Dhakal: Heart failure in systemic lupus erythematosus: A problem to address. *Trends Cardiovasc Med*. 2017 Nov 8. pii: S1050-1738(17)30165-2. (JIF= 4.598, No. of cites=0)

## Letters or Case Reports Published in International Journals

1. **Tse HF**, Shek TWH, Tai YT, Lau YK, Ma L. An unusual form of hypertrophic cardiomyopathy with rapidly progressive heart failure. *Am J Med Sci* 1996; 312: 182-6. (JIF=1.773; No. of cites= 3, first & corresponding author)
2. Ng W, **Tse HF**, Lau CP. GISSI-Prevenzione trial. *Lancet*. 1999; 354: 1555-6. (letter) (JIF=53.254; No. of cites= 9)
3. **Tse HF**, Kumara CR. Case of the month. *Am J Med*. 2000; 109; 5:426. (JIF=5.117; No. of cites=0, first & corresponding author)
4. Lee KL, Lau CP, **Tse HF**, Wan SH, Fan K. Prevention of ventricular fibrillation by pacing in a man with Brugada syndrome. *J Cardiovasc Electrophysiol*. 2000; 11:935-37. (JIF=2.873; No. of cites= 16)
5. Lee PY, **Tse HF**. Transient ischaemic attack in a young woman. *Lancet*. 2000; 355: 622. (JIF=53.254; No. of cites=1, corresponding author)
6. **Tse HF**, Yeung CK. From profound hypokalemia to fatal rhabdomyolysis after severe head injury. *Am J Med*. 2000; 109: 599-600. (JIF=5.117; No. of cites=3, first & corresponding author)
7. **Tse HF**, Lam YM, Yiu M. Three dimensional reconstruction of femoral pseudoaneurysm using contrast-enhanced axial computed tomographic angiography. *Heart*. 2000; 84: 581. (JIF=5.42.; No. of cites= 1, first & corresponding author)
8. Lee KL, **Tse HF**, Lau CP. Left atrial to right ventricular bidirectional accessory pathway in a patient with Ebstein's anomaly: How does it connect? *Pacing Clin Electrophysiol*. 2001; 24: 507-509. (JIF=1.441; No. of cites=0)
9. Lam YM, Lau CP, **Tse HF**. Calcium chloride infusion for massive nifedipine overdose. *Chest*. 2001; 119: 1280-1282. (JIF=7.652; No. of cites=25, corresponding author)
10. **Tse HF**, Lee KLF, Fan K, Lau CP. Adenosine triphosphate enhanced contrast pulmonary venogram to facilitate pulmonary vein ablation. *J Cardiovasc Electrophysiol*. 2002; 13: 300. (JIF=2.873; No. of cites= 6, first & corresponding author)
11. **Tse HF**, Ho HH. Sudden cardiac death due to hypertrophic cardiomyopathy associated with midventricular obstruction and apical aneurysm. *Heart*. 2003; 89: 178. (JIF=5.42; No. of cites=13, first & corresponding author)
12. **Tse HF**, Lau CP, Lee KLF, Morady F. Atrial tachycardia arising from an epicardial site with venous connection between the left superior pulmonary vein and superior vena cava. *J Cardiovasc Electrophysiol*. 2003; 14: 540-3. (JIF=2.873; No. of cites=4, first & corresponding author)

13. Barold SS, Lau CP, **Tse HF**, Hess M. Shortening of the sensed AV delay of a dual chamber pacemaker during normal sinus rhythm. *J Interv Card Electrophysiol.* 2003; 9: 29-34. (JIF=1.522; No. of cites=0)
14. **Tse HF**, Yiu KH. Deep vein thrombosis demonstrated by contrast-enhanced helical computed tomographic venography. *Heart.* 2004; 90: 251. (JIF=5.42; No. of cites=0, first & corresponding author)
15. Kwan SK, Xu WC, Tang M, Chan FHY, Lau CP, **Tse HF**. A novel two-layered bayesian classifier for atrial tachyarrhythmia. *Proceedings of the IASTED International Conference on Biomedical Engineering 2004*; pp. 578-581.
16. Siu CW, Jim MH, **Tse HF**. Pulmonary artery obstruction mimicking the clinical features of acute pulmonary embolism. *Heart.* 2005; 91: 212. (JIF=5.42; No. of cites=0, corresponding author )
17. Siu CW, **Tse HF**, Lau CP. Inappropriate implantable cardioverter defibrillator shock from a transcutaneous muscle stimulation device therapy. *J Interv Card Electrophysiol.* 2005;13: 73-75. (JIF=1.522; No. of cites=15)
18. Siu CW, Jim MH, Ho HH, Chu F, Chan HW, Lau CP, **Tse HF**. Recurrent acute heart failure caused by sliding hiatus hernia. *Postgrad Med J.* 2005; 81: 268-269. (JIF=2.078; No. of cites= 22, corresponding author)
19. Wu Y, Wu EX, Wong KK, Tang H, **Tse HF**, Lau CP, Yang ES. Myocardial fiber length mapping with MR diffusion tensor imaging. *Conf Proc IEEE Eng Med Biol Soc.* 2005; 7: 7004-7.
20. Wong KK, Wu Y, Ng MC, Wu Y, **Tse HF**, Lau CP, Lo G, Yang ES. Image registration in myocardial perfusion MRI. *Conf Proc IEEE Eng Med Biol Soc.* 2005; 7: 453-454.
21. Chen WH, Lee PY, Ng W, **Tse HF**, Lau CP. Is aspirin resistance or female gender associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention? Reply. *J Am Coll Cardiol.* 2005; 45: 636.(JIF=16.834; No. of cites= 0)
22. **Tse HF**, Lau CP. Chronotropic incompetence in heart failure-Reply. *J Am Coll Cardiol.* 2006; 48: 595-596. (JIF=16.834; No. of cites= 0)
23. Siu CW, Cheng LC, Woo PCY, Lau CP, **Tse HF**. A patient with relapsing pacemaker infection due to "Gram positive bacilli". *Int J Cardiol.* 2007 114: E40-41. (JIF= 4.034, No. of cites= 0, corresponding author)
24. Yiu KH, Siu CW, To KK, Jim MH, Lee KL. Lau CP, **Tse HF**. A rare cause of infective endocarditis; *Lactococcus garvieae*. *Int J Cardiol.* 2007 114: 286-287. (JIF= 4.034; No. of cites=30, corresponding author)

25. Siu CW, **Tse HF**, Lau CP. Avoidance of electromagnetic interference to implantable cardioverter-defibrillator during atrioventricular node ablation for atrial fibrillation using transvenous cryoablation. *Pacing Clin Electrophysiol.* 2006; 29: 914-6. (JIF=1.441; No. of cites=2, corresponding author).
26. Wu Y, **Tse HF**, Wu EX. Diffusion tensor MRI study of myocardium structural remodeling after infarction in porcine model. *Conf Proc IEEE Eng Med Biol Soc.* 2006;1:1069-72.
27. Cheung JS, Chow AM, Hui ES, Yang J, **Tse HF**, Wu EX. Cell Number Quantification of USPIO-labeled Stem Cells by MRI: An In Vitro Study. *Conf Proc IEEE Eng Med Biol Soc.* 2006;1:476-9.
28. Yiu KH, Siu CW, Lau CP, KLF Lee, **Tse HF**. Transvenous catheter-based microwave ablation for atrial flutter. *Heart Rhythm.* 2007; 4: 221-3. (JIF=4.743; No. of cites=5).
29. Chan WS, Wei WI, **Tse HF**. Malignant baroreflex failure after surgical resection of carotid body tumor. *Int J Cardiol.* 2007 118:e81-2. (JIF= 4.034, No. of cites= 0, corresponding author).
30. Lip GY, **Tse HF**. Management of atrial fibrillation- Reply. *Lancet* 2007; 370: 1608. (JIF= 53.254, No. of cites= 0).
31. Yiu KH, Siu CW, Lau CP, **Tse HF**. Pericarditis induced by active-fixation lead shown by positron emission tomography/computed tomography. *Heart Rhythm.* 2008;5:1493-1494 (JIF=4.743; No. of cites=1).
32. Siu CW, Cheung SC, Chan CW, Lam YM, **Tse HF**, Jim MH. Scimitar syndrome on chest x ray. *Postgrad Med J.* 2008;84:558. (JIF= 2.078, No. of cites=1).
33. Yiu KH, Lee SW, Ho HH, Chan HW, **Tse HF**. Dual coronary fistulas complicated with significant left to right heart shunt in an elderly patient. *Int J Cardiol.* 2011;149:E127-E128 (JIF= 4.034, No. of cites= 1).
34. Yiu KH, Leung YL, Siu CW, Jim MH, Chow WH, **Tse HF**. Focal pericarditis in a huge heart demonstrated by positron emission tomography/computed tomography. *Clin Nucl Med.* 2009;34:362-4. (JIF= 6.281, No. of cites= 0).
35. Ho HH, Siu CW, Lam YM, Lee HY, **Tse HF**. A rare case of severe aortic stenosis with preserved ejection fraction and normal transvalvular gradient. *Int J Cardiol.* 2011;149:E127-E128 (JIF= 4.034, No. of cites= 0).
36. Yiu KH, **Tse HF**, Lau CP. Ventricular tachycardia complicating head-up tilt test: The role of coronary artery spasm. *Pacing Clin Electrophysiol.* 2010;34:e101-e111 (JIF= 1.441, No. of cites= 0).
37. Ng AK, Ng KM, **Tse HF**, Lai WH, Chan WS, Siu CW, Fan K. Pseudo-pre-excitation unraveled down to its core. *Circulation.* 2014;130:e56-8. (JIF=18.88; No. of cites=1)

38. Hai JJ, Gill H, Tse HF, Kumana CR, Kwong YL, Siu CW. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. *Ann Hematol.* 2015;94:501-3. (JIF=2.845, No. of cites=2).
39. Chan YH, Tse HF. Embolic Origin of Osler Nodes. *Mayo Clin Proc.* 2017;92:1459-1460.

### **TITLE OF PRIZE AND AWARDS FOR RESEARCH ACHIEVEMENTS**

1. 1997-1998 Hong Kong Heart Foundation Scholarship, Hong Kong College of Cardiology
2. 1999- 2000 Sir Patrick Manson Gold Medal: for the best MD thesis of the year
3. 2002-2003 Outstanding Young Researcher Award, HKU
4. 2003 Young Investigator Award for Best Oral Presentation in the Medical Research Conference 2003 from the Medical Science Group in the Faculty of Medicine, The University of Hong Kong
5. 2003 Distinguished Research Paper Award for Young Clinicians, Hong Kong College of Physicians
6. 2006 **Late Breaking Clinical Trial in American College of Cardiology Meeting 2006:** “Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)”
7. 2006 Faculty Outstanding Research Output Award 2006: “Genomic instability in laminopathy-based premature aging. *Nature Medicine* 2006”
8. 2007 *Ground-breaking Paper* of 2006 (one of three chosen) in American Heart Association Annual Scientific Meeting 2007: “Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN channel reduces the dependence on electronic pacemaker in a sick sinus syndrome model. *Circulation.* 2006”
9. 2007. Late-breaking Basic Science (Stem Cells) Study of 2007 (one of five chosen) in American Heart Association Annual Scientific Meeting 2007: ”Genetically-driven Maturation of hESC-derived cardiomyocytes completely ablates post-transplantation arrhythmias”
10. 2007-8 Elite Reviewer 2007 for The Journal of the American College of Cardiology.
11. 2008-2009 Outstanding Researcher Award, HKU
12. 2009-2010 Elite Reviewer 2009 for The Journal of the American College of Cardiology.



13. 2010 Sir David Todd Lecture for The Hong Kong College of Physicians 2010: “New Era of Regenerative Medicine for Cardiovascular Diseases”.
14. 2012 **Late-breaking Clinical Trial in Special Clinical Session in American Heart Association Annual Scientific Meeting 2012:** “Study Prospective Randomized Study to Assess the Efficacy of Site and Rate of Atrial Pacing on Long-term Progression of Atrial Fibrillation in Sick Sinus Syndrome- Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) study”
15. 2012 BMA Medical Book Awards 2012- Highly Commended in Cardiology: **Tse HF**, Lip GY, Coats AJS (*eds*): Oxford Desk Reference. Oxford. Oxford University Press. 2011.
16. 2014 **Late-breaking Clinical Trial in Heart Rhythm Society Annual Scientific Meeting 2014:** Thoracic Spinal Cord Stimulation for HEArt Failure as a Restorative Treatment (SCS HEART Study): First-in-man Experience
17. 2017 Hong Kong Heart Foundation Lecture 2017: “Human Pluripotent Stem Cells Derived Mesenchymal Stem Cells as Novel Therapy for Treatment of Cardiovascular Diseases”.

### **INVITED LECTURES AT OVERSEAS INSTITUTES, INTERNATIONAL AND REGIONAL MEETING**

1999

1. *Faculty Member*, 19<sup>th</sup> Annual Scientific Meeting of North American Society for Pacing and Electrophysiology, USA.
2. *Faculty member*, 3<sup>rd</sup> Asian-Pacific Cardiovascular Symposium- **Plenary lecture:** “Ablation of Focal Atrial Fibrillation”

2001

1. *Faculty member*, 2001 Interventional Vascular Therapies Forum- Angiogenesis and Human Autologous Bone Marrow Transplant.
2. *Faculty member*, 6<sup>th</sup> International Symposium on Interventional Cardiology and Live Demonstration Course- Autologous Bone Marrow Transplant for Therapeutic Angiogenesis, Korea.
3. *Invited Speaker*, Conference Meeting, Zhongshan Hospital- Autologous Bone Marrow Transplant for Therapeutic Angiogenesis, China.

1. *Faculty member*, VII Asian –Pacific Symposium on Cardiac Pacing and Electrophysiology- New Focus of Energy for Catheter Ablation, China.

2002

1. *Faculty member*, Clinical Electrophysiology Meeting of Shanghai Institute of Cardiovascular Disease, China.

2. *Invited Speaker*, Conference Meeting, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston- Autologous Bone Marrow Transplant for Therapeutic Angiogenesis, USA.
3. *Faculty member*, XIII Great Wall International Congress of Cardiology, China- The Role of Long-acting Calcium Channel Blocker in the Treatment of Cardiovascular Disease, China.
4. *Invited Speaker*, Conference Meeting, Wuhan Asia Heart Disease Hospital, China- Pacing for Heart Failure, China.
5. *Faculty member*, 7<sup>th</sup> International Symposium on Interventional Cardiology and Live Demonstration Course- Non-pharmacological Treatment of Arrhythmia.
6. *Faculty member*, 4<sup>th</sup> Dong-A Transradial Coronary Intervention Course- Therapeutic Angiogenesis of Human Ischemic Myocardium by Catheter Based Intramyocardial Bone Marrow Implantation, Korea.

### 2003

1. *Faculty member*, Bi-Vent Live Demo Workshop, Thailand.
2. *Faculty member*, XII World Congress on Cardiac Pacing and Electrophysiology, Hong Kong.
3. *Faculty member*, 6<sup>th</sup> Pfizer Asian-Pacific Cardiovascular Symposium- Challenges and Treatment Options in Managing Arrhythmias, Korea.
4. *Chairperson*, European Society of Cardiology Congress 2003-Evolving Concepts for More Efficient Ablation in Atrial Fibrillation, Stockholm, Sweden.
5. *Faculty member*, Venice Arrhythmia 2003- Pacing Algorithm to Prevent Atrial Fibrillation: Do They Work, Italy.
6. *Faculty member*, EXANTA Educational Workshop-AsiaPacific: The Opportunity, The Challenge, The Evidence, China.

### 2004

1. *Faculty Member*, Asia-Pacific Re-certification Program for Biosense, China.
2. *Faculty Member*, Heart to Heart 2004, Biosense Webster, Cardiovascular Option Leader Summit. Australia.
3. *Faculty Member*, The Fourth Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Indonesia: Stem cell therapy for myogenesis and angiogenesis.
4. *Invited Speaker*, Grand Round- Department of Medicine, The University of Birmingham, UK - Stem cells therapy for Cardiovascular Disease.
5. *Faculty Member*, Septal Pacing Live Demo and Lecture, Taiwan.
6. *Faculty Member*, First Conference on Cardiovascular Clinical Trials and Pharmacotherapy, Hong Kong.

7. *Invited Speaker*, Grand Round- Department of Medicine, Weill Medical College of Cornell University, New York, USA.
  8. *Faculty Member*, XI International Symposium on Progress in Clinical Pacing, Rome, Italy.
  9. *Faculty Member*, 1st China Therapeutics symposium, China: Application of stem cell on cardiovascular disease.
  10. *Invited Speaker*, Vascular Biology Working Group, European Chapter meeting, Barcelona, Spain.
- 2005
1. *Invited Speaker*, An International Symposium in Chang Gung Memorial Hospital, Taiwan - Bone Marrow Stem Cell Therapy for Angiogenesis.
  2. *Invited Speaker*, 4<sup>th</sup> Asian Pacific Congress of Hypertension, Seoul, Korea - Endothelial Dysfunction in Hypertension: Micro and Macrovascular Abnormalities.
  3. *Panel member*, Heart to Heart meeting, Vascular Leadership Symposium, Thailand - Atrial Fibrillation Ablation.
  4. *Invited Speaker*, The 1<sup>st</sup> China Symposium on Stem Cell Transplantation in Cardiovascular Diseases and The 2<sup>nd</sup> National Symposium on Stem Cells Implantation in End-Stage Cardiovascular, Shanghai, China.
  5. *Invited Speaker*, Shanghai Institutes for Biological Science, Chinese Academy of Science & Shanghai Second Medical University, China – Therapeutic implication of Endothelial Progenitor Cells.
  6. *Faculty Member*, European Society of Cardiology Congress 2005, Stockholm, Sweden.
  7. *Invited Speaker*, American Heart Association Scientific Sessions 2006, USA: Late Breaking Clinical Trials -Prospective Randomized Trial of Direct Endomyocardial Implantation of Bone Marrow Cells for Therapeutic Angiogenesis in Coronary Artery Diseases (PROTECT-CAD).
  8. *Invited Speaker*, 8<sup>th</sup> South China International Congress of Cardiology International Symposium on Cardiac Arrhythmia and Heart Failure, China - How to mend a broken heart.
- 2006
1. *Invited Speaker*, XiZi Forum of New Cardiovascular Interventional Therapeutics (CIT-XIZI), China. Radiofrequency ablation of atrial fibrillation, China.
  2. *Invited Speaker*, 15<sup>th</sup> World Congress in Cardiac Electrophysiology and Cardiac Techniques, Nice, French Riviera, France- Site Selection for Atrial Pacing in Patients with Atrial Fibrillation.

3. *Invited Speaker*, 8<sup>th</sup> APSPE 2006, Indonesia- How Cardiac Resynchronization Therapy Works.
4. *Invited Speaker*, 3<sup>rd</sup> Stem Cell Therapy in End-Stage Cardiovascular Diseases (SCIENCE III), China - Biological Pacemaker: Fact and Fiction.
5. *Invited Speaker*, 8<sup>th</sup> Biannual International Symposium Arrhythmia Lithuania 2006 “Drug therapy for cardiac arrhythmias – what’s new and what’s to come, “Ventricular arrhythmias – is the management and outlook any better in 2006?; ”Rate control in atrial fibrillation”; & “Rate control is the best clinical practice in patients presenting with the first episode of atrial fibrillation, and not rhythm control”, Lithuania.
6. *Invited Speaker*, Taiwan Society of Critical Care Medicine, Taiwan - How to Manage Sleep Disorders in Heart Failure Patient.
7. *Invited Faculty*, The 1<sup>st</sup> Hong Kong Korea EP Case Conference, Korea.
8. *Invited Speaker*, American Heart Association Scientific Sessions, Chicago, Illinois - CRT Who will Benefit, USA.
9. *International Faculty Member*, The 2<sup>nd</sup> Asia-Pacific Atrial Fibrillation Symposium, Tokyo Japan

## 2007

1. *Invited Speaker*, University of Birmingham, UK- Future Prospective for Cardiac Regeneration & Update on Cardiac Resynchronization Therapy, UK.
2. *Invited Speaker*, King’s College London, University of London, UK. - Future Perspective on cardiac regeneration.
3. *Invited Speaker*, 9<sup>th</sup> South China International Congress of Cardiology International Symposium on Cardiac Arrhythmia and Heart Failure, China- How to Improve HDL Cholesterol.
4. *Invited Speaker*, The Korean Society of Circulation, Seoul, Korea-  
**Plenary Lecture:** “The Present and Future for Biopacemaker”
5. *Invited Speaker*, 10<sup>th</sup> Pfizer Asian Cardiology Symposium, Kuala Lumpur, Malaysia  
“ Holistic Cardiovascular Risk Management.
6. *Invited Speaker*, Vascular Leaders Summit Kuala Lumpur, Malaysia “Biological Therapies for Cardiac Arrhythmias”
7. *Invited Speaker*, The University of Occupational and Environmental Health Japan in Kita-Kyusyu City, Fukuoka, Japan “Up to date of AF Management and Pacemaker algorithm selection for AF suppression”
8. *Invited Speaker*, The 5<sup>th</sup> China AF Symposium, Beijing, China.  
Plenary Lecture:”Biological Therapies for Cardiac Arrhythmias”

9. *Invited Speaker*, ESC Vienna, Austria
  10. *Invited Speaker*, The 3<sup>rd</sup> Asia-Pacific AF Symposium, Taipei, Taiwan, "Gene Therapy, "How to Detect Recurrences AF and how important of Asymptomatic AF?" "Biological therapies for cardiac arrhythmias" "Patient Selection"
  11. *Invited Speaker*, Shanghai International Symposium on Stem Cell Research, Shanghai, China: "Adults stem cells"
  12. *Invited Speaker*, 2<sup>nd</sup> Global Interventional Conference for Chinese, Nanjing, China.
  13. *Invited Speaker*, 4<sup>th</sup> China Therapeutics Symposium: Application of stem cell on Cardiovascular disease, Hangzhou China.  
**Plenary Lecture:** "Biological Therapy for Cardiac Arrhythmia"
  14. *Invited Speaker*, The 16<sup>th</sup> Asian Pacific Congress of Cardiology, Taipei, Taiwan" Registration of Atrial fibrillation Catheter Ablation"
  15. *Invited Speaker*, United Kingdom-Hong Kong Frontiers of Science Symposium. Hong Kong
- 2008
1. *Invited Speaker*, Meet the Master, March Programme 2008 "Advances in Heart Rhythm Management"
  2. *Invited Speaker*, Japanese Circulation Society 2008 Conference Fukuoka "Does it create synergetic effect?"
  3. *Invited Speaker*, 57<sup>th</sup> Annual Scientific Session Chicago, USA "Creating Biological Pacemakers"
  4. *Invited Speaker*, The South China International Congress of Cardiology, Guangzhou, China "Advances in Arrhythmia Management"
  5. *Invited Speaker*, Safe Study Site Initiation Meeting, Nanjing, China.
  6. *Invited Speaker*, Vascular Leaders Summit Electrophysiology 2008 " Stem Cell Therapy in Cardiovascular Diseases"
  7. *Invited Speaker*, The 6<sup>th</sup> China Atrial Fibrillation, Symposium (CAFS), Dalian, China  
**Plenary Lecture:** "Stem Cell Therapy in Cardiovascular arrhythmias"
  8. *Invited Speaker*, European Society of Cardiology 2008, Munich Germany: "Progress in cardiac and Vascular tissue engineering – biological pacemaker" and chaired a session on the "Management of Syncope".
  9. *Invited Speaker*, 3<sup>rd</sup> Annual International Symposium on Ventricular arrhythmias, Miami, USA: "Stem Cell Therapy for Cardiac Regeneration: Proarrhythmic Effect?"
  10. *Invited Speaker*, Heart Failure MACAO 2008, Macau "Heart Failure with Preserved Left Ventricular Systolic Function"

11. *Invited Speaker*, Interventional Cardiovascular Training Course of the 2<sup>nd</sup> affiliated Hospital in Hanzhou,” The Advanced Technology of Active lead in Pacing and Leading the live demo demonstration cases on active leads”
  12. *Invited Speaker*, 1<sup>st</sup> Asia-Pacific Heart Rhythm Society Scientific Session:Stem Cell, New Implant Tools and Delivery System.
- 2009
1. *Invited Speaker*, The Associacao De Nefrologia De Macau Sympoium” Holistic approach on cardiovascular Risk prevention and treatment”
  2. As the *panelists*, East West Alliance 2009 Conference, “Stem Cell connections to longevity”
  3. *Invited Speaker*, The 13<sup>th</sup> Congress of the International Society for Holter and Noninvasive Electrocardiology, “State of the Art: Catheter Ablation for AF”
  4. *Invited Speaker*, The 18<sup>th</sup> Annual Scientific meeting of the Indonesian Heart Association,  
**Plenary lecture:**“Stem Cell in Cardiology”
  5. *Invited Speaker*, The Primary Care Clinic Macau, “Chinese amlodipine besylate specialists’ opinion recommendation (CLASSIC)
  6. *Invited Speaker*, Europace, 2009 “New Echo techniques: focus on mechanical activity”
  7. *Invited Speaker*, European Society of Cardiology Congress, 2009, Barcelona, Spain.”Cardiac Resynchronization therapy: Does evolving technology enhance efficacy”
  8. *Invited Speaker*, Asia Pacific Heart Rhythm Society Scientific Session, Singapore “Right ventricular lead placement: What and where” “Atrial selective anti-arrhythmia”
- 2010
1. *Invited Speaker*, The 2<sup>nd</sup> National Ventricular Arrhythmia Symposium, Nanjing, China  
**Plenary Lecture:**“Biological therapy for Ventricular Arrhythmia”
  2. *Invited Speaker*, EP Physician Education Program in Vietnam Heart Institute, Bach Mai Hospital, Vietnam
  3. *Invited Faculty Member*, 12 South China International Congress of Cardiology: “New Antithrombotic Agents for AF”
  4. *Invited Faculty Member*, Heart Rhythm 31<sup>st</sup> Annual Scientific Session, Denver, USA”, Provocative Cases for the Device Physician”
  5. *Invited Speaker*, World Congress of Cardiology, Beijing, China “Stem Cell therapy for cardiovascular diseases,”, “Optimal site ventricular pacing: where, when and how”, “Are MADIT indications applicable globally?”

6. *Invited Speaker*, European Society of Cardiology, Stockholm “Genetic aspects of arrhythmias Invasive risk stratification: when is it needed?”
7. *Invited Speaker*, Bi-annual Scientific Meeting in Xiamen, China “Starfix implantation: Tips & Tricks”.
8. *Invited Speaker*, The 21st Great Wall International Congress of Cardiology, Beijing, China “Atrial Fibrillation: Medications or Catheter Ablation”
9. *Invited Faculty Member*, The Asia- Pacific Heart Rhythm Society Scientific Session “RV Septal Pacing for Bradycardia”, “Gene and Cell Therapy for Cardiac Arrhythmias”
10. *Invited Faculty Member*, Winter Scientific Meeting of Taiwan Society of Cardiology 2010: “Choosing an Antihypertensive Drug for the Management of CV Events — Is There an Ethnic Difference?” and “New Era of Antithrombotic treatment on Stroke Prevention in Atrial Fibrillation”
11. *Chair*, The 3<sup>rd</sup> Pacific Heart Rhythm Society Scientific Session “ Memories and Future” From Pursuit of the Mechanisms of Cardiac Arrhythmias , “Basic Research for VT/VF and Stem Cell Therapy

*Speaker*, The 3<sup>rd</sup> Pacific Heart Rhythm Society Scientific Session “PV Septal Pacing for Bradycardia”, “Gene and Cell Therapy for Cardiac Arrhythmias

## 2011

1. *Invited Faculty Member*, Global Thrombosis Forum, 2011, Barcelona, Spain  
**Plenary Lecture:** “Controlling AF: Rate versus Rhythm Control”
2. *Invited Speaker*, 2<sup>nd</sup> Asia Pacific Congenital and Structural Heart Intervention Symposium 2010, Hong Kong “ Transcatheter Aortic Valvular Implantation”
3. *Invited Speaker*, 6<sup>th</sup> International Symposium on Healthy Aging A New Golden Age, Hong Kong “Personalised Medicine for Patients with Cardiovascular Diseases”
4. *Invited Faculty Member*, 13th South China International Congress of Cardiology (SCC), 2011, China  
**Plenary Lecture:** “Stem cell therapy for angiogenesis and arrhythmia”
5. *Invited Member*, Heart Rhythm 32<sup>st</sup> Annual Scientific Session, San Francisco, USA.”Antiarrhythmic therapy for maintaining of sinus rhythm”, “Monitoring Outcome Using Pacemaker Diagnostics”
6. *Visiting Professor*, USC Keck School of Medicine, University of Southern California, USA  
**Dean’s Translational Science Lecture Series:** “New Era of Regenerative Medicine for Cardiovascular Diseases”
7. *Visiting Professor*, University of Minnesota, USA  
**Visiting Professor Lecture:** “Novel Insight from Gene & Stem Cell Platform for Cardiac Arrhythmias ”

8. *Visiting Professor*, University of Minnesota, USA  
**Visiting Professor Lecture:** “Novel Insight from Gene & Stem Cell Platform for Cardiac Arrhythmias”
  9. *Invited Speaker*, The 5<sup>th</sup> Oriental Congress of Cardiology Shanghai, China “The Effectiveness of Non-contact Mapping in Patients with complex arrhythmias”
  10. *Invited Speaker*, Hong Kong Primary Care Conference, Hong Kong  
“Management of Hypertension and CV Hypertension and CV Diseases with ARBS’
  11. *Invited Speaker*, Asia Pacific Atrial Fibrillation Expert Input Fourm, Singapore “Why Should we maintain Sinus Rhythm?”
  12. *Invited Speaker*, 9<sup>th</sup> China Atrial Fibrillation, Symposium, Beijing, “ What’s new on AF management guideline?”
  13. *Invited Speaker*, 4<sup>th</sup> Asia Pacific Heart Rhythm Society Scientific Sessions “ECG algorithm for epicardial VT/VPB”, “Idealized pacing therapy with optimal rate adaptive feature/programming
  14. *Invited Speaker*, Boston Scientific Ltd during 4<sup>th</sup> Asia Pacific Heart Rhythm Society v Scientific Sessions meeting, “Idealized pacing therapy with optimal rate adaptive feature/programming
  15. *Invited Speaker*, “ Kuala Lumpur Valve Summit 2011” Oral Anticoagulants in Stroke Prevention”, “New Treatment Strategies to Address Unmet Needs in Stroke Prevention in AF”
  16. *Invited Speaker*, The Vatican, Italy, “ Clinical Focus: Cardiovascular Disease”
  17. *Invited Speaker*, “ South East Asia Stroke Prevention in AF Advisory”, SPAF clinical research updates”,
- 2012**
1. *Invited Speaker*, The Fourth Ventricular Arrhythmia Symposium of China (VAS-China), Nanjing, China ,” Prevention of Ventricular tachycardia with spinal cord stimulation”
  2. *Invited Speaker*, The 6<sup>th</sup> Oriental Congress of Cardiology (OCC 2012), Shanghai, China “ Spinal Cord stimulation for treatment of heart failure”
  3. *Invited Speaker*, Meet the Masters, Tokyo, Japan, “ Current Concept of Pharmacological Therapy”
  4. *Invited Speaker*, ESC Congress 2012, Munich, Germany “ Intermittent versus continuous thoracic spinal cord stimulation for treatment of ischemic heart failure”
  5. *Invited Speaker*, 2012 Symposium on New Advancements in Cardiovascular Disease, Macau “Progression of New Oral Anti-coagulants in Stroke Prevention for Patients with AF



6. *Invited Speaker*, ESC Congress 2012, Munich, Germany “ Intermittent versus continuous thoracic spinal cord stimulation for treatment of ischemic heart failure”
  7. *Invited Speaker*, APHRS, Taipei, Taiwan, “Dronedarone in Clinical Practice: Peals and Pitfalls, “Advanced AF Technique, Renal Denervation for Hypertension “*Stem Cell for Evaluating and Treating Arrhythmia-Expert meeting*
  8. *Invited Speaker*, AHA 2012, Los Angeles, US, “ CRT Ambulatory Monitoring to Optimize Care”
  9. *Invited Speaker*, Takeda Cardioascular Academy, Osaka, Japan “ Cardiovascular Disease & Hypertension 2012”
- 2013
1. *Invited Speaker*, ODYSSEY Investigator Meeting for Protocol EFC11570, Brisbane, Australia “ Very low LDL-C: Is there reason for concern?”
  2. *Invited Speaker*, Asia Pacific Regional Conference, Singapore, “ What difficulties physicians and patients experience when a chronic lead exhibits a failure, and what steps are taken to address the situation”
  3. *Invited Speaker*, Asia Go-to-Launch Meeting, Bangkok, Thailand, “ AF Situation in Asia and Unmet Medical Needs, “ Voice of the Experts, overview of warfarin and aspirin safety and efficacy in stroke prevention in NVAf, “ INR & TTR: clinical importance and implications”
  9. *Invited Speaker*, The 5<sup>th</sup> Ventricular Arrhythmia Symposium of China, Nanjing, China “ Benefits of remote monitoring in management of ventricular arrhythmias in patients with device , “Future of device therapy for cardiac arrhythmia”
  10. *Invited Speaker*, 香山科學會議第 454 次學術討論會, 杭州 ”Exome sequencing and induced pluripotent stem cells for diagnosis and modeling of inherited cardiomyopathy”
  11. *Invited Speaker*, Biopharma Asia Convention, Singapore “ Applications of iPSC Platform for Diagnosis and treatment of Cardiovascular Diseases”
  12. *Chair*, Heart Rhythm, Denver, US, “Optimization of CRT using sensor and device diagnostics”
  13. *Invited Speaker*, **Heart Rhythm Society Meeting, Denver, US**, “Spinal Cord Stimulation” and “Implanted Devices for Autonomic Nervous System Modulation in HF”
  14. *Invited Speaker*, **Taiwan Society of Cardiology, Taipei, Taiwan**: “New direction in the development of Anti-arrhythmic drugs” ,” Current, Evolving and Futuristic Therapies for AF”
  15. *Invited Speaker*, **28<sup>th</sup> Annual Meeting of the Japanese Heart Rhythm Society**, “ Atrial Fibrillation and Stroke. New horizon in anticoagulation”

16. *Invited Speaker, The 7<sup>th</sup> Qianjiang International Cardiovascular Congress, Hangzhou, China, “ Futuristic Cardiac Implantable Electronic Device For Cardiac Rhythm Management” “心衰的神经调节治疗”*
17. *Invited Speaker, Macau Association of Cardiovascular Interventions 2013, “ Interpretation of the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012”*
18. *Invited Speaker, ESC 2013, Netherlands, “A randomized placebo controlled trial of endomyocardial implantation of autologous bone marrow mononuclear cells in advanced ischemic Heart Failure (END-HF)” & Catheter-based renal denervation improves cardiac function in a porcine model of ischemic heart failure”*
19. *Invited Speaker, 7<sup>th</sup> Asia Pacific Cardiology Update USM 2013, Malaysia “ Evaluation for Cardiac Resynchronisation Device Therapy” & “Stem cell Therapy in Heart Failure”*

#### 2014

1. *Invited Speaker, The 6<sup>th</sup> Ventricular Arrhythmia Symposium of China, Nanjing, China” “ Future device therapy for heart failure and ventricular arrhythmias”*
2. *Invited Speaker, Pacing Summit, Haizhou, China, “香港起搏植入臨床研究發展與近況”*
3. *Chair, 2014 Asia- Pacific Cardiovascular Symposium Guangzhou, China,” Beta Blockers for Management of Cardiovascular diseases: are all beta-blockers the same?*
4. *Invited Speaker, Annual meeting of Taiwan Heart Rhythm Society in Taipei, Taiwan ,”Atrial Fibrillation and Stroke Burden in Asia: From Guideline to Real World Practice”*
5. *Invited Speaker, NOACs Stroke Prevention in Atrial Fibrillation, Malaysia 2014 “NOACs for Stroke Prevention in Atrial Fibrillation- Selecting the Right Treatment for the Right Patient ‘ , “Stroke prevention in AF – Translating Guidelines into Clinical Practice”*
6. *Invited Speaker, APHRS Summit Scientific Programme, Singapore 2014, “An MRI conditional device is needed for all patient”*
7. *Invited Speaker, The 16<sup>th</sup> South China International Congress of Cardiology, Guangzhou, China,” Treatment of ventricular tachycardia storm in patients with LMNA A/C related dilated cardiomyopathy”*
8. *Invited Speaker, Heart Rhythm 2014, US , Dual-targeted Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS Heart):First-in man Experience*
9. *Chair, Heart Rhythm 2014, US , New Technologies and new approaches*

10. *Invited Speaker, AF Global Advisory Board, Tokyo Japan,* "Real world and current standard care in AF patients –regional perspectives
  11. *Invited Speaker,* 2014 心血管病治療進展會議, 澳門急性肺梗死的處理
  12. *Chair, Cardiostim 2014, Nice, France,* "Meet the Experts"Using CHADS2-VASC and has bled in everyday clinical practice"
  13. *Invited Speaker, Macau Cardiology Association*"Cardioprotection of Beta-blockers in Cardiovascular diseases"
  14. *Invited Speaker, 29<sup>th</sup> Annual Meeting of the Japanese Heart Rhythm Society, Tokyo* "Subcutaneous ICD:Protection without Touching the Heart"
  15. *Invited Speaker, Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Expert Forum, Taipei, Taiwan* "Clinical perspectives:Challenging cases in AF management – use of VKAs and/or aspirin and decision-making"
  16. *Invited Speaker, European Society of Cardiology Congress 2014, Barcelona, Spain,* "Remodeling of cardiac sympathetic innervation with thoracic spinal cord stimulation improves left ventricular function in a porcine model of ischemic cardiomyopathy"
  17. *Invited Speaker, The 16<sup>th</sup> International Symposium on Hypertension & related disease, Shanghai, China,*" Visit-to-visit blood pressure variability and cardiovascular outcomes in hypertensive patients"
  18. *Invited Speaker, Asia Pacific Stroke Conference, Taipei, Taiwan,*" WS5 Genetic Translational Workshop
- 2015**
1. *Invited Speaker,* China International Cardiac Pacing Summit, Haikou, China, "Thoracic Spinal Cord Stimulation for Heart Failure as a restorative Treatment (SCS Heart Study"
  2. *Invited Speaker,* Interactions Summit in SPAF across Mainland China Beijing, "NOAC in Asian Patient,"
  3. *Invited Speaker,* AFNET and EHRA meeting, European Heart House, Sophia Antipolis France, "Prevention of AF related complication: Asian-Pacific Perspective"
  4. *Invited Speaker,* Heart Rhythm Society, US, "Spinal Cord Stimulation for Heart Failure and Ventricular Arrhythmias in a Joint Session Entitled Advances in Device Therapy"
  5. *Invited Speaker,* INS 12<sup>th</sup> Congress, Canada, "Spinal Cord Stimulation to treat Heart Failure"
  6. *Invited Speaker,* Stroke Prevention in AF Masterclass in Asia, Taiwan "Stroke Prevention in non-valvular AF in the real world

7. *Invited Speaker*, EHRA Europace- CARDIOSTIM 2015, Milan, Italy “ Device Mangement using remote monitoring”
8. *Invited Speaker*,Phyathai Cardiac Symposium, Bangkok, Thailand “ Trouble Shooting in NOACs Related coagulopathy and bleeding “ Current knowledge in NOACS and the introudciton to the upcoming reserachers”
9. *Invited Speaker*,Asia Novartis Biomedical Symposium, Taipei, Taiwan, “ Patients Specific Indcued Pluriopent Stem Cell Derived In-vitro and in-vivo Drug Screening
10. *Invited Speaker*, Chinese Heart Rhythm Society Annual Sessions, Beijing, China“ *Stem Cells –Embryonic and Induced pluripotent Stem Cells and its application in regenerative medicine*”
11. *Invited Speaker*, **Macau Physician Assocation fo Public Hospital, Macau** “ Lifetime Benefit of Lower LDL- C:Evidence from CV outcome Trials
12. *Invited Speaker*, **ESC Congress 2015, London, UK** , Poster Presentation: Diabetic cardiac autonomic dysfunction predicts adverse vascular function and clinical heart failure: Counter-physiological dissociation of resting heart rate with PR Interval
13. *Invited Speaker*, **Scientific Annual Congress of Chinese Society of Cardiology/The 9<sup>th</sup> Oriental Congress of Cardiology,Shanghai, China** “ Asian Experience of Total Subcutaneous ICD
14. *Invited Speaker*, **XV World Congress of Arrhythmias, Beijing , China,**” LV-only Pacing Should Be Considered in All Patient with LBBB in CRT Therapy “;”Neuro-Modulation for Heart Failure or Ventricular Arrhythmias”,” Spinal Cord Stimulation Treatment Management
15. *Chair*, **XV World Congress of Arrhythmias, Beijing , China**, “Autonomic Modulation” and “Incidence and prevention of SCD Worldwide”
16. *Invited Speaker*,**Venice Arrhythmia, Italy**, “The Asia Pacific Heart Rhythm Society guidelines,” Upgrading from conventional PM to CRT: When and how(CRT-P vs CRT-D)”
17. *Invited Speaker*, **7<sup>th</sup> Asia-Pacific Heart Rhythm Scientific Session, New Delhi, India**, “Stroke risk and anticoagulation in the Asian population, Use of novel anticoagulant (NOCA) in clinical practice, “Patient Selection”, Multipoint CS stimulation, Stroke Risk and anticoagulation in the Asian population
18. *Invited Speaker*, **APHRS, Melbourne, Australia**, “AF3 Device detected and silent atrial fibrillation Remote Device monitoring: is there a mortality benefit? Does clinical practice reflect the studies? Emerging registry data

19. *Invited Speaker, NANS Tonic Versus Burst Mode of Spinal Cord Stimulation for Treatment of Ischemic Heart Failure, Las Vegas, United States*, Topic versus burst mode of spinal cord stimulation for treatment of ischemic heart failure”
  20. *Invited Speaker, American Heart Association Scientific Sessions 2015, Orlando*
- 2016
1. *Invited Speaker, China International Pacing Summit (CIPS) Haikou China,* “Multiple point coronary sinus pacing, “Case Sharing on devices”
  2. *Invited Speaker, Bayer Xarelto Forum: Anticoagulation and Non—Valvular AF: the Practice, The patient,*” The latest insights from real-life settings on the prevention of atrial fibrillation related strokes
  3. *Invited Speaker, VAS China, Nanjing, China,* “Clinical application of SICD
  4. *Invited Speaker, Ventricular Arrhythmia 2016. Taipei, Taiwan,*” The usage of Rhythmia 3D mapping system in Atrial arrhythmia: Hong Kong Experience
  5. *Invited Speaker, ACC 2016 Chicago United States,* “Increasing ICD Adoption in Asia: Current Status and Challenges”
  6. *Invited Speaker, Seminar for CHCSJ Cardiologists in Macau,* “Cardio-protection of beta-blockers along CV continuum”
  7. *Invited Speaker, 2016 Satellite Symposium New Insights to SPAF from Global to Asia Taipei, Taiwan,*” Recent Advances in stroke Prevention in NVAF: The role of NOACS in Asia”
  8. *Invited Speaker, Oriental Congress of Cardiology, Shanghai, China,* “High Density mapping and ablation of atrial tachyarrhythmias Human Stem cell platform for modeling and drug testing of inherited cardiomyopathy”
  9. *Invited Speaker, The 9<sup>th</sup> Heart Rhythm Forum of Jiangsu Province, China,* “生理性起搏未來方向”
  10. *Invited Speaker, MACI Forum 2016 ,Macau,*” Novel Lipid Management”
  11. *Invited Speaker, SPNVAF Masterclass June 2016,* “Spotlight on Apixaban in NVAF: randomized clinical trial data and real-world experience, Stroke Prevention in NVAF: The Asian perspective”
  12. *Invited Speaker, China Innovations in Cardiology 2016 (CIC2016), Nanjing, China* Novel Technology for CIED
  13. *Invited Speaker, European Society of Cardiology Congress 2016, Rome, Italy* Regional heterogeneity in norepinephrine spillover in heart failure with preserved ejection fraction: insight from a porcine model of severe hypertension
  14. *Invited Speaker, The 8th Annual Symposium on Translational Circulatory and Stem Cell Research, Kaohsiung, Taiwan* Keynote Speech, Human pluripotent stem

cells derived mesenchymal stem cells as novel therapy for treatment of cardiovascular diseases

15. *Invited Speaker, APHRS 2016, Seoul, Korea*, “Subcutaneous ICD in Asia” “High Density Mapping of Complex Atrial Arrhythmias” “Human Stem Cell Model for Human Inherited Cardiomyopathy”
16. *Invited Speaker, Macau Rehabilitation Association 2016, Macau*, “Sports Injuries: Prevention and Treatment”
17. *Invited Speaker, American heart Association Scientific Session 2016, New Orleans, United States*, “Cardiovascular Risk Models, Risk Scores, and Risk Stratifying Tools”
18. *Invited Speaker, XVII International Symposium, Rome Italy Presentation: Spinal Cord stimulation*
19. *Invited Speaker, The 9<sup>th</sup> Guangzhou International Conference on Stem Cell and Regenerative Medicine, Guangzhou, China* “Human pluripotent stem cells derived mesenchymal stem cells as novel therapy for treatment of cardiovascular diseases”

## 2017

1. *Invited Speaker, VAS China 2017, Nanjing, China*, “Human Stem cell platform for drug screening in inherited cardiomyopathy”
2. *Invited Speaker, Asia Atrial Fibrillation Scientific Forum, Kanazawa, Japan*, “Improving disease awareness and diagnosis of AF”
3. *Invited Speaker, China International Pacing Summit (CIPS) 2017, Haikou, China*, SICD Implantation case video review session
4. *Invited Speaker, SPNVAF Masterclass, Bangkok, Thailand*, “Optimizing dosing of NOACs: Looking beyond frequency” “Apixaban: Key clinical trial data and real-world experience”
5. *Invited Speaker, Macau Lecture* “The latest real world evidence of NOAC for patient with non –valvular AF”
6. *Invited Speaker, Asia Atrial Fibrillation Scientific Forum, Kanazawa, Japan*, “Improving disease awareness and diagnosis of AF”
7. *Invited Speaker, Heart Rhythm Chicago, United States*, “Anticoagulation Treatment in Patients With Non-Valvular Atrial Fibrillation: Real-World Clinical Practice in Hong Kong”, “Current State of the ECG Patch Monitoring Technologies for Assessment of Malignant Arrhythmias”
8. *Invited Speaker, OCC Meeting, Shanghai, China* “Increasing ICD Adoption in Asia: Current Status and Challenges” “AF Screening”

9. *Invited Speaker, SPNVAF Masterclass 2017,” Apixaban: key clinical trial data and real-world experience”,”Optimizing dosing of NOACs: Looking beyond frequency”*
10. *Invited Speaker, MACI Forum, Macau, “Update in the management of heart failure”*
11. *Invited Speaker, 10<sup>th</sup> Heart Rhythm forum of Jiangsu Province, “ Advances in CIED”*
12. *Invited Speaker, European Cardiology Congress 2017, Barcelona, Spain “Does subclinical atrial tachyarrhythmia matter in terms of prognosis?”*
13. *Invited Speaker, The 10<sup>th</sup> Asia Pacific Heart Rhythm Society session, Yokohama, Japan “The safety and feasibility of S-ICD in an Asian population, “ “S-ICD in patient with structural heart disease*
14. *Chair The 10<sup>th</sup> Asia Pacific Heart Rhythm Society session, Yokohama, Japan Circadian rhythm/autonomic nervous system and arrhythmias*
15. *Invited Speaker, Cardiology Association Expert Symposium, Macau” Antithrombotic strategies post- PCI: What do we know so far?*
16. *Invited Speaker, Macau Heart Foundation 2017,”中風 say Bye Bye”*

## 2018

17. *Invited Speaker, VAS China 2018, Nanjing, China”Subcutaneous ICD Implantation: current status and future directions.”*
18. *Invited Speaker, 2<sup>nd</sup> Global Scientific Summit, Lisbon Portugal”AF Patients of Asian Origin*
19. *Chair, 2<sup>nd</sup> Global Scientific Summit, Lisbon, Portugal “Case Discussion”*
20. *Invited Speaker, MACI Symposium, Macau,” 新指引產的背景和意義”*
21. *Invited Speaker, Mexico Masterclass 2018, Mexico,” Late Breaking from ACC 2018”*
22. *Invited Speaker, CHCSJ Cardiology Lecture, Macau, What is the latest update on PCSK9 inhibitors*
23. *Invited Speaker, Heart Rhythm Sessions, Boston, United States  
Improving disease awareness and diagnosis of AF in a Joint Session entitled Fighting Against the Global Burden of Stroke and AF*
24. *Chair: Asian Pacific Society of Cardiology Congress, Taipei, Taiwan  
Molecular Diagnosis in Cardiovascular Disease*
25. *Invited Speaker, Asian Pacific Society of Cardiology Congress, Taipei, Taiwan  
Molecular Diagnosis in Cardiac Arrhythmia - focus on AF*

26. *Invited Speaker*, Oriental Congress of Cardiology 2018, Shanghai, China  
Latest advances in CIED Without transvenous leads  
High density mapping and ablation in patients with complex congenital heart diseases
27. *Invited Speaker*, CASNA Annual Australia 2018 Device detected atrial high rate episodes: Significance and management, High-resolution mapping of atrial arrhythmias in repaired congenital heart disease
28. *Invited Speaker*, CASNA Annual Australia 2018 Device detected atrial high rate episodes: Significance and management, High-resolution mapping of atrial arrhythmias in repaired congenital heart disease
29. *Chair*, European Society of Cardiology (ESC Congress, 2018, Aug 26-29 (Munich, Germany) Basic Science, Cardiac Diseases
30. *Invited Speaker*, The 13th Biennial Congress of Chinese Society of Pacing and Electrophysiology, Nanjing, China, “成人先天性心脏病房性心律失常的高密度标测及消融”
31. *Invited Speaker*, 23<sup>rd</sup> Asesan Federation of Cardiology Congress, Bangkok, Thailand, “NOAC and warfarin Asian Population”

### **ORGANIZER OF INTERNATIONAL MEETING**

1. 2001 *Chairman*, Organizing Committee of 5<sup>th</sup> Annual Scientific Meeting of Institute of Cardiovascular Sciences and Medicine, The University of Hong Kong
2. 2003 *Chairman*, Publication Committee, XII World Congress on Cardiac Pacing and Electrophysiology.
3. 2003 *Chairman*, Publication and IT Committee, First Conference on Cardiovascular Clinical Trials and Pharmacotherapy (CCTAP), incorporating the 2<sup>nd</sup> WHF Global Conference on Cardiovascular Clinical Trials and 13<sup>th</sup> International Society of Cardiovascular Pharmacotherapy Congress.
4. 2005 *Chairman*, Organizing Committee, Joint Clinical Symposium of Heart, Brain, Hormone and Healthy Aging Center of The University of Hong Kong and Mayo Clinic: New Diagnostic and Therapeutic Techniques for Aging Diseases.
5. 2006 *Chairman*, Organizing Committee of 1<sup>st</sup> Annual Scientific Meeting of Research Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong: International Symposium on Healthy Aging: A Global Challenge for the 21st Century.
6. 2006 Co-Chairman, Organizing Committee, 3<sup>rd</sup> Stem Cell Therapy in End-Stage Cardiovascular Diseases (SCIENCE III)
7. 2007 *Chairman*, Publication and Scientific Programme Committee, CardioRhythm 2007.



8. 2007 *Member*, Organizing Committee, Massachusetts General Hospital-The University of Hong Kong-Nature China Forum
9. 2008 *Chairman*, Publication and Scientific Programme Committee, CardioRhythm 2009.
10. 2010 *Member*, Organizing Committee and *Chairman*, Scientific Programme Committee, CardioRhythm 2011.
11. 2013 *Member*, Organizing Committee and *Chairman*, Scientific Programme Committee, CardioRhythm 2013, and 6<sup>th</sup> Asia-Pacific Heart Rhythm Society meeting Society
12. 2015, Co-Chairman of CardioRhythm 2015

### **ADVISORY BROAD AND REGIONAL COORDINATORS IN INTERNATIONAL MULTICENTER RESEARCH**

1. 2001-2005 *Local Coordinator* in Hong Kong, World Pacing Registry
2. 2001-2003 *National Coordinator* in Hong Kong, Stroke Prophylaxis Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF III): Multicentre, Randomized, Open Label, Parallel Group, Efficacy and Safety of H 376/95 Compared to Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation
3. 2003- Present *Member*, Advisory Broad, GEMINI-AALA: Clinical Utility of CADUET (amlodipine/ atorvastatin) to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia in Asia, the Middle East and Latin America.
4. 2004 *Member*, Asia Pacific Exanta Advisory Broad.
5. 2004 *Member*, St. Jude Medical, Asia Clinical Advisory Broad.
6. 2004 *Working Group Member*, Scientific Advisory on “The Role of Permanent Pacing to Prevent Atrial Fibrillation”, Council of Clinical Cardiology; ECG and Arrhythmias Committee, American Heart Association
7. 2005 *Member*, Asia Pacific Natrecor Advisory Broad.
8. 2005- Present *Member*, Medical Advisory Broad, Medtronic Physiologic Pacing Program (MP<sup>3</sup>)
9. 2005- Present *Medical Consultant*, Cordis Webers, Johnson & Johnson, USA.
10. 2005- Present *Medical Consultant*, St Jude Medical CRM, USA.
11. 2006-Present *Member*, Steering Committee of SAFE study.

12. 2006- 2008 *Member*, Medical Advisory Broad, Crycor Inc., USA.
13. 2006- Present *Member*, Hong Kong Cardiovascular Task Force, Pfizer HK
14. 2006-2010 *Member*, Steering Committee of OPTIMIZE study.
15. 2007- Present *Member*, Asia Region Advisory Board, Pfizer
16. 2008-2013 *National coordinator and Member* of Steering Committee of STABILITY study.
17. 2009-Present *Member*, Atrial Fibrillation Management Regional Advisory Board, Sanofi Aventis
18. 2009-Present *National coordinator* of RECORD-AF Registry
19. 2009-Present *National coordinator* of PRIMULA study
20. 2010-Present *National coordinator* of PALLAS study
21. 2010-Present *Member*, Stroke Prevention in Atrial Fibrillation Advisory Board (Boehringer Ingelheim)
22. 2010-Present *Member*, Takeda Asia Diabetes Advisory Board
23. 2012-Present *National coordinator and Member* of Steering Committee of ODYSSEY study.
24. 2014-Present *National Lead Investigator and Member* of Steering Committee of THEMIS study
25. 2014-Present *Principle Investigator and Member* of Steering Committee of ENABLE MRI stud
26. 2015-Present *Medical Consultant*, Boston Scientific, USA.
27. 2015-Present *Member* of Steering Committee: Study 16275: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both.

## **EXTERNAL EXAMINER OR GRANT REVIEWER**

1. 2002- Present *External reviewer*, Hong Kong Research Grants Council
4. 2005- Present *External reviewer*, Singapore National Medical Research Council

5. 2008 *External reviewer*, Sandwell & West Birmingham Hospital Trust Research
6. 2008 *External reviewer*, Heart Research UK Clinical Grant
7. 2009 *External Examiner*, National University of Malaysia (Universiti Kebangsaan Malaysia).
8. 2010 *External reviewer*, Swiss National Science Foundation
9. 2011 *External reviewer*, R & D Excellence Proposals, Kentucky Science and Engineering Foundation
10. 2011-2016 *Member*, Innovation & Technology Support Programme Assessment Panel on *Biotechnology*, Innovation and Technology Fund, HKSAR
11. 2012-present *Member*, Hong Kong Research Grants Council (RGC) Assessment Panel on Joint Research Schemes (JRS) in Biology & Medicine field.
12. 2012-present *External reviewer*, Canada Excellence Research Chairs program, Canada.
13. 2013-present *Member*, Panel for the Health and Medical Research Fund (HMRF) for HKSAR Government
14. 2017-present *External reviewer*, The Netherlands Organisation for Scientific Research
32. 2017-present *Member*, Assessment Panel on *Enterprise Support Scheme*, Innovation and Technology Commission, HKSAR

## **REVIWER OF INTERNATIONAL JOURNAL**

1. *Internal Medicine (6)*:  
Achieve of Medical Research; Annals of Medicine; Lancet; American Journal of Medicine; Journal of Hong Kong Medical Association; British Medical Journal; Journal of Internal Medicine.
2. *Cardiovascular Medicine (18)*:  
Arteriosclerosis, Thrombosis, and Vascular Biology; American Journal of Cardiology; Cardiovascular Research; Chest; Circulation; European Heart Journal; European Journal of Heart Failure; Europace; Expert Review of Medical Device; Heart; Heart Rhythm; International Journal of Cardiology; Journal of American College of Cardiology; Journal of Cardiovascular Electrophysiology; Journal of Hong Kong College of Cardiology; Journal of Interventional Electrophysiology; Journal of Human Hypertension; Pacing and Clinical Electrophysiology
3. *Others (9)*:

Blood Coagulation & Fibrinolysis; Diabetes; Diabetic Care; Expert Opinion on Pharmacotherapy; Stroke; Thrombosis Research; International Journal of Obesity; Vascular Health and Risk Management; Drug, Thrombosis Hemostasis.

## **EDITORIAL MEMEBR OF INTERNATIONAL JOURNALS**

1. 2005- Present *Editorial Consultants*, Journal of American College of Cardiology
2. 2006- Present *Member of the Editorial Board*, Pacing and Clinical Electrophysiology
3. 2006- 2008 *Member of the Editorial Board*, Journal of Cardiovascular Pharmacology and Therapeutics
4. 2006- Present *Member*, Editorial Advisory Board of Recent Patents on Engineering
5. 2007 - Present *Board Member*, The Open Nanoscience Journal
6. 2007- Present *Member of the Editorial Board*, Europace
7. 2009 *Guest Editor*, Theme Issue on “Stem Cells” in Thrombosis and Haemostasis
8. 2010- Present *Member of the Editorial Board*, Heart Rhythm
9. 2011-13 *Associate Editor*, Journal of Cardiovascular Translational Research
10. 2011 *Guest Editor*, Review Series on “Stem Cells for Drug Screening” in Journal of Cardiovascular Pharmacology
11. 2014 *Chief Editor*, Hong Kong Edition of the “Journal of American College of Cardiology”
12. 2014 *Member of the Editorial Board*, Journal of Cardiovascular Translational Research
13. 2014 *Member of the Editorial Board*, European Heart Journal – Cardiovascular Pharmacotherapy
14. 2017 *Associate Editor*, Europace
15. 2017 *Associate Editor*, Journal of Arrhythmia

## **ADMINISTRATION**

### **University/Faculty/Department**

1. 2001-2003 *Fellow*, St John St. John College, The University of Hong Kong
2. 2001- Present *Chairman of Executive Committee*, and Director, Sun Chieh Yeh Cardiovascular Research and Training Laboratory, the University of Hong Kong.
3. 2001- Present *Member*, Committee on Research, Postgraduate Education & Accommodation (CRPA), Department of Medicine, The University of Hong Kong
4. 2004- 2007 *Deputy Director*, Institute of Cardiovascular Sciences and Medicine, the University of Hong Kong.
5. 2005- 2008 Assistant Dean (External Affairs & Fund Raising), Li Ka Shing Faculty of Medicine, The University of Hong Kong.
6. 2005- Present *Deputy Director*, Research Centre of Heart, Brain, Hormone and Healthy Aging Research Center, the University of Hong Kong
7. 2005- 2008 *Chairman*, Committee on Continuous Professional Education Committee, Department of Medicine, The University of Hong Kong
8. 2005- Present *Member*, Dr. Mary Hui Ling Li Memorial Prize Examining Committee
9. 2006- Present *Member*, University of Hong Kong / Hospital Authority Hong Kong West Cluster Institutional Review Board
10. 2007- Present *Master*, Madam SH Ho Residence for Medical Students, the University of Hong Kong.
11. 2008- 2009 *Member*, Small Group on Seed Funding for Basic Research Programme, University Research Committee (URC), HKU
12. 2011 *Member*, Subcommittee of the Outstanding Young Researcher Award, HKU

### **Hospital/ College/ Community**

1. 2000- 2004 *Member*, Queen Mary Hospital Cardiopulmonary Resuscitation Training Task Force

2. 2001- Present *Member*, Executive Committee, Sun Chieh Yeh Heart Foundation
3. 2002- 2004 *Member*, Medical Record Subcommittee, Queen Mary Hospital
4. 2001- Present *Trainer*, Advanced Internal Medicine and Cardiology, Hong Kong College of Physician.
5. 2005- Present *Examiner*, Annual assessment of Advanced Internal Medicine, Hong Kong College of Physician.
6. 2005- present Honorary Consultant, Department of Medicine, Queen Mary Hospital, Hospital Authority
7. 2006- present Honorary Consultant, Department of Medicine, Kwong Wah Hospital, Hospital Authority
8. 2007-present Honorary Consultant, Department of Medicine, Tung Wah Hospital, Hospital Authority
9. 2007-present Honorary Consultant, Department of Medicine, Ruttonjee Hospital, Hospital Authority
10. 2010-present *Member*, Clinical Advisory Group on Hong Kong Reference Framework for Hypertension Care in Adults in Primary Care Settings, HKSAR
11. 2011-present *Honorary Advisor*, “Care for Your Heart- Cardiac Patients Mutual Support Association”

## **TEACHING**

### **Undergraduate Teaching**

1. 2001- Present *Departmental Representative and Clinical Skills Coordinator*, MBBS I Cardiovascular System Block Planning Group
2. 2002- Present *Member*, Clinical Skills and Interpersonal Skills Sub-committee
3. 2002- Present *Member*, Problem-based Learning Sub-committee
4. 2003- 2006 *Supervisor*, **Ms. Sin Pui Yee, Helena**, Full-time MRes(Med) student in Cardiology- Quality of Life in Atrial Fibrillation
5. 2004- 2007 *Co-Supervisor*, B.Eng. in Medical Engineering Final year project-  
 2004- Mr. Chan Ka Wai: Monitoring of sleep apnea  
 2004- Mr. Cheung Shing Chung: Monitoring of biological parameters using intra-cardiac electrogram.  
 2004- Ms. Leung Hiu Man: 3D reconstruction of coronary artery stenosis using intravascular ultrasound

- 2006- Ms. Chow April: Stem Cell Labeling for In Vivo MRI
6. 2005- 2007 *Coordinator in Medicine*, Integrated Block of MBBS III
  7. 2004- 2007 *Supervisor*, **Ms. Ho Lok Yan**, Full-time **MRes(Med)** student in Cardiology- Antithrombotic Therapy for Chinese Patients with Atrial Fibrillation
  8. 2005- 2008 *Supervisor*, **Mr. Lau Kui Kai, Gary**, Full-time **MRes(Med)** student in Cardiology- Relationship of Cardiovascular Risk Factors in Chinese Diabetics to Biochemical & Non-invasive Clinical Markers of Atherosclerosis
  9. 2006- 2009 *Supervisor*, **Mr. Wong Ching Yuen**, Full-time **MRes(Med)** student in Cardiology - Diet and vascular function in patients with diabetes
  10. 2007 – 2010 *Supervisor*, **Ms Dai Yuk Ling Eunice**, Full-time **MRes(Med)** student in Cardiology – Effect of Coenzyme Q10 on vascular function in patients with cardiovascular disease with or without the use of statin.
  11. 2007 – 2010 *Supervisor*, **Mr.Luk Ting Hin Terence**, Full-time **MRes(Med)** student in Cardiology – Exercise and vascular function
  12. 2009-2012 *Supervisor*, **Mr Yiu Yuen Fung**, Full Time **MREs(Med)** student in Cardiology - Endothelial dysfunction in chronic inflammatory diseases
  12. 2013-Present *Supervisor*, **Mr Cheung Hei Lok Emmanuel** Full Time **MREs(Med)** student in Cardiology - Testosterone and Heart Failure

### Postgraduate Teaching

1. 2003- 2007 *Supervisor*, **Mr. Wang Kai**, Full-time **PhD** student in Cardiology (Type B) – Structure-function and physiological properties of HCN-encoded Pacemaker channels
2. 2004- 2006 *Supervisor*, **Dr. Hu Rui**, Full-time **MPhil** student in Cardiology (Type B)- Applications of Non-Invasive Vascular Image Techniques in Cardiovascular Risk Assessment and Management
3. 2005- 2008 *Supervisor*, **Mr. Chan Yan Chi**, Full-time **PhD** student in Cardiology (Type B)- Genetic Isolation & Purification of Cardiac Derivatives of Human Embryonic Stem Cells for Subsequent Characterization of Cardiomyocytes
4. 2006- 2008 *Supervisor*, **Dr. Chen Hua**, Full-time **MPhil** student in Cardiology (Type B) –Stem cells and cardiovascular diseases
5. 2006- 2008 *Supervisor*, **Dr. Qiuwaxi Jianadi**, Full-time **MPhil** student in Cardiology (Type C) –Stem cells and cardiovascular diseases.

6. 2006-2009 Supervisor, **Dr. Li Mingfang**, Full-time **PhD** student in Cardiology (Type A) – Adiponectin and endothelial progenitor cells
7. 2007- 2015 Supervisor, **Dr. Liu Yuan**, Full-time **PhD** student in Cardiology (Type B) – Novel therapies for cardiac arrhythmias
8. 2006-2012 Supervisor, **Ms Chan Hiu Ting**, Part-time **PhD** student in Cardiology (Type C) – Diet and cardiovascular diseases
9. 2008- 2014 Supervisor, **Dr. Liao Song-Yan**, Part-time **PhD** student in Cardiology – Human embryonic stem cells
10. 2008- 2015 Supervisor, **Ms. Pandora Mei-Chu Yip**, Full-time **PhD** student in Cardiology – Human embryonic stem cells
11. 2008- 2014 Supervisor, **Mr. Lai Wing Hon**, Part-time **PhD** student in Cardiology – Human embryonic stem cells
12. 2009 - 2013 Supervisor, **Ms Zhang Yuelin**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell Therapy for Cardiovascular Diseases
13. 2009-2013 Supervisor, **Ms. Zhang Jiao**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell and ion channel
14. 2010-2014 Supervisor, **Ms. Liang Xiaoting**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell and cardiac regeneration
15. 2012 – Present, Supervisor, **Dr Xu Jianyong**, Full Time **PhD** student in Cardiology (Type B)- Induced Pluripotent Stem Cells for Diagnosis and Treatment of Cardiovascular disease
16. 16. 2013 – Present, Supervisor, **Dr Yang Jianyin**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell based regenerative medicine
17. 17. 2013 – 2015, Supervisor, **Ms Zhen Zhe**, Full Time **MPhil** student in Cardiology (Type B)- Stem Cell based Regenerative Medicine
18. 18. 2015 – Present, Supervisor, **Ms Zhen Zhe**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell based Regenerative Medicine
19. 2015 – Present, Supervisor, **Miss Ran Xinru**, Full Time **PhD** student in Cardiology (Type B)- Stem Cell Based Modeling of Cardiovascular Disease
20. 2017 – Present, Supervisor, **Mr Sun Sijia**, Full Time **PhD** student in Cardiology (Type B)- “In Channel in cardiovascular diseases”



## **Clinical Trainees/ Fellows/ Research Associate**

1. 2001- 2004 *Supervisor, Dr. Siu Chung-Wah*, Department of Medicine, Queen Mary Hospital, **Cardiology trainee.**
2. 2001- 2004 *Supervisor, Dr. Ho Hee-Hwa*, Department of Medicine, Queen Mary Hospital, **Cardiology trainee.**
3. 2001- 2004 *Supervisor, Dr. Miu Raymond*, Department of Medicine, Queen Mary Hospital, **Cardiology trainee.**
4. 2001-2002 *Supervisor, Dr. Zhan Hong*, Department of Emergency, The 1<sup>st</sup> Affiliated Hospital of Zhong Shan University, China, **Dr. Cheng Yu Tung Fellowships 2000/2001**
5. 2002-2003 *Supervisor, Dr. Hu Rui*, Department of Cardiology, Tinshan Hospital, Medical Center of Fudan University, Shanghai, China, **Dr. Cheng Yu Tung Fellowships 2002/2003; Honorary Clinical Associate in Cardiology**
6. 2003- 2005 *Supervisor, Dr. Zhang Qing-yong*, Assistant Researcher, Tinshan Hospital, Fudan University Zhongshan Hospital, Shanghai, China, **Honorary Clinical Associate in Cardiology.**
7. 2004- 2006 *Supervisor, Dr. Zhu Shu-Guang*, Department of Cardiology, , China, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, **Honorary Clinical Associate in Cardiology**
8. 2004- Present *Supervisor, Dr. Zhang Xue-Hua*, Cardiology Division, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou China, **Honorary Clinical Associate in Cardiology**
9. 2005- Present *Supervisor, Dr. Liao Songyan*, Faculty of Pharmacy. Bengbu Medical College, Benbu., China, **Honorary Clinical Associate in Cardiology**
10. 2005-2006 *Supervisor, Dr. Chen Hua*, Department of Cardiology, Beijing Anzhen Hospital of Capital University of Medical Sciences, Beijing, China **Dr. Cheng Yu Tung Fellowships 2005/2006**
11. 2004- Present *Supervisor, Dr. Ryan Ko Lap Yan*, Department of Medicine, Queen Mary Hospital, **Cardiology trainee.**
12. 2004- Present *Supervisor, Dr. Yiu Kai Hang*, Department of Medicine, Queen Mary Hospital, **Cardiology trainee.**
13. 2004- 2005 *Supervisor, Dr. Xue Tian*, Department of Medicine, The University of Hong Kong, **Post-doctoral Fellow.**
14. 2005- 2007 *Supervisor, Dr. Karen Au*, Institute of Cardiovascular Science and Medicine, The University of Hong Kong, **Post-doctoral Fellow.**

15. 2005- 2007 *Supervisor*, Dr. Lau Yee Man, Research Centre of Heart, Brain, Hormone & Healthy Aging, The University of Hong Kong, **Post-doctoral Fellow**.
16. 2006 – 2007 *Advisor*, Dr Jim Man Hong, **Doctor of Medicine (MD)- Sir Patrick Manson Gold Medicine (2007-2008)**
17. 2007-Present *Supervisor*, Dr. Jenny Ho, Research Centre of Heart, Brain, Hormone & Healthy Aging, The University of Hong Kong, **Post-doctoral Fellow**
18. 2007 – 2010 *Advisor*, Dr Siu Chung Wah, **Doctor of Medicine (MD)- Sir Patrick Manson Gold Medicine (2009-2010)**
19. 2011 – Present, *Advisor*, Dr Yiu Kai Hang, **Doct of Medicine (MD)**
20. 2008 – 2009 *Advisor*, Dr Ronald Lee, **Doctor of Medicine (MD)**
21. 2008 - 2011 *Supervisor*, Dr. Kong Chi Wing, Marco, Research Centre of Heart, Brain, Hormone & Healthy Aging, The University of Hong Kong, **Post-doctoral Fellow**.
22. 2009- 2011 *Supervisor*, Dr Chan Yau Chi, The University of Hong Kong, **Post-doctoral Fellow**
23. 2012 – Present, *Supervisor*, Dr Liu Yuan, The University of Hong Kong, **Post- doctoral Fellow**
24. 2013- Present, *Supervisor*, Dr KM Ng, The University of Hong Kong, **Research Assistant Professor**
25. 2014- Present *Supervisor*, Dr Lee Yee Ki, The University of Hong Kong, **Post-doctoral Fellow**

#### *Undergraduate*

1. 2002-2003 *Chief Organizer*, Final MBBS Clinical Examination in Medicine (OSCE)
2. 2002- Present *Internal Examiner*, MBBS I-II OSCE Examination
3. 2002- Present *Internal Examiner*, MBBS III Formative Examination
4. 2004- Present *Internal Examiner*, BChiMed Examination
5. 2005- Present *Internal Examiner*, BDS Assessment
6. 2005- Present *Internal Examiner*, MBBS IV OSCE Examination
6. 2009- 2010 *External Examiner*, National University of Malaysia (Universiti Kebangsaan Malaysia).

### ***Postgraduate***

1. 2003 *Internal Examiner*, Mr. Lam Tai Chung, MRes (Med) Thesis: "Genetic and Environmental Factors of Hypertension"
2. 2003 *Internal Examiner*, Dr. Hui Ling, PhD Thesis: "Dobutamine Stress Echocardiography for Children with Acquired and Congenital Cardiac Diseases"
3. 2004 *Internal Examiner*, Dr. Wang Yan, PhD Thesis: "Atherosclerotic Disease of the Carotid, Coronary and Renal Arteries: Diagnosis, Angioplasty and the Effect of Stent Surface on Early Thrombosis and Restenosis".
4. 2005 *External Examiner for The Chinese University of Hong Kong*, Dr. Zhang Yan, PhD Thesis: "Assessment of Left Ventricular Remodeling with Doppler Echocardiography in Patients after Acute Myocardial Infarction Compared with Cardiovascular Magnetic Resonance Imaging"
5. 2006 *Internal Examiner*, Dr Li Hua, PhD Thesis "Cell and Gene Therapies for Diabetes – Exploration of Novel Therapeutic Approaches"
6. 2007 *Internal Examiner*, Dr Lee Yuk Kwan Mary PhD Thesis "Molecular Changes in Regenerated and Senescent Cultured Endothelial Cells"
7. 2007 *Internal Examiner*, Dr Yang Fan, PhD Thesis "Intervertebral disc regeneration using mesenchymal stem cells – A mouse model study"
8. 2007 *Internal Examiner*, Dr Wang Xuelai, PhD Thesis "Post-MI depression, inflammatory markers and cardiac prognosis in Chinese patients"
9. 2007 *Chairman, Examination committee*, Dr Yu Che Kwan, PhD Thesis "Remifentanyl induces delayed cardioprotection in the rat against ischaemic and reperfusion injury via Kappa-, delta, mu-opioid receptors and inducible heat shock protein 70"
10. 2008 *Chairman, Examination Committee*, Dr Hui King Cheung, M Phil Thesis "Biomarkers for Esophageal Squamous Cell Carcinoma"
11. 2009 *Internal Examiner*, Dr Lam Chung Mei Jamie, PhD Thesis "Obstructive Sleep Apnea and Cardiometabolic Complications"
12. 2010 *Internal Examiner*, Dr Yiu Wai Ki, PhD Thesis "The Effect of Supercooling and Re-warming on Vascular Cells Survival and Proliferation"
13. 2010 *Chairman, Examination Committee*, Ms. Long Meijing, MPhil Thesis "Prevalence of electrocardiographic abnormalities and the relationship between alcohol use and electrocardiographic left ventricular hypertrophy in older Chinese people: the Guangzhou Bioback Cohort Study"

14. 2012 *Chairman, Examination Committee*, Mr Qu Zao, , MPhil Thesis “Expression of Sphingosine-1- Phosphate Receptor in Abdominal Aortic Aneurysm”
15. 2013 *Internal examiner*, Mr Qing Kaixiong, PhD Thesis “Thoracic Endovascular Stent Graft Repair (TEVAR) For Treating Type B Aortic Dissections (TBAD): Hemodynamic and Morphologic Perspective
16. 2013 *Chairman*, Miss Chen Meipian , PhD Thesis “Effects of Iron Overload on Apoptosis and Titin Proteolysis in Cardiomyocytes”
- 17.2015 *Chairman*, Miss Chan Yin Tung, Crystal, PhD Thesis, “Investigation of microRNA-516a-5p, microRNA-1260 and low-density lipoprotein receptor-related protein-1 in abdominal aortic aneurysm
- 18.2016 *Internal examiner*, Mr OU Jiale, PhD Thesis “Fenestrated Endovascular Aortic Repair (FEVAR) for Complex Abdominal Aortic Aneurysm (AAA): A Morphologic and Hemodynamic Study
- 19.2017 *Internal examiner*, Miss Detremmerie Charlotte Marie Simonne, PhD Thesis “Pharmacological activation of biased soluble guanylyl cyclase activity in the blood vessel wall

### **Others**

1. 2000 - 2002 *Tutor*, FCCS Provider Courses
2. 2000 - Present *Program Director*, Animal Training Workshop for Heart Failure Therapy Implant Physician Course
3. 2001-2002 *Program Director*, Clinical and Training Course for the Biosense Webster Technology “NOGA”
4. 2002- Present *Tutor*, Certificate in Intensive Care Nursing, SPACE, The University of Hong Kong
5. 2002- 2003 *Course Director*, Certificate Course on Cardiovascular Medicine for Non-specialist, The University of Hong Kong
6. 2005- 2009 *Programme Organizer*, Postgraduate Diploma in Diagnosis and Therapeutic in Internal Medicine, The University of Hong Kong

## **PUBLIC RELATIONSHIP AND EXTERNAL MEDIA ACTIVITIES**

### **Press Release**

2003

1. **HKU** **Press Release:** “Stem Cells Therapy: Novel strategy for heart tissue regeneration in patients after heart attack” (Mass Media: 20)

2. **HKU** **Press Release** “7th Annual Scientific Meeting – Stem Cells Therapy: Novel strategy for heart tissue regeneration for heart disease” Press Conference (Media Total: 8)
- 2004
3. **HKU** **Press Releases:** Medical Research and the Community “Functional role of pacemaker current, I(f) in sinoatrial node probed by somatic gene transfer of bioengineered HCN channels in swine” (Electronic Media: 9, Newspaper: 17, Portals: 21, Other media: 1, Media Total: 44)
- 2005
4. **HKU** **Press Releases:** Catheter Ablation: A Radical Cure for Atrial Fibrillation (Newspaper:9, Portals: 5, Media Total: 14)
5. **HKU** **Press Releases:** “揭開未老先衰之謎 兒童早老症的致病機理”
- 2006
6. **International Press Releases:** - American College of Cardiology 2006, USA: “Prospective Randomized Trial of Direct Endomyocardial Implantation of Bone Marrow Cells for Therapeutic Angiogenesis in Coronary Artery Diseases (PROTECT-CAD)
7. **HKU** **Press Release:** Investigation on Bioartificial Sinus Node Provides Important Clinical Insights into Cardiac Impulse Generation
8. **International Press Releases:** The 21<sup>st</sup> Scientific Meeting of the International Society of Hypertension, Oct 15 – 19, 2006, Fukuoka, Japan.”Gemini AALA presentation”.
- 2007
9. **HKU** **Press conference:** Research Find that Combined Therapy for Hypertension and High Cholesterol Reduces 10-Year Risk of Cardiovascular Diseases by more than Half.
- 2008
10. **HKU** **Press Conference:** Novel HKU Researches shed New Lights on the Measurement and Prevention of Atherosclerosis.
11. **HKU** **Press Conference:** Detecting Blood levels of C-Reactive Protein: HKU Researches Unveil Hidden Cardiovascular Risk of the Population And Identify Potential Treatment Agent
- 2009
12. **Cardio Rhythm 2009**  
**Press Conference:** New Technologies Improve the Success Rate of Catheter Ablation Procedure for Atrial Fibrillation
13. **HKU** **Press Conference:** Strategic Research Development in Stem Cell & Regenerative Medicine
- 2010
14. **HKU** **Press Conference:** HKU Scientists Bring New Hopes to Translate Human Stem Cell Technologies to the Clinic
- 2011
15. **HKU** **Press Conference**  
HKU’s Breakthroughs in Stem Cell Research New Hopes for Treating Human Diseases

16. **HKU** **Public talk** – HKU Scientists Bring New Hopes to Translate Human Stem Cell Technologies to the Clinic
17. **Astra Zeneca** **Public talk** – Women’s heart health  
2012
- 18 **HKU** **Press Conference**  
HKU  
服用薄血藥華法林的心房顫動患者  
經常進食可影響藥效的草本食材須留意謹慎用藥
- 19 **HKU** **Public talk** – World Stroke Day and Atrial Fibrillation  
2014
- 20 **HKU** **Press Conference**  
HKU performs the first implant of a newly developed defibrillator in Asia
- 21 **World Heart Day** **Public talk**  
Hong Kong College of Cardiology  
三高治療，全方位攻略
22. **創世電視** **Media Interview** “How to reduce the risk of SADS”  
2015
- 23 **HKU** **Press Conference**  
**HKU performs the first-in-man restorative treatment – the dual-targeted thoracic spinal cord stimulation for heart failure**
- 24 **HKU** **Press Conference**  
HKU Faculty Public Lecture promotion newspaper column.” HKU developed the atrial fibrillation (AF) management apps and Launch of HKU –private doctors AF screening programme
- 2016
- 25 **HKU** **Interviewee, Filming of surgical operation, Subcutaneous implantable cardioverter(S-ICD) implananation procedure, patient face and commercial branding**
- 2017
- 26 **RTHK** **Interviewee, of RTHK Radio 3 programme "Hong Kong Today**
- 27 **RTHK** **Interviewee, “The Making of Healers” (大醫之道).**
- 28 **HKU** **Press Conference**  
**HKU Faculty HKU Develops Chimeric Mouse Liver Model Helps Familial Hypercholesterolemia Patients Test Drug Response**
- 29 **Interviewee, Cable TV News 《Health and Fitness》**

**2018**

**27 RTHK**

**Interviewee of RTHK , 港人港健康 , 心律不正**

**28 HKU**

**Press Conference**

**HKU Faculty** International collaborative research teams discover novel genetic markers for blood lipids and coronary artery disease